Effect of Adjunctive Oral Cannabidiol (CBD) vs. Placebo on Convulsive Seizure Frequency in Dravet Syndrome

Supplement 1

1 Table of Contents ........................................................................................................................................ 1
2 Original Trial Protocol .................................................................................................................................. 2
3 Amendments to the Original Protocol .......................................................................................................... 105
4 Original (Final) Statistical Analysis Plan ..................................................................................................... 110
TITLE: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.

STUDY CODE: GWEP1424

EudraCT NUMBER: 2014-002939-34

GW RESEARCH LTD
PORTON DOWN SCIENCE PARK
SALISBURY
WILTSHIRE SP4 0JQ

TEL: PPD FAX: PPD

Confidentiality Statement

This document contains confidential information of GW Research Ltd that must not be disclosed to anyone other than the recipient study staff and members of the Institutional Review Board/Ethics Committee. This information cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of GW Research Ltd.
Investigator Agreement

I have read the attached protocol entitled "A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome", dated 22 Jul 14 and agree to abide by all provisions set forth therein.

I agree to comply with applicable regulatory requirement(s); the FDA regulations relating to good clinical practice and clinical trials and the European Union (EU) Clinical Trials Directive (2001/20/EC) and subsequent applicable regulatory/statutory instruments, or the International Conference on Harmonization Tripartite Guideline on Good Clinical Practice (ICH GCP) where the EU Directive does not apply and to complete a Form 1572 if required.

I am not aware that any conflicts of interest, financial or otherwise, exist for myself, my spouse [or legal partner] and dependent children and agree to confirm this in writing if required and update as necessary.

I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of GW Research Ltd.

Center No: __________________________________________

Print Name: __________________________________________ Date: ____________________________ (DD Month YYYY)

Principal Investigator

Signature: __________________________________________

GW Authorization

Print Name: FPD __________________________ Date: 0S It/A6. J. J/ f ______ (DD Month YYYY)

Clinical Manager

Signature: __________________________

Confidential
# PROTOCOL SYNOPSIS

<table>
<thead>
<tr>
<th>Study Title</th>
<th>A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Study Type</td>
<td>Phase Three Study</td>
</tr>
<tr>
<td>Indication</td>
<td>Dravet syndrome (DS)</td>
</tr>
<tr>
<td>Primary Objective</td>
<td>To assess the efficacy of GWP42003-P as an adjunctive antiepileptic treatment compared with placebo, with respect to the percentage change from baseline during the maintenance period of the study in convulsive seizure frequency. The dose response effect between two GWP42003-P Dose Levels and placebo will also be explored. Convulsive seizures are defined as tonic-clonic, tonic, clonic or atonic and non-convulsive seizures as myoclonic, partial or absence.</td>
</tr>
</tbody>
</table>
| Secondary Objective(s)    | • To assess changes from baseline in non-convulsive seizure frequency, usage of rescue medication, number of inpatient hospitalizations due to epilepsy, sleep disruption, daytime sleepiness, quality of life and conduct behavioral and cognitive assessments in patients taking GWP42003-P as an adjunctive treatment, when compared with placebo.  
  • To assess the safety of both GWP42003-P doses when compared with placebo. |
| Study Design              | This study is a 1:1:1 randomized, double-blind, 14-week comparison of two Dose Levels of GWP42003-P versus placebo. The treatment period will consist of a two-week titration period followed by a 12-week maintenance period. The treatment period will be followed by a 10-day taper period and a four-week follow-up period. The study will aim to determine the efficacy, safety and tolerability of two Dose Levels of GWP42003-P compared with placebo. The High Dose Level will be as recommended by the Data Safety Monitoring Committee (DSMC) after assessment of safety and pharmacokinetic data from Part A of study GWEP1332. The Low Dose Level will be defined as 50% of the High Dose Level. Patients in the placebo group will be split into two equivalent cohorts: half receiving Low Dose Level dosing volumes and half receiving High Dose Level dosing volumes. The first patient will not enroll into this study until the DSMC has reviewed the safety data from Part A of study GWEP1332.  
  Following study completion, all patients will be invited to continue to receive GWP42003-P in an open label extension (OLE) study (under a separate protocol). |
| Primary Endpoint          | The primary endpoint is the mean percentage change from baseline in convulsive seizure frequency during the maintenance period (Day 15 to the end of the evaluable period) in patients taking GWP42003-P |
The following endpoints will be compared between the three treatment groups over the 12-week, double-blind maintenance period:

- Number of patients experiencing a >25% worsening, −25 to +25% no change, 25–50% improvement, 50–75% improvement or >75% improvement in convulsive seizures from baseline.
- Number of patients who are convulsive seizure free.
- Percentage changes from baseline in non-convulsive seizure frequency.
- Change in types of seizures.
- Changes from baseline in usage of rescue medication.
- Changes from baseline in number of inpatient hospitalizations due to epilepsy.
- Changes from baseline in Sleep Disruption 0–10 Numerical Rating Scale (0–10 NRS) score.
- Changes from baseline in Epworth Daytime Sleepiness Scale (EDSS) score.
- Changes from baseline in the Quality of Life in Childhood Epilepsy (QOLCE) score.
- Changes from baseline in the Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) score.
- Change in cognitive function as measured with a cognitive assessment battery.
- Caregiver Global Impression of Change (CGIC).

The safety profile of GWP42003-P compared with placebo will also be assessed at each Dose Level by measuring:

- Adverse events (AEs).
- Vital signs.
- Physical examination parameters.
- 12-lead Electrocardiogram (ECG).
- Laboratory parameters.
- Columbia-Suicide Severity Rating Scale (C-SSRS) score.
- Cannabis Withdrawal Scale (CWS) score.
- Abuse liability.

A total of 120 patients will be enrolled to receive one of two Dose Levels of active investigational medicinal product (IMP) or placebo on a 1:1:1 basis (40 patients per treatment group). Patients in the placebo group will be split into two cohorts (20 receiving Low Dose Level dosing volumes and 20 receiving High Dose Level dosing volumes), but it is assumed that these two cohorts can be pooled for the analyses.
of efficacy.
If it is assumed that patients in the placebo group will experience a mean reduction in convulsive seizure frequency of 10% (from baseline), this sample size of 40 patients per group will be sufficient to detect a difference of 40% between treatments (i.e., patients receiving GWP42003-P will experience at least a 50% reduction in convulsive seizures). This is based on a standard deviation of 63%, using a two-tailed 5% significance level and 80% power.

Summary of Patient Eligibility Criteria

<table>
<thead>
<tr>
<th>Inclusion:</th>
<th>Patients meeting the following criteria will be considered eligible for this study:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Patient and/or parent(s)/legal representative must be willing and able to give informed assent/consent for participation in the study (see Section 15.2).</td>
</tr>
<tr>
<td></td>
<td>• Patient and their caregiver must be willing and able (in the investigator’s opinion) to comply with all study requirements.</td>
</tr>
<tr>
<td></td>
<td>• Patient must be male or female aged between two and 18 years (inclusive).</td>
</tr>
<tr>
<td></td>
<td>• Patient must have a documented history of DS which is not completely controlled by current antiepileptic drugs (AEDs).</td>
</tr>
<tr>
<td></td>
<td>• Patient must be experiencing four or more convulsive seizures (i.e., tonic-clonic, tonic, clonic, atonic seizures) during the 28-day baseline observation period.</td>
</tr>
<tr>
<td></td>
<td>• Patient must be taking one or more AEDs at a dose which has/have been stable for at least four weeks.</td>
</tr>
<tr>
<td></td>
<td>• All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation) must have been stable for four weeks prior to screening and patient and caregiver are willing to maintain a stable regimen throughout the study.</td>
</tr>
<tr>
<td></td>
<td>• Patient and/or parent(s)/legal representative is willing to allow his or her primary care practitioner and consultant to be notified of participation in the study.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusion:</th>
<th>The patient may not enter the study if ANY of the following apply:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Patient has clinically significant unstable medical conditions other than epilepsy.</td>
</tr>
<tr>
<td></td>
<td>• Patient has had clinically relevant symptoms or a clinically significant illness in the four weeks prior to screening or randomization, other than epilepsy.</td>
</tr>
<tr>
<td></td>
<td>• Patient has clinically significant abnormal laboratory values, in the investigator’s opinion, at screening or randomization.</td>
</tr>
<tr>
<td></td>
<td>• Patient has clinically relevant abnormalities in the ECG measured at screening or randomization.</td>
</tr>
</tbody>
</table>
|            | • Patient has any concurrent cardiovascular conditions which will, in
the investigator’s opinion, interfere with the ability to assess their ECGs.

- Patient has a history or presence of alcohol or substance abuse within the last two years prior to the study or daily consumption of five or more alcohol-containing beverages.

- Patient is currently using, or has in the past used, recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the three months prior to study entry and is unwilling to abstain for the duration of the study.

- Patient has a history of symptoms (e.g., dizziness, light-headedness, blurred vision, palpitations, weakness, syncope) related to a drop in blood pressure due to postural changes.

- Patient has ingested alcohol in the 24-hour period prior to the first study visit and/or is unwilling to abstain from drinking alcohol throughout the treatment period.

- Patient has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMPs (e.g., sesame oil).

- Female patient is of child bearing potential or male patient’s partner is of child bearing potential; unless willing to ensure that they or their partner use effective contraception, for example oral contraception, double barrier, intra-uterine device, during the study and for three months thereafter (however a male condom should not be used in conjunction with a female condom).

- Female patient is pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter.

- Patient has been part of a clinical trial involving another IMP in the previous six months.

- Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, may influence the result of the study, or affect the patient’s ability to participate in the study.

- Patient has significantly impaired hepatic function at screening (Visit 1) or randomization (Visit 2) (Alanine aminotransferase [ALT] >5 × upper limit of normal [ULN] or total bilirubin [TBL] >2 × ULN) OR the ALT or Aspartate aminotransferase (AST) >3 × ULN and (TBL >2 × ULN or international normalized ratio [INR] >1.5). This criterion can only be confirmed once the laboratory results are available; patients randomized into the study who are later found not to meet this criterion should be withdrawn from the study.

- Following a physical examination the patient has any abnormalities that, in the opinion of the investigator, would prevent the patient from safe participation in the study.
### Criteria for Withdrawal

- Patient is unwilling to abstain from donation of blood during the study.
- There are plans for the patient to travel outside their country of residence during the study.
- Patient has previously been randomized into this study.
- Any history of suicidal behavior or any suicidal ideation of type four or five on the C-SSRS at screening.

### Investigational Medicinal Product: Dosage, Regimen, Formulation and Mode of Administration

GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol, added sweetener [sucralose] and strawberry flavoring).

Placebo oral solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

Dosage: Patients will titrate the IMP to the target Dose Level. Patients will then remain at this Dose Level for the duration of the treatment period of the study.

The High Dose Level will be determined by the DSMC of Part A of study GWEP1332. The maximum dose considered will be 20 mg/kg/day.

The Low Dose Level will be defined as 50% of the High Dose Level.
**IMP will be taken twice daily (morning and evening).**

<table>
<thead>
<tr>
<th>Control Group</th>
<th>The control group will receive placebo matching the assigned IMP Dose Level.</th>
</tr>
</thead>
</table>
| Procedures    | During Visit 1 (Day −28), the following assessments will be made: demographics, medical history (including seizure frequency over the last six months and voltage-gated sodium channel α1 subunit gene [SCN1A] mutation status), vital signs, postural blood pressure, physical examination (including height and body weight), ECG, C-SSRS (Children’s Baseline), and visit procedure-related AEs. If the mutation status of SCN1A is unknown, a blood sample will be taken for SCN1A analysis (this can be taken at any visit during the study). Clinical laboratory samples (urine [where possible] and blood) will be taken for hematology, biochemistry, urinalysis, a urine Δ⁹-tetrahydrocannabinol (THC) screen and a serum pregnancy test (if appropriate). Patients or their caregivers will also be asked for information regarding concomitant medications and/or changes to medication (including AEDs). Eligible patients will then begin the 28-day baseline observation period. Patients or their caregivers will be issued with Interactive Voice Response System (IVRS) details and will be instructed on how to use it to record daily seizure information. Patients or their caregivers will also be given a paper diary to record usage of rescue medication, concomitant AEDs and AEs, and will be instructed on how to do so. At each subsequent clinic visit (Visits 2, 3, 4, 6 and 8), the following assessments will be made: vital signs, physical examination (including height and body weight), ECG, EDSS, Sleep Disruption 0–10 NRS, CGIC (assessment not completed at Visit 2), cognitive assessment battery (Visits 2 and 8 only), QOLCE (Visits 2 and 8 only), C-SSRS (Children’s Last Visit) and the Vineland-II. Clinical laboratory samples (urine [where possible] and blood) will be taken for hematology, biochemistry and urinalysis. The patient’s IVRS report and paper diary will be reviewed and the information recorded along with information regarding AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs). The investigator must assess adherence to the dosing regimen from Visit 2 onwards. After 28 (±3) days, patients will return to the clinic at Visit 2 (Day 1). In addition to the above assessments, postural blood pressure and the CWS will be assessed and a test to detect THC and a pregnancy test, if appropriate, will also be performed. The investigator will assess the patient’s daily number of convulsive seizures from the patient’s IVRS data. Patients who have experienced four or more convulsive seizures (i.e., tonic-clonic, tonic, clonic or atonic seizures) during the baseline period and who meet all of the other inclusion and none of the exclusion criteria will be eligible to continue in the study. If a patient does not meet the eligibility criteria within this period, consideration
will be given to rescreen at a later date. Eligible patients will then be randomized to receive one of two Dose Levels of GWP42003-P or placebo in a 1:1:1 allocation ratio using the IVRS. Patients in the placebo group will be split into two equivalent cohorts; half receiving Low Dose Level dosing volumes and half receiving High Dose Level dosing volumes.

At Visit 2, caregivers will be asked to write a brief description of the patient’s overall condition as a memory aid for the CGIC at subsequent visits or withdrawal.

Patients will then receive sufficient IMP, as assigned by the IVRS, every 28 to 42 days for the 14-week treatment period. Each patient will take their first dose of IMP at Visit 2 (Day 1). Patients or their caregivers will be instructed on using the IVRS’s daily dosing record, as well as how to record IMP dosing information in the paper diary.

Patients will titrate to their target Dose Level using the regimen provided via the IVRS. If an unacceptable AE develops at any time during titration, dosing should initially be suspended or amended, as appropriate, until the event has resolved. After titration, patients should continue on a stable dosing regimen at the dose they achieved at the end of the titration period. If that dose becomes poorly tolerated during the post-titration period, the investigator may consider temporarily or permanently reducing the dose for the remainder of the study. However, where possible, the patient should be encouraged to return to the target dose.

Patients will return to the clinic for further visits at Visit 3 (Day 15±3), Visit 4 (Day 29±3), Visit 6 (Day 57±3) and Visit 8 (Day 99±3). Adherence to the titration regimen and compliance will be assessed for safety reasons. Additional safety assessments will be made by telephone at Visit 5 (Day 43±3) and at Visit 7 (Day 71±3). During these calls, patients or their caregivers will be asked for information regarding AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to their medication (including AEDs). Visit 8 is the ‘End of Treatment’ visit and a test to detect THC and a pregnancy test (if appropriate) will be performed. The Caregiver Impression of IMP Palatability will also be assessed.

At Visit 8, patients who have completed all of the scheduled study visits will be offered the option to enter an OLE study. Entry is to be on the same day as Visit 8 (Day 99) or within seven days of Visit 8. Patients not entering the OLE study at this visit will commence a taper period (down-titrating 10% per day for 10 days), and additional IMP will be dispensed, if required. Patients who require early termination prior to Visit 8 should also begin the taper period at the time the decision is made to discontinue (unless continued dosing is not possible due to an AE). The IVRS will generate the patient’s daily IMP dosing volumes for the 10-day taper period, during which time IVRS and diary information will continue to be recorded. The taper period may be
interrupted if the patient wishes to enter the OLE study within the seven days of Visit 8.

Following completion or cessation of the taper period, patients will return to the clinic for Visit 9 (‘End of Taper Period’ Visit) where the following assessments will be made: vital signs, physical examination (including height and body weight), C-SSRS (Children’s Last Visit) and CWS. The patient’s IVRS report and paper diary will be reviewed and the information recorded along with information regarding AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs). For patients not entering the OLE study, Visit 9 should occur 10 (+3) days after Visit 8 (i.e., on Day 109(+3)). For patients who delay entry into the OLE study, Visit 9 should occur on the day the patient enters the OLE study and within seven days of Visit 8 (i.e., up to Day 106), to allow the patient to enter the OLE study within this timeframe.

A safety follow-up visit (Visit 10) is required for patients who do not enter the OLE study or who withdraw from the study early. This visit should occur four weeks after Visit 9 (i.e., on Day 137±3), or withdrawal from treatment, and can be conducted by telephone. Patients or their caregivers will be asked for information on AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs).

For patients not entering the OLE study, safety telephone calls will be made weekly (±3 days) from Visit 9 until Visit 10.

Patients who enter the OLE study on Day 99 will not attend Visits 9 or 10.

**Monitoring of Drug Abuse Liability (for patients 12 years of age and older):**

During the routine collection of AEs in this study, if AEs are reported which can illuminate an abuse potential signal (specific AEs detailed in Section 9.1.15.1.1), then the investigator or study coordinator is required to complete an additional Supplemental Adverse Event Form and a Site Classification Form (investigator only) following further discussion of the event(s) with the patient/caregiver.

The second trigger that will require the investigator or study coordinator to discuss abuse potential signals with the patient/caregiver is drug accountability issues regarding overuse of the IMP or missing bottles.

Irrespective of the above, all patients/caregivers will be interviewed at their final dosing visit (Visit 8/9) or withdrawal visit and a Study Medication Use and Behavior Survey will be completed by the investigator or study coordinator.

A formal Adjudication Committee will be appointed and assigned to this initiative to classify triggered cases. The Adjudication Committee will meet on a periodic basis to review and assess all of the information
The following endpoints will be described and compared between the three treatment groups, using appropriate statistical methods, over the 12-week, double-blind maintenance period:

- Mean percentage change from baseline in the frequency of convulsive seizures.
- Number of patients experiencing a >25% worsening, −25 to +25% no change, 25–50% improvement, 50–75% improvement or >75% improvement in convulsive seizures from baseline.
- Number of patients who are convulsive seizure free.
- Percentage change from baseline in non-convulsive seizure frequency.
- Change in types of seizures.
- Change from baseline in use of rescue medication.
- Change from baseline in number of inpatient hospitalizations due to epilepsy.
- Change from baseline in Sleep Disruption 0–10 NRS score.
- Change from baseline in EDSS score.
- Change from baseline in QOLCE score.
- Change from baseline in cognitive assessment battery.
- Change from baseline in Vineland-II score.
- CGIC.

All statistical tests will be two-tailed and carried out at the 5% level of significance.

All safety data will be summarized using appropriate statistical methods.

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>GW Research Ltd</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Porton Down Science Park</td>
</tr>
<tr>
<td></td>
<td>Salisbury</td>
</tr>
<tr>
<td></td>
<td>Wiltshire SP4 0JQ</td>
</tr>
</tbody>
</table>
* For patients not entering the OLE study at Visit 8. Patients who opt not to enter the OLE study must have weekly (±3 days) safety telephone calls until Visit 10.

** For patients not entering the OLE study; can be conducted by telephone.
# Table of Contents

184
185
186
187
188
189
190

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PROTOCOL SYNOPSIS</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>OBJECTIVES</td>
<td>24</td>
</tr>
<tr>
<td>3</td>
<td>BACKGROUND AND RATIONALE</td>
<td>25</td>
</tr>
<tr>
<td>4</td>
<td>EXPERIMENTAL PLAN</td>
<td>31</td>
</tr>
<tr>
<td>5</td>
<td>INVESTIGATIONAL MEDICINAL PRODUCT</td>
<td>33</td>
</tr>
</tbody>
</table>

**1 PROTOCOL SYNOPSIS**

Table of Contents .................................................................................................................. 13
Table of Appendices .............................................................................................................. 18
List of In-text Tables ............................................................................................................. 19
List of In-text Figures ............................................................................................................ 20
List of Abbreviations ............................................................................................................. 21
Definition of Terms .............................................................................................................. 23

**2 OBJECTIVES**

2.1 Primary ......................................................................................................................... 24
2.2 Secondary ....................................................................................................................... 24

**3 BACKGROUND AND RATIONALE**

3.1 Disease .......................................................................................................................... 25
3.2 GWP42003-P Background ........................................................................................... 28
3.3 Rationale ....................................................................................................................... 29
3.3.1 Selection of Study Dose .............................................................................................. 29
3.4 Clinical Hypothesis .................................................................................................... 30

**4 EXPERIMENTAL PLAN**

4.1 Study Design .................................................................................................................. 31
4.1.1 Primary Endpoint ...................................................................................................... 31
4.1.2 Secondary Endpoint(s) ............................................................................................. 31
4.2 Number of Centers ....................................................................................................... 32
4.3 Number of Patients ....................................................................................................... 32

**5 INVESTIGATIONAL MEDICINAL PRODUCT**

5.1 GWP42003-P Oral Solution ......................................................................................... 33
5.2 Placebo Oral Solution .................................................................................................. 33
5.3 Packaging, Storage and Drug Accountability ............................................................ 33
5.3.1 Packaging and Labelling ........................................................................................ 33
5.3.2 Storage ..................................................................................................................... 34
5.3.3 Supply and Return of Investigational Medicinal Product ..................................... 34
9.1.11.5 Cognitive Assessment Battery ................................................................. 50
9.1.11.6 Vineland Adaptive Behavior Scales (Second Edition) .............................. 51
9.1.11.7 Columbia-Suicide Severity Rating Scale (Children’s) .................................. 51
9.1.11.8 Caregiver Impression of Investigational Medicinal Product Palatability ................................................................. 51
9.1.11.9 Cannabis Withdrawal Scale ....................................................................... 52
9.1.12 Patient Diary .............................................................................................. 52
9.1.13 Investigational Medicinal Product Accountability ........................................... 52
9.1.14 Adverse Events ........................................................................................... 53
9.1.15 Monitoring of Drug Abuse Liability (for Patients 12 Years of Age and Older) ........................................................................................................... 53
9.1.15.1 Monitoring of Adverse Events ..................................................................... 54
9.1.15.1.1 List of ‘Triggering Adverse Events of Interest’ ........................................ 54
9.1.15.1.2 Supplemental Adverse Event Form .......................................................... 54
9.1.15.2 Monitoring Drug Accountability Discrepancies ........................................ 55
9.1.15.2.1 List of ‘Triggering Drug Accountability Discrepancies’ .............................. 55
9.1.15.2.2 Supplemental Drug Accountability Form ............................................... 55
9.1.15.3 Site Classification Form ............................................................................. 56
9.1.15.4 Study Medication Use and Behavior Survey ................................................. 56
9.1.15.5 Adjudication Committee: Assessment of Abuse Potential of GWP420003-P .............................................................................................................. 56
9.2 Study Procedures by Visit .................................................................................. 59
9.2.1 Visit 1 (Day −28, Screening) .......................................................................... 59
9.2.2 Visit 2 (Day 1, Randomization) ....................................................................... 60
9.2.3 Visit 3 (Day 15) ............................................................................................ 61
9.2.4 Visit 4 (Day 29) ............................................................................................ 61
9.2.5 Visit 5 (Day 43, Safety Telephone Call) ............................................................. 62
9.2.6 Visit 6 (Day 57) ............................................................................................. 62
9.2.7 Visit 7 (Day 71, Safety Telephone Call) ............................................................. 62
9.2.8 Visit 8 (Day 99, End of Treatment) ................................................................. 63
9.2.9 Visit 9 (Day 100–106 or Day 109, End of Taper Period) .................................... 64
9.2.10 Visit 10 (Day 137, Safety Follow-Up) ............................................................. 64
9.2.11 Safety Telephone Calls ................................................................................. 65
10 WITHDRAWAL .................................................................................................... 66
11 URGENT SAFETY MEASURES ................................................... 68

12 ADVERSE EVENT REPORTING ............................................. 69

  12.1 Definitions ........................................................................ 69
  12.1.1 Adverse Event ............................................................... 69
  12.1.2 Investigator .................................................................... 69
  12.2 Serious Adverse Events ..................................................... 69
  12.3 Reporting Procedures for Serious Adverse Events ............... 70
  12.3.1 Potential Cases of Drug-Induced Liver Injury .................... 71
  12.4 Pregnancy ...................................................................... 71
  12.5 Causality Assessment ....................................................... 71
  12.6 Reporting Procedures for All Adverse Events ..................... 72
  12.7 Follow-up Procedures for Adverse Events ......................... 74
  12.8 Reporting Clinically Significant Laboratory Results ............ 74
  12.9 Notification of Safety Information to Investigators, Regulatory
       Authorities and Ethics Committees ....................................... 75

13 STATISTICAL CONSIDERATIONS ......................................... 77

  13.1 Sample Size, Power and Significance Levels ...................... 77
  13.2 Interim Analysis ............................................................... 77
  13.3 Analysis Sets .................................................................... 77
  13.3.1 Protocol Deviations ...................................................... 78
  13.4 General Considerations .................................................... 78
  13.5 Accountability and Background Characteristics .................. 78
  13.5.1 Enrollment and Disposition .......................................... 78
  13.5.2 Baseline and Demographic Characteristics ..................... 78
  13.5.3 Medical History ........................................................... 78
  13.5.4 Concomitant Medication .............................................. 79
  13.6 Endpoints and Statistical Methods ..................................... 79
  13.6.1 Evaluable Period .......................................................... 79
  13.6.2 Primary Endpoint(s) ...................................................... 80
  13.6.3 Secondary Endpoint(s) .................................................. 80
  13.6.4 Handling of Missing Data ............................................. 81
  13.6.5 Safety ......................................................................... 82
  13.6.5.1 Treatment Compliance and Extent of Treatment Exposure 82
13.6.5.2 Adverse Events
13.6.5.3 Clinical Laboratory Data
13.6.5.4 Vital Signs, 12-lead Electrocardiogram, Physical Examination, Columbia-Suicide Severity Rating Scale and Other Safety Data

14 DATA SAFETY MONITORING COMMITTEE

15 REGULATORY AND ETHICAL OBLIGATIONS

15.1 Declaration of Helsinki
15.2 Informed Consent/Assent
15.3 Institutional Review Board/Ethics Committee
15.4 Pre-Study Documentation Requirements
15.5 Patient Confidentiality

16 ADMINISTRATIVE AND LEGAL OBLIGATIONS

16.1 Protocol Amendments and End of Study or Termination
16.2 Study Documentation and Storage
16.3 Study Monitoring and Data Collection
16.4 Electronic Data collected by Interactive Voice Response System
16.5 Quality Assurance
16.6 Compensation
16.7 Publication Policy
16.8 Intellectual Property Rights
16.9 Confidential Information

17 REFERENCES

Appendix 2.1 Investigator Details
Appendix 2.2 Sponsor Contact Details
# Table of Appendices

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPENDIX 1</td>
<td>Schedule of Assessments</td>
<td>100</td>
</tr>
<tr>
<td>APPENDIX 2</td>
<td>Study Personnel</td>
<td>102</td>
</tr>
<tr>
<td>Appendix 2.1</td>
<td>Investigator Details</td>
<td>102</td>
</tr>
<tr>
<td>Appendix 2.2</td>
<td>Sponsor Contact Details</td>
<td>102</td>
</tr>
</tbody>
</table>
List of In-text Tables

378  Table 5.1-1  Formulation of GWP42003-P Oral Solution .......................... 33
379  Table 5.2-1  Formulation of Placebo Oral Solution .................................... 33
380  Table 9.1-1  Hematology, Biochemistry, Urinalysis and THC Screen .......... 47
381  Table 9.1-2  Neuropsychological Protocol for Epilepsy Patients
               Treated with Cannabidiol - Patient Measures .............................. 50
382  Table 9.1-3  Neuropsychological Protocol for Epilepsy Patients
               Treated with Cannabidiol - Parent Measures ............................... 50
List of In-text Figures

392 Figure 1-1 Study Design and Treatment Schema ........................................... 12
393 Figure 9-1 Flow Diagram for Identifying and Evaluating Clinical
394 Trial Adverse Event Data Through Systematic
395 Categorization, Tabulation and Analysis which can
396 Illuminate an Abuse Potential Signal (for Patients 12
397 Years of Age and Older) ........................................................................ 58
## List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AEDs</td>
<td>Antiepileptic drugs</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>CBD</td>
<td>Cannabidiol</td>
</tr>
<tr>
<td>CGIC</td>
<td>Caregiver Global Impression of Change</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence Interval</td>
</tr>
<tr>
<td>CIOMS</td>
<td>Council for International Organizations of Medical Sciences</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CRO</td>
<td>Contract Research Organization</td>
</tr>
<tr>
<td>C-SSRS</td>
<td>Columbia-Suicide Severity Rating Scale</td>
</tr>
<tr>
<td>CWS</td>
<td>Cannabis Withdrawal Scale</td>
</tr>
<tr>
<td>DS</td>
<td>Dravet syndrome</td>
</tr>
<tr>
<td>DSMC</td>
<td>Data Safety Monitoring Committee</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics Committee</td>
</tr>
<tr>
<td>ECG</td>
<td>12-lead Electrocardiogram</td>
</tr>
<tr>
<td>EDSS</td>
<td>Epworth Daytime Sleepiness Scale</td>
</tr>
<tr>
<td>EEG</td>
<td>Electroencephalogram</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>GW</td>
<td>GW Research Ltd</td>
</tr>
<tr>
<td>GWP</td>
<td>GW Pharma Ltd</td>
</tr>
<tr>
<td>IB</td>
<td>Investigator Brochure</td>
</tr>
<tr>
<td>ICH GCP</td>
<td>International Conference on Harmonization Tripartite Guideline for Good Clinical Practice</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>INR</td>
<td>International Normalized Ratio</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional Review Board</td>
</tr>
<tr>
<td>ITT</td>
<td>Intention to Treat</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive Voice Response System</td>
</tr>
<tr>
<td>LOCF</td>
<td>Last Observation Carried Forward</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>MMRM</td>
<td>Mixed-Effect Model Repeated Measures</td>
</tr>
<tr>
<td>0–10 NRS</td>
<td>0–10 Numerical Rating Scale</td>
</tr>
<tr>
<td>OLE</td>
<td>Open label extension</td>
</tr>
<tr>
<td>PI</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>PP</td>
<td>Per Protocol</td>
</tr>
<tr>
<td>PVD</td>
<td>Pharmacovigilance Department</td>
</tr>
<tr>
<td>QOLCE</td>
<td>Quality of Life in Childhood Epilepsy</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>SCN1A</td>
<td>Voltage-gated sodium channel α1 subunit gene</td>
</tr>
<tr>
<td>SMEI</td>
<td>Severe Myoclonic Epilepsy in Infancy</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reaction</td>
</tr>
<tr>
<td>TBL</td>
<td>Total Bilirubin</td>
</tr>
<tr>
<td>THC</td>
<td>Δ⁹-tetrahydrocannabinol</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper limit of normal</td>
</tr>
<tr>
<td>Vineland-II</td>
<td>Vineland Adaptive Behavior Scales, Second Edition</td>
</tr>
<tr>
<td>VNS</td>
<td>Vagus Nerve Stimulation</td>
</tr>
</tbody>
</table>
### Definition of Terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>The 28-day period from screening (Visit 1 [Day −28]) to randomization (Visit 2 [Day 1]).</td>
</tr>
<tr>
<td>Day 1</td>
<td>The day a patient first receives investigational medicinal product or placebo.</td>
</tr>
<tr>
<td>End of treatment</td>
<td>Completion of the treatment period (Visit 8 [Day 99]) or withdrawal.</td>
</tr>
<tr>
<td>End of study</td>
<td>Completion of the Clinical Study Report.</td>
</tr>
<tr>
<td>High Dose Level</td>
<td>The maximum target dose of GW42003-P as determined by the Data Safety Monitoring Committee of study GWEP1332 Part A (up to 20 mg/kg/day), or equivalent volume of placebo.</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product (Study Medication). Used to describe both investigational active product and reference therapy (placebo).</td>
</tr>
<tr>
<td>INR</td>
<td>International Normalized Ratio is a calculation made to standardize prothrombin time.</td>
</tr>
<tr>
<td>Investigator</td>
<td>Study Principal Investigator or a formally delegated study physician.</td>
</tr>
<tr>
<td>Low Dose Level</td>
<td>50% of the High Dose Level of GW42003-P, or equivalent volume of placebo.</td>
</tr>
</tbody>
</table>
2  OBJECTIVES

2.1  Primary

To assess the efficacy of GWP42003-P as an adjunctive antiepileptic treatment compared with placebo, with respect to the percentage change from baseline during the maintenance period of the study in convulsive seizure frequency. The dose response effect between two GWP42003-P Dose Levels and placebo will also be explored. Convulsive seizures are defined as tonic-clonic, tonic, clonic or atonic and non-convulsive seizures as myoclonic, partial or absence.

2.2  Secondary

- To assess changes from baseline in non-convulsive seizure frequency, usage of rescue medication, number of inpatient hospitalizations due to epilepsy, sleep disruption, daytime sleepiness, quality of life and conduct behavioral and cognitive assessments in patients taking GWP42003-P as an adjunctive treatment, when compared with placebo.

- To assess the safety of both GWP42003-P doses when compared with placebo.
3 BACKGROUND AND RATIONALE

3.1 Disease

Dravet syndrome (DS), also known as Severe Myoclonic Epilepsy in Infancy (SMEI), is a rare form of severe epilepsy with onset in early childhood. It has an incidence of less than one per 40,000 and accounts for 1.4% of epilepsies in children aged <15 years\textsuperscript{1, 2, 3}. DS is characterized by a variety of treatment-resistant seizures (febrile and afebrile, generalized and unilateral, clonic or tonic-clonic) that occur in the first year of life and has a poor cognitive prognosis. Onset usually occurs between four and eight months of age and manifests typically as a prolonged (>15 min) clonic, generalized or unilateral convulsive seizure, often triggered by fever, that can evolve into status epilepticus\textsuperscript{4, 5, 6}. After a typical period of two weeks to two months, further febrile seizures occur and afebrile seizures also appear. In addition to convulsive seizures, other seizure types appear between the ages of one and four years, including myoclonic seizures, focal seizures, atypical absences and obtundation statuses (in which consciousness is impaired). Significant developmental delay becomes apparent from the second year onwards and associated neuropsychological disturbances, such as attention deficit/hyperactivity disorder, are common. Beyond five years of age, convulsive seizures decrease but persist and occur mainly in sleep. Myoclonic and absence seizures tend to disappear and focal seizures either persist or decrease. Although psychomotor development and behavior tend to improve over time, cognitive impairment persists throughout the patient’s lifetime\textsuperscript{4, 5, 6}.

Myoclonic seizures are a defining characteristic of DS and can be massive, predominantly involving axial muscles, or erratic/segmental, which are mainly limited to the distal limbs and face. Massive myoclonic seizures are often associated with electroencephalogram (EEG) paroxysms and can be variable in intensity, with outcomes ranging from falling (drop attack) to causing only small, saccadic movements of the head, shoulders or trunk\textsuperscript{4, 5, 6}. Erratic myoclonic seizures do not have an EEG correlate and are typically mild in intensity, although they can affect fine motor coordination. Some patients with DS experience both massive and erratic myoclonic seizures, yet these seizures can be absent in some DS patients. Such cases are defined as “borderline” SMEI and may have different EEG features to typical SMEI, although the course and outcome of the disease remain the same\textsuperscript{2, 6, 7}.

Genetic analyses have revealed that more than 70% of patients with DS have mutations in the voltage-gated sodium channel \(\alpha_1\) subunit gene (\textit{SCN1A})\textsuperscript{8, 9, 10, 11, 12, 13}. \textit{SCN1A} encodes the pore-forming subunit of the Na\textsubscript{v}1.1 voltage-gated sodium
channel and there are currently more than 700 published SCN1A mutations, 90% of which occur in DS patients. Approximately two-thirds of these mutations give rise to truncations while the remaining third are missense mutations that are predicted to severely impair channel function. In addition, intragenic and whole gene deletions of SCN1A as well as deletions within the 5’ promoter sequence have also been identified in DS patients that are otherwise SCN1A-mutation-negative. Most SCN1A mutations in DS patients arise de novo, although approximately 5% of cases involve inheritance of familial SCN1A mutations from a mildly affected parent. In familial cases of DS, the phenotype and severity of epilepsy can be clinically variable among family members carrying the same SCN1A mutation. This heterogeneity is proposed to be due to variable familial expression of SCN1A mutations, mediated either by SCN1A mosaicsims or by the genetic and environmental background. Candidate modifier genes currently include SCN9A (encoding the pore-forming subunit of the Nav1.7 voltage-gated sodium channel) and CACNB4 (encoding the β4 auxiliary subunit of high-voltage activated calcium channels), variants of which have been found in DS patients with SCN1A mutations. Mouse models in which SCN1A is either mutated or knocked out have demonstrated that the α1 subunit is critical for the excitability and in vivo function of inhibitory hippocampal and cortical interneurons. Reduced firing of these inhibitory interneurons would compromise network inhibition and cause a hyperexcitable gain-of-function effect that may underlie the severe epilepsy seen in DS. Moreover, SCN1A mutant mice reproduce the characteristic temperature- and age-dependent seizures and EEG paroxysms observed in DS, although the phenotypic variability of DS patients with SCN1A mutations remains unexplained.

More than 20% of patients with DS have no detectable mutations in SCN1A and it is possible that many of these patients harbor mutations in regulatory elements located outside coding regions. Familial and de novo mutations of PCDH19 (encoding protocadherin 19) have been reported in a subset of SCN1A-mutation-negative DS patients and it is estimated that PCDH19 mutations could account for 5% of all DS cases. Additional genes in which mutations cause DS include GABRG2 (encoding the γ2 subunit of γ-aminobutyric acid-A receptors), SCN1B (encoding the β1 auxiliary subunit of voltage-gated sodium channels) and SCN2A (encoding the pore-forming subunit of the Nav1.2 voltage-gated sodium channel), although very few cases have been reported.
DS is one of the most pharmacoresistant forms of epilepsy, with all seizure types extremely refractory to conventional antiepileptic drugs (AEDs), especially during the first several years. Sodium valproate is often used to prevent the initial recurrent convulsive febrile seizures and benzodiazepines (e.g., diazepam, midazolam, clonazepam or clobazam) are frequently co-administered to limit the duration of long-lasting seizures. In most cases however, the relief provided by these agents is insufficient\textsuperscript{33, 34}. Certain AEDs can paradoxically worsen seizures in DS patients, namely lamotrigine, carbamazepine and vigabatrin, and the use of certain barbiturates at high doses is associated with a poor outcome\textsuperscript{35, 36, 37}. Potassium bromide can be effective at controlling convulsive status epilepticus and was found to be the most efficacious AED in a Japanese cohort of DS patients\textsuperscript{38}. A study of DS patients treated with potassium bromide as adjunctive therapy showed a reduction in seizures in 81\% of patients in the first three months, with 30\% becoming seizure-free\textsuperscript{39}. However, this compound has no effect on focal and tonic seizures and any initial efficacy is often not maintained long-term\textsuperscript{34, 39}.

To date, the only AED that has proved efficacious in the majority of DS patients in placebo-controlled, double-blind trials is stiripentol\textsuperscript{40, 41, 42}. In these studies, stiripentol was administered as adjunctive therapy to sodium valproate and clobazam. At least two thirds of patients experienced a >50\% reduction in seizure frequency in the stiripentol arms of these studies versus <10\% of patients in the placebo arms\textsuperscript{40, 41}. A subsequent meta-analysis of these studies showed that stiripentol reduced the overall seizure rate by 70\%\textsuperscript{42}. Both the frequency and duration of seizures remained significantly reduced at a median of 2.9 years follow-up, with the greatest efficacy observed in infants\textsuperscript{36}. Both short-term and long-term benefits of stiripentol as adjunctive therapy have also been demonstrated in an open-label study of Japanese DS patients, with responder rates of 61\% and 48\% at six weeks and six months, respectively\textsuperscript{43}. Stiripentol is generally well tolerated and can improve seizure control in DS patients receiving pharmacotherapy other than valproate and/or clobazam\textsuperscript{43, 44}.

Topiramate and levetiracetam are two further AEDs that have undergone preliminary trials as adjunctive therapy in DS patients. In three open-label studies, more than half of patients receiving topiramate as add-on therapy achieved >50\% reduction in seizure frequency, with 17\% becoming seizure-free for at least four months in all cases\textsuperscript{45, 46, 47}. Similar results were demonstrated in a single open-label trial of levetiracetam, with 64\% of patients experiencing >50\% reduction in tonic-clonic seizures at 12 weeks\textsuperscript{48}. Although these new AEDs appear promising, larger
randomized placebo-controlled studies are required to accurately assess their efficacy in the treatment of DS. Non-pharmacological treatments of DS that have demonstrated benefit as adjunctive therapy to AEDs include vagus nerve stimulation (VNS)\textsuperscript{49, 50} and the introduction of a ketogenic diet\textsuperscript{51, 52, 53, 54}. Despite the therapies listed above, DS remains one of the most pharmacoresistant epilepsy syndromes. Consequently, there is a clear need for new, efficacious, pharmaceutical treatments.

### 3.2 GWP42003-P Background

The cannabis plant (\textit{Cannabis sativa} L.) produce trichomes that synthesize a large number of pharmacologically active compounds called phytocannabinoids. The most abundant of these are $\Delta^9$-tetrahydrocannabinol (THC) and cannabidiol (CBD), although the amounts and proportions of the various phytocannabinoids in each plant vary by strain and can be adjusted by breeding.

The Investigational Medicinal Product (IMP), GWP42003-P, is formulated from extracts prepared from \textit{Cannabis sativa} L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (>95%) CBD that typically contains less than 0.5% (w/w) THC. The pure CBD is subsequently dissolved in excipients with added sweetener and flavoring.

The pharmacological effects of phytocannabinoids are thought to be mediated primarily via their interaction with the endocannabinoid system, which consists of cannabinoid receptors, endogenous ligands (endocannabinoids) and enzymes for endocannabinoid synthesis and degradation. Two G-protein-coupled receptors for cannabinoids have so far been identified, designated cannabinoid CB\textsubscript{1} and CB\textsubscript{2} receptors. CBD does not bind to either of these receptors with any great affinity but does modulate the metabolizing enzymes of the endocannabinoid system. CBD also affects conduction of ion channels and acts on other G-protein-coupled receptors such as the transient receptor potential channel TRPV1\textsuperscript{55} and the orphan receptor GPR55\textsuperscript{56}.

Importantly, CBD lacks detectable psychoactivity as found with THC. Further to this, CBD has demonstrated anticonvulsant, antipsychotic, anxiolytic, neuroprotective, antioxidant and anti-inflammatory activity\textsuperscript{57}. Very little data concerning adverse events (AEs) of CBD in humans exists to date. However, doses of up to 1500 mg CBD per day are reported to be well tolerated in humans\textsuperscript{58}.
3.3 Rationale

Given the limitations of current synthetic AEDs, it has been hypothesized that CBD can be tested for efficacy in children with pharmacoresistant epilepsy. A recent parent survey has reported that 84% of children with treatment-resistant epilepsy experienced a reduction in seizures while taking CBD-enriched cannabis, with over half of those reporting >80% reduction in seizure frequency. The majority of children had been diagnosed with DS, two thirds of which experienced ≥50% reduction in seizure frequency with one patient (8.3%) achieving complete seizure freedom. The CBD-enriched cannabis was behaviorally well tolerated and children often experienced improved sleep, increased alertness, and better mood.

The primary objective of this study is to evaluate the efficacy of GWP42003-P as an adjunctive antiepileptic treatment compared with placebo, with respect to the percentage change from baseline during the maintenance period of the study in convulsive seizure frequency, in children and young adults with DS. The dose response effect between two GWP42003-P Dose Levels and placebo will also be explored. Additional objectives include evaluating changes from baseline in non-convulsive seizure frequency, usage of rescue medication, number of inpatient hospitalizations due to epilepsy, sleep disruption, daytime sleepiness, cognitive function, quality of life and adaptive behaviors in patients taking GWP42003-P in combination with AEDs compared with placebo. These endpoints are among those recommended by the European Medicines Agency guideline on clinical investigation of medicinal products in the treatment of epileptic disorders.

3.3.1 Selection of Study Dose

Doses up to 800 mg CBD per day for up to eight weeks have been well tolerated in adults in GW Research Ltd (GW) clinical study GWMD09112, which, assuming an average weight of 70 kg, equates to 11.4 mg/kg. In the literature, doses of CBD have been given up to 1500 mg CBD per day for four weeks in adults, which, in a 70 kg human, equates to a daily dose of 21.4 mg/kg CBD.

GWP42003-P is currently being used by physicians for treatment of patients with intractable epilepsy resulting from a variety of etiologies in two open Individual Expanded Access Investigational New Drug (IND) studies and five open Intermediate Expanded Access IND studies. In the ongoing Individual Expanded Access IND studies, the initial dosing has been cautious (100 mg [morning] + 150 mg [afternoon/evening]), progressively increasing to 400 mg CBD/day; doses up to
22 mg/kg per day have been well tolerated in an individual pediatric patient. The Sponsor is not aware of any safety issues arising from the dosing used in the Individual Expanded Access INDs. Treatment is expected to begin imminently in the Intermediate Expanded Access INDs. Based on the above, a daily maximum dose of 20 mg/kg CBD (given as two divided doses) was selected for the phase two/three study in patients with DS (GWEP1332). At the end of Part A of the GWEP1332 study a Data Safety Monitoring Committee (DSMC) will recommend the target dose and titration schedule for all subsequent studies, including this study (GWEP1424). The maximum dose patients can receive during the maintenance phase will be 20 mg/kg/day. During the maintenance phase, investigators may decrease the dose if a patient experiences intolerance. Patients whose dose has been decreased can have their dose increased again, if the tolerability improves.

3.4 Clinical Hypothesis

Pre-clinical studies have shown CBD to have anti-seizure and antiepileptic activity in a range of models. Anecdotal evidence and some literature reports\(^{60}\) suggest that CBD is an effective AED in children with DS as discussed in Section 3.3. The hypothesis underlying this study is that CBD has a positive risk/benefit outcome in the adjunctive treatment of DS.
4 EXPERIMENTAL PLAN

4.1 Study Design

This study is a 1:1:1 randomized, double-blind, 14-week comparison of two Dose Levels of GWP42003-P versus placebo (40 patients per treatment group). The treatment period will consist of a two-week titration period followed by a 12-week maintenance period. The treatment period will be followed by a 10-day taper period and a four-week follow-up period. The study will aim to determine the efficacy, safety and tolerability of two Dose Levels of GWP42003-P compared with placebo. The High Dose Level will be as recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332. The Low Dose Level will be defined as 50% of the High Dose Level. Patients in the placebo group will be split into two equivalent cohorts; half receiving Low Dose Level dosing volumes and half receiving High Dose Level dosing volumes. The first patient will not enroll into this study until the DSMC has reviewed the safety data from Part A of study GWEP1332.

Following study completion, all patients will be invited to continue to receive GWP42003-P in an open label extension (OLE) study (under a separate protocol).

A study schema (Figure 1-1), presented at the end of Section 1, depicts the overall study design. More detailed information on treatment and study procedures is provided in Section 8 and Section 9, respectively.

4.1.1 Primary Endpoint

The primary endpoint is the mean percentage change from baseline in convulsive seizure frequency during the maintenance period (Day 15 to the end of the evaluable period) in patients taking GWP42003-P compared with placebo.

4.1.2 Secondary Endpoint(s)

The following endpoints will be compared between the three treatment groups over the 12-week, double-blind maintenance period:

- Number of patients experiencing a >25% worsening, −25 to +25% no change, 25–50% improvement, 50–75% improvement or >75% improvement in convulsive seizures from baseline.
- Number of patients who are convulsive seizure free.
- Percentage changes from baseline in non-convulsive seizure frequency.
• Change in types of seizures.
• Changes from baseline in usage of rescue medication.
• Changes from baseline in number of inpatient hospitalizations due to epilepsy.
• Changes from baseline in Sleep Disruption 0–10 Numerical Rating Scale (0–10 NRS) score.
• Changes from baseline in Epworth Daytime Sleepiness Scale (EDSS) score.
• Changes from baseline in number of inpatient hospitalizations due to epilepsy.
• Changes from baseline in Sleep Disruption 0–10 Numerical Rating Scale (0–10 NRS) score.
• Changes from baseline in Epworth Daytime Sleepiness Scale (EDSS) score.
• Changes from baseline in the Quality of Life in Childhood Epilepsy (QOLCE) score.
• Change in cognitive function as measured with a cognitive assessment battery.
• Changes from baseline in the Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) score.
• Caregiver Global Impression of Change (CGIC).

The safety profile of GWP42003-P compared with placebo will also be assessed at each Dose Level by measuring:

• AEs.
• Vital signs.
• Physical examination parameters.
• 12-lead Electrocardiogram (ECG).
• Laboratory parameters.
• Columbia-Suicide Severity Rating Scale (C-SSRS) score.
• Cannabis Withdrawal Scale (CWS) score.
• Abuse liability.

4.2 Number of Centers

Approximately 30 centers are expected to participate in this study.

4.3 Number of Patients

If patients fail screening they will be replaced until the target numbers of patients are achieved.

A total of 120 patients will be enrolled. The 120 patients will be randomly allocated to receive one of two Dose Levels of active IMP or placebo on a 1:1:1 basis (40 patients per treatment group).

The sample size calculation is explained fully in Section 13.1.
5 INVESTIGATIONAL MEDICINAL PRODUCT

Please refer to the separate Pharmacy Manual for more detailed information on the IMP.

5.1 GWP42003-P Oral Solution

GWP42003-P oral solution is presented as an oily solution containing 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring (Table 5.1-1).

Table 5.1-1 Formulation of GWP42003-P Oral Solution

<table>
<thead>
<tr>
<th>Material</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBD</td>
<td>100 mg/mL</td>
</tr>
<tr>
<td>Anhydrous ethanol</td>
<td>79 mg/mL</td>
</tr>
<tr>
<td>Sucralose</td>
<td>0.5 mg/mL</td>
</tr>
<tr>
<td>Strawberry flavoring</td>
<td>0.2 mg/mL</td>
</tr>
<tr>
<td>Sesame oil</td>
<td>make up to 1 mL</td>
</tr>
</tbody>
</table>

5.2 Placebo Oral Solution

Placebo oral solution contains the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring (Table 5.2-1).

Table 5.2-1 Formulation of Placebo Oral Solution

<table>
<thead>
<tr>
<th>Material</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anhydrous ethanol</td>
<td>79 mg/mL</td>
</tr>
<tr>
<td>Sucralose</td>
<td>0.5 mg/mL</td>
</tr>
<tr>
<td>Strawberry flavoring</td>
<td>0.2 mg/mL</td>
</tr>
<tr>
<td>Sesame oil</td>
<td>make up to 1 mL</td>
</tr>
</tbody>
</table>

5.3 Packaging, Storage and Drug Accountability

5.3.1 Packaging and Labelling

The IMP will be manufactured and packaged by GW Pharma Ltd (GWP). It will be distributed by GWP or delegated contractors. The IMP will be presented in 100 mL amber glass bottles with child-resistant caps and packed in cartons. Sufficient IMP will be dispensed at each relevant visit considering the dose group and weight of each patient. A unique pack identification number will be used to identify each box and the medication it contains. The pack numbers will cross check with the batch numbers held at GWP and the IMP information held on the Interactive Voice Response System (IVRS). GWP will ensure that all IMP provided is fully labelled.
and packaged. Label text will comply with European Union (EU) guidance on Good Manufacturing Practice, Annex 13 Labelling. In addition, any local country requirements in accordance with local Drug Law or Regulatory Requirement will be included in the final label text.

Directions of use, name, address, telephone number of investigator or main contact for information about the product or the clinical trial will be provided separately to the patient.

5.3.2 Storage

The IMP must be stored upright at room temperature (<30°C) and must not be refrigerated or frozen. It must also be kept away from heat and direct sunlight.

The IMP must be stored in compliance with the local regulations for a controlled drug (if applicable to country). The sponsor must approve storage location and facilities.

Should storage conditions deviate from these specified requirements, the GW study monitor should be contacted immediately to confirm if the IMP remains suitable for use. IMP should be placed under quarantine until confirmation is received that IMP is suitable for use.

Temperature records of the storage location must be maintained on a daily basis (a minimum of Monday–Friday, excluding public holidays) from date of receipt of first shipment until end of study dispensing period at each site. These records must contain at least the minimum and maximum daily temperatures and should be made available to the appropriate GW personnel for review throughout the study.

5.3.3 Supply and Return of Investigational Medicinal Product

Once a site has been activated via the IVRS at study initiation, IMP will be shipped to a responsible person, such as the pharmacist, at the investigator’s center, who will check the amount received (against the IVRS Shipment Request) and the condition of the drug. Details of the IMP received will be recorded in the IMP accountability record (see Section 5.3.4). The site will acknowledge IMP receipt via the IVRS and will complete any receipt forms required. IMP will be dispensed and returned as detailed in Section 8.4 with further IMP shipments to be initiated by the IVRS. As directed, all supplies, including unused, partially used, or empty containers, will be returned to GWP or destroyed at the center if agreed in writing by the study monitor.
5.3.4 Investigational Medicinal Product Accountability

The investigator has overall responsibility for the accountability of all used and unused IMP. A drug accountability record for the IMPs must be kept current and should contain:

- The dates and quantities of IMP received from GWP.
- Patient’s identification.
- Date and quantity of IMP dispensed.
- The initials of the dispenser.
- Date and quantity of IMP returned to the investigator/pharmacy.

A record of returned IMP must be completed and included in the shipment of used and unused IMP to GWP. At the end of the study a record/statement of reconciliation must be completed and provided to GWP.

These inventories must be made available for inspection by an authorized GW or GWP representative and local officials or regulatory agency inspectors.

Please refer to the separate Pharmacy Manual for more detailed information on the IMP.
6 PATIENT ELIGIBILITY

Investigators will be required to maintain a log that includes limited information about all screened patients (initials, age, gender; as allowed per local regulations) and outcome of screening.

6.1 Inclusion Criteria

For inclusion in the study, patients must fulfil ALL of the following criteria:

6.1.1 Patient and/or parent(s)/legal representative must be willing and able to give informed assent/consent for participation in the study (see Section 15.2).

6.1.2 Patient and their caregiver must be willing and able (in the investigator’s opinion) to comply with all study requirements.

6.1.3 Patient must be male or female aged between two and 18 years (inclusive).

6.1.4 Patient must have a documented history of DS which is not completely controlled by current AEDs.

6.1.5 Patient must be experiencing four or more convulsive seizures (i.e., tonic-clonic, tonic, clonic, atonic seizures) during the 28-day baseline observation period.

6.1.6 Patient must be taking one or more AEDs at a dose which has/have been stable for at least four weeks.

6.1.7 All medications or interventions for epilepsy (including ketogenic diet and VNS) must have been stable for four weeks prior to screening and patient and caregiver are willing to maintain a stable regimen throughout the study.

6.1.8 Patient and/or parent(s)/legal representative is willing to allow his or her primary care practitioner and consultant to be notified of participation in the study.

6.2 Exclusion Criteria

The patient may not enter the study if ANY of the following apply:

6.2.1 Patient has clinically significant unstable medical conditions other than epilepsy.

6.2.2 Patient has had clinically relevant symptoms or a clinically significant illness in the four weeks prior to screening or randomization, other than epilepsy.

6.2.3 Patient has clinically significant abnormal laboratory values, in the investigator’s opinion, at screening or randomization.
6.2.4 Patient has clinically relevant abnormalities in the ECG measured at screening or randomization.

6.2.5 Patient has any concurrent cardiovascular conditions which will, in the investigator’s opinion, interfere with the ability to assess their ECGs.

6.2.6 Patient has a history or presence of alcohol or substance abuse within the last two years prior to the study or daily consumption of five or more alcohol-containing beverages.

6.2.7 Patient is currently using, or has in the past used, recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the three months prior to study entry and is unwilling to abstain for the duration of the study.

6.2.8 Patient has a history of symptoms (e.g., dizziness, light-headedness, blurred vision, palpitations, weakness, syncope) related to a drop in blood pressure due to postural changes.

6.2.9 Patient has ingested alcohol in the 24-hour period prior to the first study visit and/or is unwilling to abstain from drinking alcohol throughout the treatment period.

6.2.10 Patient has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMPs (e.g., sesame oil).

6.2.11 Female patient is of child bearing potential or male patient’s partner is of child bearing potential; unless willing to ensure that they or their partner use effective contraception, for example oral contraception, double barrier, intra-uterine device, during the study and for three months thereafter (however a male condom should not be used in conjunction with a female condom).

6.2.12 Female patient is pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter.

6.2.13 Patient has been part of a clinical trial involving another IMP in the previous six months.

6.2.14 Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, may influence the result of the study, or affect the patient’s ability to participate in the study.

6.2.15 Patient has significantly impaired hepatic function at screening (Visit 1) or randomization (Visit 2) (Alanine aminotransferase [ALT] >5 × upper limit of normal [ULN] or total bilirubin [TBL] >2 × ULN) OR the ALT or Aspartate aminotransferase (AST) >3 × ULN and (TBL >2 × ULN or international normalized ratio [INR] >1.5). This criterion can only be confirmed once the laboratory results are available; patients randomized into the study who are later found not to meet this criterion should be withdrawn from the study.

6.2.16 Following a physical examination the patient has any abnormalities that, in the opinion of the investigator, would prevent the patient from safe participation in the study.
6.2.17 Patient is unwilling to abstain from donation of blood during the study.
6.2.18 There are plans for the patient to travel outside their country of residence during the study.
6.2.19 Patient has previously been randomized into this study.
6.2.20 Any history of suicidal behavior or any suicidal ideation of type four or five on the C-SSRS at screening.
7 PATIENT ENROLLMENT

Before patients may be entered into the study, GW requires a copy of the relevant center’s Ethical Committee (EC) or Institutional Review Board (IRB) written approval of the protocol, informed consent/assent forms and other patient information material. Patients will be considered enrolled in the study from the time of providing written informed consent/assent. All patients and/or parent(s)/legal representatives, where appropriate, must personally sign and date the consent/assent form prior to any procedures being performed (refer to Section 9.1.1 and Section 15.2).

7.1 Treatment Assignment

At the start of Visit 1, a screening number will be assigned to each patient using an IVRS. After completion of assessments and confirmation of eligibility at Visit 2, patients will be assigned a unique patient number (to be used for the remaining duration of the study) and randomly allocated to one of two Dose Levels of GWP42003-P or placebo using the IVRS. GWP will provide all IMP in a packed and labelled state and the IVRS will identify the pack number to be dispensed to the patient at each visit, according to the treatment assigned in the randomization schedule.

7.2 Randomization

The allocation of IMP to treatment number will be done according to a randomization schedule produced by an independent statistician. The randomization schedule will be held centrally and not divulged to any other person involved in the study until the database has been locked and unblinding authorized by the relevant GW personnel.
8 TREATMENT PROCEDURES

8.1 Investigational Medicinal Product Dosage, Administration and Schedule

The IMP will be presented as an oral solution containing either the active pharmaceutical ingredient and excipients (in the case of GWP42003-P) or only excipients (in the case of placebo). For details regarding IMP formulations, see Section 5.

The IMP will consist of two types of medication:

- GWP42003-P Oral Solution containing 100 mg/mL CBD.
- Placebo Oral Solution containing excipients.

Patients will be assigned one of two Dose Levels of active IMP or placebo on a 1:1:1 basis (40 patients per treatment group). Patients in the placebo group will be split into two cohorts (20 receiving Low Dose Level dosing volumes and 20 receiving High Dose Level dosing volumes), but it is assumed that these two cohorts can be pooled for the analyses of efficacy. The High Dose Level will be determined by the DSMC of Part A of study GWEP1332. The maximum dose considered will be 20 mg/kg/day. The Low Dose Level will be defined as 50% of the High Dose Level.

8.1.1 Dose Administration

The IMP will be administered orally by the patient or their caregiver twice each day (morning and evening) using the syringe(s) provided. The IMP will be swallowed and may be taken with other concomitant medications, as directed by the investigator.

8.1.2 Dose Escalation, Dose Adjustments and Down-Titration

Titration regimens will be produced for the High Dose Level, Low Dose Level and placebo treatment groups. All patients will be weighed during Visit 2 and the daily volumes of IMP solution to be taken during the two-week titration period and for the remainder of the maintenance period will be calculated via the IVRS and the dosing regimen provided to the patient and/or caregiver. Further information on dispensing procedures will be provided in a separate Pharmacy Manual.

Each patient will take their first dose of IMP at Visit 2 (Day 1) and their final maintenance dose of IMP at Visit 8 (Day 99). If an unacceptable AE develops at any time during the titration period, dosing should initially be suspended or amended, at the investigator’s discretion, until the event has resolved. During the maintenance
period, patients should continue on a stable dosing regimen at the target Dose Level. If that dose becomes poorly tolerated, the investigator may consider temporarily or permanently reducing the dosage for the remainder of the maintenance period. However, where possible, the patient should be encouraged to return to the target Dose Level.

Patients who do not immediately enter the OLE study at Visit 8 or withdraw early will have their dose of IMP tapered gradually (10% each day) over a period of 10 days. However, the taper period may be interrupted if the patient wishes to enter the OLE study within seven days of Visit 8. Patients who require early termination prior to Visit 8 should also begin the taper period at the time the decision is made to discontinue (unless continued dosing is not possible due to an AE). Patients participating in the taper period will return used and unused IMP to the clinic at Visit 9.

### 8.2 Concomitant Therapy

It is theoretically possible that GWP42003-P may modify the metabolism of other drugs (including AEDs) administered concurrently and there remains the possibility of pharmacological interactions between GWP42003-P and other concurrently administered drugs. Doses of any concomitant AEDs must have been stable for at least four weeks prior to screening and must remain stable throughout the study period. Further information on drug interactions can be found in the Investigator Brochure (IB). The use of rescue medication is allowed when necessary. Any medication, other than the IMP, taken during the study must be recorded on the Case Report Form (CRF). Any non-pharmacological therapies (e.g., ketogenic diet, VNS) must also be stable up to four weeks prior to screening and throughout the duration of the study.

### 8.3 Prohibited Therapy During Study Period

The following medications are prohibited for the duration of the study starting from acquisition of patient consent/assent. However, any patients taking these medications after screening should not be withdrawn from the study unless there are safety concerns. If applicable, the possible effects of these medications on the primary endpoint will be considered during the assessment of the evaluable period (see Section 13.6.1).
• Any new medications or interventions for epilepsy (including ketogenic diet and VNS) or changes in dosage.
• Recreational or medicinal cannabis or synthetic cannabinoid based medications (including Sativex) within three months prior to or during the study.
• Any other IMP taken as part of a clinical trial within six months or during the study.

8.4 Compliance in Investigational Medicinal Product Administration

The IMP is dispensed to the patient at each of the following visits:

• Visit 2 (Day 1).
• Visit 4 (Day 29).
• Visit 6 (Day 57).
• Visit 8 (Day 99) (for patients not entering the OLE study on Day 99; if required).

Patients or their caregivers will confirm the daily dose has been administered using the IVRS and record the total volume of IMP administered on each treatment day using the paper diary. Patients will be asked to return all IMP (used and unused) to each relevant visit (Visits 4, 6, 8 and 9). The site will check the returned IMP against the usage recorded using the IVRS report and diary. Any discrepancies will be discussed with the patient/caregiver and documented accordingly within the patient’s source documents.

The investigator must inform GW promptly of all missing or unaccountable IMP. Refer to Section 9.1.15.2.1 for the list of ‘Triggering Drug Accountability Discrepancies’ associated with monitoring of drug abuse liability.

Records of IMP accountability will be maintained according to Section 5.3.4.

8.5 Access to Blinded Treatment Assignment

The identity of IMP assigned to patients will be held by the IVRS. The principal investigator (PI) at each site, or his/her designee, is responsible for ensuring that information on how to access the IVRS for an individual patient is available to the relevant staff in case of an emergency and unblinding is required. A patient’s treatment assignment should only be unblinded when knowledge of the treatment is essential to make a decision on the medical management of the patient. Unblinding for any other reason will be considered a protocol deviation.
The investigator is encouraged to contact GW to discuss the rationale for unblinding prior to doing so. However, to prevent delays to the investigator or medical personnel responding to a potentially emergent situation, unblinding of study medication will not be dependent upon the investigator receiving approval from GW (i.e., the investigator will be able to obtain the code break information independent of contacting GW).

If the investigator does unblind they must contact GW within one working day of the event and must document the time, date and reason(s) for unblinding in the patient’s CRF.
9 STUDY PROCEDURES

A list of the required study procedures is provided in the subsections that follow, refer also to the Schedule of Assessments (APPENDIX 1). Assessments or tests that are not done and examinations that are not conducted must be reported as such on the CRFs.

The location of the source data for the following procedures will be documented, per center, in a signed ‘Source Data Verification’ plan, for further details see Section 16.2.

9.1 Study Procedure Listing

To be eligible for the study, the patient must have agreed that if they or their partner are of child bearing potential they are willing to use effective contraception for the duration of the study and for three months thereafter. A highly effective method of birth control is defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomized partner (CPMP/ICH/286/95 mod). Abstinence, as referenced above, is only acceptable as true abstinence: when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

9.1.1 Informed Consent/Assent

The parent(s)/legal representative of minor patients must personally sign and date the EC/IRB approved consent form before any study specific procedures are performed or any patient related data is recorded for the study. In addition, in cases where the patient possesses adequate understanding, assent will be taken along with parent(s)/legal representative consent, using EC/IRB approved assent forms. Assent is defined as the minor’s permission or affirmative agreement to participate in the study. The explicit wish of a minor, who is capable of forming an opinion and assessing the information provided, to refuse participation in, or to be withdrawn from, the clinical trial at any time must be considered by the investigator.

Adult patients with an adequate level of understanding must personally sign and date the EC/IRB approved informed consent form before any study specific procedures are performed or any patient related data are recorded for the study. For adult patients
with an insufficient level of understanding of what is proposed, only parent(s)/legal representative consent will be sought.

For patients who go from being a minor to an adult (as per the country or state’s age-of-majority regulation) during the course of the study, a new informed consent will be signed if the participant possesses an adequate understanding to do so.

GW requires a physician to be present for consent and assent and to also sign the consent and assent forms.

9.1.2 Demographics

The following information will be obtained for each patient: date of birth, gender and ethnic origin.

9.1.3 Medical History

Relevant, significant medical history (including seizure frequency over the last six months) will be obtained and is defined as any condition or disease that:

- May affect the condition under study.
- Is ongoing on entry into the study.
- Has occurred within one year prior to screening (Visit 1).

The mutation status (positive or negative for mutation) of the SCN1A gene will be determined through the patient’s medical records. If the mutation status of SCN1A is unknown, SCN1A analysis will be carried out during the study analysis (a blood sample can be taken at any clinic visit).

9.1.4 Inpatient Epilepsy-Related Hospitalizations

The number of inpatient hospitalizations that are, in the investigator’s opinion, due to epilepsy will be recorded in the patient’s CRF and through the Serious Adverse Events (SAE) reporting process.

9.1.5 Concomitant Medication

Details of all current and recent medication (i.e., taken within the previous 14 days), including AEDs, will be recorded at each study visit. AEDs used during the study should be maintained at a stable dose. Any changes in concomitant medication during
the study must be recorded in the CRF at study visits. Patients should stop taking any
prohibited therapy prior to the screening visit, as defined in Section 8.3.

9.1.6 Physical Examination

Physical examinations will include height and body weight measurements.

9.1.7 Vital Signs

Vital sign measurements, taken in a sitting position at rest for five minutes, will be
completed alongside the physical examination. Postural blood pressure should be
measured after five minutes in supine position and, if possible, two minutes in
standing position. Blood pressure must be recorded using the same arm throughout
the study.

9.1.8 12-Lead Electrocardiogram

An ECG will be performed, after five minutes in a supine position. A physician must
review the ECG and any abnormal findings considered to indicate significant medical
history or AEs must be recorded appropriately in the CRF. Additional ECG
measurements can be taken at any time during the study, if clinically indicated.

9.1.9 Clinical Laboratory Sampling

Laboratory tests will include hematology, biochemistry and urinalysis (provided urine
can be obtained, with the exception of screening where a urine sample for THC screen
must be obtained). Analysis of all clinical blood samples, pregnancy tests (using
serum) and tests to detect the presence of THC will be conducted at a central clinical
laboratory.

Urine samples for biochemistry will be analyzed at the study center by use of a
dipstick with any relevant findings being sent for further urinalysis at the central
laboratory (urinalysis, microscopy, culture and sensitivity, as applicable). In cases
where urine samples cannot be analyzed at site due to local regulations, a full set of
urine samples should be sent to the central laboratory for analysis.

The THC results will be reported back to the study site to permit confirmation of
eligibility and to be used as a measure of study compliance (i.e., to confirm that the
patient did not take cannabis during the course of the study).
The investigator and study monitor will be provided with a list of the normal ranges used by the testing laboratory for all variables assayed during the study and a statement of accreditation (or similar) for the laboratory. Clinical laboratory sample parameters are detailed in Table 9.1-1.

<table>
<thead>
<tr>
<th>Biochemistry (serum)</th>
<th>Hematology (whole blood)</th>
<th>Urinalysis (urine)</th>
<th>Pregnancy Test (serum)</th>
<th>THC screen (urine)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alanine aminotransferase (ALT)</td>
<td>Hematocrit</td>
<td>Bilirubin (serum)</td>
<td>THC</td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>Hemoglobin</td>
<td>Blood</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>Mean cell volume</td>
<td>Glucose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspartate aminotransferase (AST)</td>
<td>Mean corpuscular hemoglobin</td>
<td>Ketones</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>Platelets</td>
<td>Nitrites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>Red blood cell count</td>
<td>pH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estimates of glomerular filtration rate</td>
<td>White blood cell count with automated differential</td>
<td>Protein</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gamma-glutamyl transferase</td>
<td>Specific gravity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td></td>
<td>Urobilinogen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-cholesterol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prolactin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prothrombin time (plasma)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin (TBL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total protein</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urea</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Investigators at study sites will be notified of safety laboratory test results. All laboratory results will be reviewed and the reports signed by an investigator. Any results considered to be of clinical significance must be addressed and followed up as clinically appropriate. See Section 12.3.1 for guidance on evaluation of potential drug induced liver injury. All laboratory results considered to represent an AE must be documented on the CRF.

Repeat samples will be taken, if required, for clinical follow-up or if the sample is lost or damaged. Any abnormal end of treatment clinical laboratory result of clinical significance must be repeated at regular intervals until it returns to normal, or until an investigator is satisfied that the abnormality is not related to the IMP and needs no further investigation.

Sample volume requirements and processing procedures will be detailed in a separate laboratory manual. The patient/caregiver must be advised that it may not be safe for the patient to undertake further blood tests within one month of any study-related
blood draws and to inform the investigator if they suffered any blood loss during the one-month period leading up to a planned blood draw.

9.1.10 Interactive Voice Response System

The IVRS will be used to collect patient reported diary data (refer to Section 9.1.12), to assign patients to treatment groups and to provide treatment allocation information in the event of patient unblinding. The IVRS will also be used to manage IMP supply.

A member of the study team must contact the IVRS at each clinic visit in order to:

- Obtain a patient’s screening number (Visit 1).
- Randomize a patient and obtain their patient number (Visit 2).
- Obtain dispensing information (Visits 2, 4, 6 and 8).
- Provide completion/taper/premature termination information (Visit 8 and 9).

Training will be given to all sites prior to the start of the study.

9.1.11 Questionnaires and Assessments Completed at Scheduled Visits

The same caregiver should complete/answer the questionnaires/assessments in order to maintain consistency. The C-SSRS is to be administered by the investigator or his/her qualified designee at every visit as indicated in the time and events table. (Qualified designee is defined as physician, osteopath, nurse practitioner, clinical psychologist or physician’s assistant, who is licensed and has completed the C-SSRS training within the last 2 years). The survey should be administered by the same assessor, where possible, throughout the study.

9.1.11.1 Sleep Disruption 0–10 Numerical Rating Scale

The patient’s caregiver will be asked:

- “On a scale of ‘0 to 10’, please indicate the number that best describes your child’s sleep disruption in the last week.”

The markers range from 0 = slept extremely well, to 10 = unable to sleep at all.

If the main caregiver is not available at the appropriate visit then this information can be captured over the telephone, ideally on the day of the visit or otherwise within three days.
9.1.11.2 Epworth Daytime Sleepiness Scale

The EDSS is a questionnaire that provides a measure of a person’s general level of daytime sleepiness, or their average sleep propensity in daily life. The EDSS contains eight questions that are rated on a four-point numerical scale (0–3). The total EDSS score is the sum of the eight item-scores and can range between 0 and 24. Higher total scores represent greater levels of daytime sleepiness.

The EDSS will be completed by the patient’s caregiver. If the main caregiver is not available at the appropriate visit then this information can be captured over the telephone, ideally on the day of the visit or otherwise within three days.

9.1.11.3 Caregiver Global Impression of Change

The CGIC comprises the following question to be rated on a seven-point scale:

- Since your child started treatment, please assess the status of your child’s overall condition (comparing their condition now to their condition before treatment) using the scale below.

The markers are: Very Much Improved; Much Improved; Slightly Improved; No Change; Slightly Worse; Much Worse Very Much Worse.

The caregiver will be asked to assess the status of the patient’s overall condition at Visit 2 (i.e., prior to commencement of IMP) as a memory aid for subsequent visits. If the main caregiver is not available at the appropriate visit then this information can be captured over the telephone, ideally on the day of the visit or otherwise within three days.

9.1.11.4 Quality of Life in Childhood Epilepsy

The QOLCE questionnaire was designed specifically to measure quality of life in children with epilepsy and is composed of 16 subscales assessing seven domains of Health Related Quality of Life (physical function, social function, emotional well-being, cognition, behavior, general health and general quality of life). The QOLCE must be completed by a parent or caregiver who interacts with the child on a consistent, daily basis. It should take 20–30 minutes to complete.
9.1.11.5 Cognitive Assessment Battery

The cognitive assessment battery will be administered at Visit 2 before receiving study medication and repeated at Visit 8 or when the patient completes treatment. The items are age specific and the age of the patient at entry will be the age used when choosing the items to be given. Children and adults are to complete the battery as able. It is expected that a number of patients will only be able to complete part of the battery and some may not be able to complete it at all. Parent and/or caregivers are to complete certain items. The battery items are available in English, French, and Spanish (so will only be administered to a sub-group of countries: USA, UK, France and Spain) and need to be given by an experienced psychometrician. A summary of the battery is shown below in Table 9.1-2 and Table 9.1-3.

Table 9.1-2 Neuropsychological Protocol for Epilepsy Patients Treated with Cannabidiol - Patient Measures

<table>
<thead>
<tr>
<th>Function</th>
<th>Patient Measures</th>
<th>Age Range</th>
<th>Approximate Administration Time for Psychometrician</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intelligence IQ</td>
<td>WPPSI-4 Vocabulary, Matrix Reasoning</td>
<td>2;6 - 5;11 years</td>
<td>30 minutes</td>
</tr>
<tr>
<td></td>
<td>WASI-2 Vocabulary, Matrix Reasoning (Including Wechsler: ‘Digit Span’ subtest from WISC-4 and WAIS-4; ‘Coding’ subtest from WISC-4 &amp; WAIS-4; ‘Bug Search’ from WPPSI-4)</td>
<td>6 - adult</td>
<td>45 minutes</td>
</tr>
<tr>
<td>Attention/Exec Funct</td>
<td>Trail Making Test D-KEFS</td>
<td>9 - adult</td>
<td>5 minutes</td>
</tr>
<tr>
<td>Trail Making</td>
<td>NEPSY-2 Word Generation</td>
<td>2 - 5 years</td>
<td>5 minutes</td>
</tr>
<tr>
<td>Language Naming Fluency</td>
<td>Expressive One-Word Picture Vocabulary Test-4th Ed</td>
<td>2 - adult</td>
<td>5 minutes</td>
</tr>
<tr>
<td></td>
<td>F-A-S and Animals</td>
<td>6 - adult</td>
<td>5 minutes</td>
</tr>
<tr>
<td>Visual-Spatial VMI</td>
<td>Developmental Test of Visual Motor Integration-6</td>
<td>2 - adult</td>
<td>5 minutes</td>
</tr>
<tr>
<td>Fine Motor Speed Pegs</td>
<td>Purdue Pegboard</td>
<td>4 - adult</td>
<td>5 minutes</td>
</tr>
</tbody>
</table>

Table 9.1-3 Neuropsychological Protocol for Epilepsy Patients Treated with Cannabidiol - Parent Measures

<table>
<thead>
<tr>
<th>Function</th>
<th>Parent Measures</th>
<th>Age Range</th>
<th>Approximate Administration Time for Parents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive</td>
<td>Behavior Rating Inventory of Executive Function (Parent and Teacher)</td>
<td>3 - 21 years</td>
<td>10 minutes</td>
</tr>
<tr>
<td>Attention</td>
<td>ADHD Checklist (Parent and Teacher)</td>
<td>All ages</td>
<td>5 minutes</td>
</tr>
<tr>
<td>Mood/Anxiety</td>
<td>BASC-2</td>
<td>3 - 21</td>
<td>20 minutes</td>
</tr>
</tbody>
</table>
Table 9.1-3  Neuropsychological Protocol for Epilepsy Patients Treated with Cannabidiol - Parent Measures

<table>
<thead>
<tr>
<th>Function</th>
<th>Parent Measures</th>
<th>Age Range</th>
<th>Approximate Administration Time for Parents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free-form report</td>
<td>Report Form (Parent and Teacher)</td>
<td>All ages</td>
<td>5 minutes</td>
</tr>
<tr>
<td>SES</td>
<td>SES Scale (Parent and Teacher)</td>
<td>All ages</td>
<td>5 minutes (during first assessment only)</td>
</tr>
</tbody>
</table>

9.1.11.6  Vineland Adaptive Behavior Scales (Second Edition)

The Vineland-II is an individually administered instrument for assessing adaptive behaviors. Communication, Daily Living Skills, Socialization, and Motor Skills will be assessed by the caregiver using a rating scale.

9.1.11.7  Columbia-Suicide Severity Rating Scale (Children’s)

The definitions of behavioral suicidal events used in this scale are based on those used in the Columbia Suicide History Form. Questions are asked on suicidal behavior, suicidal ideation and intensity of ideation. At screening (Visit 1), questions will be in relation to lifetime experiences (Children’s Baseline). Questioning at all subsequent visits will be in relation to the last assessment (Children’s Since Last Visit).

The C-SSRS is to be administered by the investigator or his/her qualified designee at every visit as indicated in the time and events table. (Qualified designee is defined as physician, osteopath, nurse practitioner, clinical psychologist or physician’s assistant, who is licensed and has completed the C-SSRS training within the last 2 years). The survey should be administered by the same assessor, where possible, throughout the study. Assessments will be conducted only if patients are of an appropriate age (six years of age and older).

9.1.11.8  Caregiver Impression of Investigational Medicinal Product Palatability

The caregiver will be asked the following question to be rated on a five-point scale:

- Overall, how acceptable did your child find the study medication?

The markers are: Liked it a lot; Liked it; Neither liked nor disliked it, Didn’t like it, Didn’t like it at all.
If the main caregiver is not available at the appropriate visit then this information can be captured over the telephone, ideally on the day of the visit or otherwise within three days.

9.1.11.9 Cannabis Withdrawal Scale

The CWS is a 19-item scale with each item (withdrawal symptom) measured on a 0–10 NRS (0 = Not at all; 5 = Moderately; 10 = Extremely). The patient or their caregiver is asked to record the extent to which each withdrawal symptom was experienced in the last 24 hours and also to rate the negative impact on normal daily activities (i.e., two separate scores are recorded for each item using the same 0–10 NRS). Scores are summed over the 19 items for each measure. Assessments will be conducted only if patients are of an appropriate age (six years of age and older).

9.1.12 Patient Diary

Seizure information and IMP dose administration data will be collected through an IVRS telephone diary completed daily throughout the study. The patient or their caregiver will also complete a paper diary daily to record daily IMP dosing volumes, usage of rescue medication, concomitant AEDs and AEs throughout the study.

The number and type of convulsive and non-convulsive seizures as well as information on usage of rescue medication, concomitant AEDs and AEs will be collected each day from screening (Visit 1) until completion of dosing (Visit 8/9) or withdrawal. Information on IMP intake will also be recorded each day from randomization (Visit 2) until completion of dosing (Visit 8/9) or withdrawal.

9.1.13 Investigational Medicinal Product Accountability

IMP will be dispensed at each of the following visits:

- Visit 2 (Day 1).
- Visit 4 (Day 29).
- Visit 6 (Day 57).
- Visit 8 (Day 99) (for patients not entering the OLE study on Day 99; if required).

Patients will be asked to return all IMP (used and unused) to each relevant visit (Visits 4, 6, 8 and 9). The site will check the returned IMP against the usage recorded
using the IVRS report and diary. Any discrepancies will be discussed with the patient/caregiver and documented accordingly within the patient’s source documents.

Refer to Section 9.1.15.2.1 for the list of ‘Triggering Drug Accountability Discrepancies’ associated with monitoring of drug abuse liability.

9.1.14  Adverse Events

Any adverse changes in the patient’s medical condition, following completion of the consent/assent form by the patient, will be recorded on the CRF as AEs, questioning the patient further if necessary. All AEs occurring during the study, whether or not attributed to the IMP, observed by the investigator or reported by the patient will be recorded in the CRF.

SAEs must be reported to GW Pharmacovigilance Department (PVD) within 24 hours of discovery or notification of the event, and recorded in the CRF.

Refer to Section 12 for definitions, procedures and further information.

The number of inpatient hospitalizations that are, in the investigator’s opinion, due to epilepsy will be recorded in the patient’s CRF and through the SAE reporting process.

Refer to Section 9.1.15.1.1 for the list of ‘Triggering AEs of Interest’ associated with monitoring of drug abuse liability.

9.1.15  Monitoring of Drug Abuse Liability (for Patients 12 Years of Age and Older)

There are two triggers that will require the investigator or study coordinator to discuss abuse potential signals with the patient or their caregiver. These are either AEs of interest that may be reported by the patient/caregiver, or drug accountability issues regarding overuse of the IMP or missing bottles. Different questionnaires will be completed by the site depending upon which trigger occurs (see Figure 9-1).

Irrespective of the above, all patients/caregivers will be interviewed at their final dosing visit (Visit 8/9) or withdrawal visit and a Study Medication Use and Behavior Survey will be completed by the investigator or study coordinator. Investigators and study coordinators will be provided with training on how to complete and perform the processes outlined in this section. This training must be completed and documented by the relevant site staff prior to implementation at site.
9.1.15.1 Monitoring of Adverse Events

AE information will be collected according to Section 9.1.14.

9.1.15.1.1 List of ‘Triggering Adverse Events of Interest’

During the collection of AEs, if the patient reports an AE consistent with any of the following categories, then the investigator or study coordinator is required to complete an additional Supplemental Adverse Event Form and a Site Classification Form (investigator only) following further discussion of the event(s) with the patient or their caregiver. The categories are:

- Euphoria or inappropriate elation.
- Inappropriate laughter or exhilaration.
- Mood changes.
- Drunk, high or intoxicated.
- Hallucinations (visual or auditory), dissociations, disorientation, agitation.
- Disturbance in cognition, memory, or attention.
- Drug abuse.
- Drug withdrawal or drug withdrawal syndrome.
- Addiction.
- Overdose.
- Misuse of IMP.
- Thoughts of suicide, attempted suicide or suicide.

An AE that is consistent with the above categories will be known as a ‘triggering AE of interest’ for the purposes of this study.

9.1.15.1.2 Supplemental Adverse Event Form

This form consists of 15 questions regarding the AE and use of IMP. It is completed as part of an interview with the patient/caregiver when a triggering AE of interest is reported. It is important that this is completed by a trained investigator or study coordinator with the patient/caregiver present. The answers on the Supplemental Adverse Event Form will then be transcribed into the patient’s CRF for the study. If the Supplemental Adverse Event Form cannot be completed at the time the triggering AE of interest is reported, then the site should contact the patient/caregiver to obtain the required answers as soon as possible.
9.1.15.2 Monitoring Drug Accountability Discrepancies

Any time after enrollment until final collection of study data, drug accountability discrepancies are monitored as follows:

- At routine Drug Accountability collection times (i.e., Visits 2, 4, 6 and 8): the site personnel will collect the IMP clinical supplies and make sure the usage is in line with the expectations reported within the IVRS report and paper diary.
- At any time that the site is informed by either the IVRS or by the patient/caregiver about any overuse of IMP, suspected misuse, abuse, or diversion.

9.1.15.2.1 List of ‘Triggering Drug Accountability Discrepancies’

If there are any discrepancies in drug accountability as outlined by the criteria below, known as ‘triggering drug accountability discrepancies’, then the trained investigator or study coordinator will complete a Supplemental Drug Accountability Form and Site Classification Form (investigator only) following further discussion of the event(s) with the patient/caregiver. The triggering drug accountability discrepancies are as follows:

- Missing bottle(s).
- Compliance issues where one or more bottles are used compared to what was the expected use, according to the IVRS report and paper diary.
- Returned IMP supply with evidence of tampering.
- Greater than the target daily dose as recorded in the IVRS report and paper diary.

9.1.15.2.2 Supplemental Drug Accountability Form

This form consists of eight questions regarding various aspects of drug accountability and patient usage. It is completed as part of an interview with the patient/caregiver when a triggering drug accountability discrepancy is identified. It is important that this is completed by a trained investigator or study coordinator with the patient/caregiver present. The answers on the Supplemental Drug Accountability Form will then be transcribed into the patient’s CRF for the study. The accountability reporting procedures will still occur. If the Supplemental Drug Accountability Form cannot be completed at the time the triggering drug accountability discrepancy is identified, then the site should contact the patient/caregiver by telephone to obtain the required answers as soon as possible. (Note: IMP refers to GWP42003-P or placebo, not other concomitant medications).
9.1.15.3 Site Classification Form

The investigator should review the applicable Supplemental Adverse Event Form or Supplemental Drug Accountability Form, and then complete the Site Classification Form. For each Supplemental Adverse Event Form or Supplemental Drug Accountability Form completed, there should be an associated Site Classification Form.

The Site Classification Form requires the investigator to assign the finding to an appropriate classification and then to also assign the possible relationship to the IMP. The investigator is also required to indicate the level of the certainty of the classification. The answers from the Site Classification Form will then be transcribed into the patient's CRF for the study.

9.1.15.4 Study Medication Use and Behavior Survey

This form consists of 18 questions regarding the use of the IMP. The trained investigator or study coordinator will complete this survey as an interview with the patient/caregiver at the final dosing visit (Visit 8/9) or withdrawal visit. The answers on the Study Medication Use and Behavior Survey will then be transcribed into the patient’s CRF for the study.

The Study Medication Use and Behavior Survey will be completed for all patients 12 years of age and older in the study and not only those that have reported a triggering AE or drug accountability discrepancy.

9.1.15.5 Adjudication Committee: Assessment of Abuse Potential of GWP42003-P

Any triggering AE or triggering drug accountability must be notified to the GW PVD using the same fax number for SAE reporting within 24 hours of becoming aware of the event.

A formal Adjudication Committee will be appointed and assigned to this initiative to classify triggered cases. The Adjudication Committee will meet on a periodic basis to review and assess all of the information collected on triggered cases. Only data from patients who have completed the study will be assessed.

A detailed charter will be agreed, which will describe the roles, responsibilities and duties of the members of Adjudication Committee. The Committee will review all of
the information collected in the process and in the assessment of the abuse potential of GWP42003-P, such as:

- All triggering AE information.
- Supplemental Adverse Event Form (if applicable).
- All triggering drug accountability discrepancies.
- Supplemental Drug Accountability Form (if applicable).
- Site Classification Form.
- Study Medication Use and Behavioral Survey.
- Additional information from site(s) as requested by the Committee.

The Adjudication Committee will assess all of the information. It will form a position on the classification of each event and will write a study-related report, detailing the conclusions and recommendations.

The overall process is summarized in Figure 9-1.
Figure 9-1 Flow Diagram for Identifying and Evaluating Clinical Trial Adverse Event Data Through Systematic Categorization, Tabulation and Analysis which can Illuminate an Abuse Potential Signal (for Patients 12 Years of Age and Older)

<table>
<thead>
<tr>
<th>Stage 1</th>
<th>Patients with ‘Triggering Adverse Events of Interest’</th>
<th>Patients with ‘Triggering Drug Accountability Discrepancy’</th>
<th>All patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 2</td>
<td>When a Triggering Adverse Event of Interest is identified, a patient interview is conducted with the <strong>Supplemental Adverse Event Form</strong> and, if applicable, the <strong>Supplemental Drug Accountability Form</strong>.</td>
<td>When a Triggering Drug Accountability discrepancy is identified, a patient interview is conducted with the <strong>Supplemental Drug Accountability Form</strong> and, if applicable, the <strong>Supplemental Adverse Event Form</strong>.</td>
<td></td>
</tr>
<tr>
<td>Stage 3</td>
<td>Investigator completes a <strong>Site Classification Form</strong> after supplemental information is collected, drug accountability evaluated, and the patient evaluated. One Site Classification Form is completed per Supplemental Adverse Event Form or Drug Accountability Form.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 4</td>
<td>Site completes <strong>Study Medication Use and Behavior Survey</strong> at end of dosing.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage 5</td>
<td><strong>Adjudication Committee</strong> Evaluates all of the information collected (as detailed above in stages 1–4) in the assessment of the abuse potential of GWP42003-P and completes a report. Committee submits a report to GW.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
9.2 Study Procedures by Visit

Patients and their parent(s)/legal representative will be invited to participate in the study and will be issued with the patient information and informed assent or the patient/parent(s)/legal representative information and informed consent (as applicable). Following adequate time to discuss the study with the investigator, nurse, relatives or caregiver, patients/parent(s)/legal representatives who provide written informed consent/assent at Visit 1 will be enrolled into the study.

9.2.1 Visit 1 (Day −28, Screening)

The following assessments will be made at Visit 1: demographics, medical history (including seizure frequency over the last six months and SCN1A mutation status), vital signs, postural blood pressure, physical examination (including height and body weight), ECG, C-SSRS (Children’s Baseline) and visit procedure-related AEs. If the mutation status of SCN1A is unknown, a blood sample will be taken for SCN1A analysis (this can be taken at any visit during the study). Clinical laboratory samples (urine and blood) will be taken for hematology, biochemistry, urinalysis (where possible), a urine THC screen (required) and a pregnancy test (using a serum sample, as appropriate). Patients or their caregivers will also be asked for information regarding concomitant medications and/or changes to medication (including AEDs). Patients who satisfy all inclusion and none of the exclusion criteria specified in Section 6 will then begin the 28-day baseline observation period.

The IVRS must be contacted by the site to register the screening visit and issue the screening number. If this does not occur, the patient will not be able to call into the telephone diary.

Patients or their caregivers will be issued with the IVRS details and will be instructed on how to use it to record daily seizure information. Patients or their caregivers will also be given a paper diary to record usage of rescue medication, concomitant AEDs and AEs and will be instructed on how to do so.

The investigator should review the laboratory results as soon as these become available. If the results show a patient is ineligible, the patient must be withdrawn from the study.
9.2.2 Visit 2 (Day 1, Randomization)

This visit will occur 28 days after Visit 1. A visit window of ±3 days from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day where possible.

The following assessments will be made at Visit 2: vital signs, postural blood pressure, physical examination (including height and body weight) and ECG. Clinical laboratory samples (blood and urine [where possible]) will be taken for hematology, biochemistry, urinalysis, a urine THC screen and a pregnancy test (using a serum sample, as appropriate). The patient’s IVRS report and paper diary will be reviewed and the information recorded along with information regarding AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs).

The investigator must assess the patient’s daily number of convulsive seizures from the patient’s IVRS data. Patients who have experienced four or more convulsive seizures (i.e., tonic-clonic, tonic, clonic, atonic seizures) during the baseline period and who meet all of the other inclusion and none of the exclusion criteria specified in Section 6 will be eligible to continue in the study. If a patient does not meet the eligibility criteria within this period, consideration will be given to rescreen at a later date.

Eligible patients will then be randomized to receive one of two Dose Levels of GWP42003-P or placebo using the IVRS (see Section 7.1). Patients in the placebo group will be split into two equivalent cohorts: half receiving Low Dose Level dosing volumes and half receiving High Dose Level dosing volumes.

Following randomization, patients will remain at the clinic where the following assessments will be performed prior to the administration of study medication: EDSS, Sleep Disruption 0–10 NRS, QOLCE, C-SSRS (Children’s Since Last Visit), cognitive assessment battery, CWS and the Vineland-II. Caregivers will be asked to write a brief description of the patient’s overall condition as a memory aid for the CGIC at subsequent visits or withdrawal. Patients will then receive sufficient IMP and a dosing regimen as assigned by the IVRS for the following four weeks. Each patient will take their first dose of IMP at the clinic and will titrate to their target Dose Level during the following two weeks. Patients or their caregivers will be instructed on using the IVRS’s daily dosing record, as well as how to record IMP dosing information in the paper diary.
The investigator should review the laboratory results as soon as these become available. If the results show a patient is ineligible, the patient must be withdrawn from the study.

9.2.3 Visit 3 (Day 15)

This visit will occur 14 days after randomization (Visit 2). A visit window of ±3 days from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day where possible.

The following assessments will be made at Visit 3: vital signs, physical examination (including height and body weight), ECG, EDSS, Sleep Disruption 0–10 NRS, CGIC, C-SSRS (Children’s Since Last Visit) and the Vineland-II. Clinical laboratory samples (blood and urine [where possible]) will be taken for hematology, biochemistry and urinalysis. The patient’s IVRS report and paper diary will be reviewed and the information recorded along with information regarding AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs). The investigator must assess adherence to the titration regimen.

9.2.4 Visit 4 (Day 29)

This visit will occur 28 days after randomization (Visit 2). A visit window of ±3 days from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day where possible.

The following assessments will be made at Visit 4: vital signs, physical examination (including height and body weight), ECG, EDSS, Sleep Disruption 0–10 NRS, CGIC, C-SSRS (Children’s Since Last Visit) and the Vineland-II. Clinical laboratory samples (blood and urine [where possible]) will be taken for hematology, biochemistry and urinalysis. The patient’s IVRS report and paper diary will be reviewed and the information recorded along with information regarding AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs). The investigator must assess adherence to the dosing regimen.

All IMP (used and unused) will be collected and a check of the returned IMP against usage should be made. The IVRS will be contacted for treatment pack assignment. Patients will receive sufficient IMP as assigned by the IVRS for the following four weeks.
9.2.5 Visit 5 (Day 43, Safety Telephone Call)

This visit will occur 42 days after randomization (Visit 2). A visit window of ±3 days from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day where possible.

Visit 5 will be completed by telephone. Patients or their caregivers will be asked for information on AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs).

9.2.6 Visit 6 (Day 57)

This visit will occur 56 days after randomization (Visit 2). A visit window of ±3 days from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day where possible.

The following assessments will be made at Visit 6: vital signs, physical examination (including height and body weight), ECG, EDSS, Sleep Disruption 0–10 NRS, CGIC, C-SSRS (Children’s Since Last Visit) and the Vineland-II. Clinical laboratory samples (blood and urine [where possible]) will be taken for hematology, biochemistry and urinalysis. The patient’s IVRS report and paper diary will be reviewed and the information recorded along with information regarding AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs). The investigator must assess adherence to the dosing regimen.

All IMP (used and unused) will be collected and a check of the returned IMP against usage should be made. The IVRS will be contacted for treatment pack assignment. Patients will receive sufficient IMP as assigned by the IVRS for the following six weeks.

9.2.7 Visit 7 (Day 71, Safety Telephone Call)

This visit will occur 70 days after randomization (Visit 2). A visit window of ±3 days from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day where possible.

Visit 7 will be completed by telephone. Patients or their caregivers will be asked for information on AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs).
9.2.8 Visit 8 (Day 99, End of Treatment)

This visit will occur 98 days after randomization (Visit 2) or earlier if the patient withdraws from the study. A visit window of ±3 days from the scheduled visit date is permitted, but it is preferred that the visit is performed on the scheduled visit day where possible.

The following assessments will be made at Visit 8: vital signs, physical examination (including height and body weight), ECG, EDSS, Sleep Disruption 0–10 NRS, CGIC, QOLCE, C-SSRS (Children’s Since Last Visit), cognitive assessment battery and the Vineland-II. The Caregiver Impression of IMP Palatability will also be assessed.

Clinical laboratory samples (blood and urine [where possible]) will be taken for hematology, biochemistry, urinalysis, a urine THC screen (required) and a pregnancy test (using a serum sample, as appropriate). The patient’s IVRS report and paper diary will be reviewed and the information recorded along with information regarding AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs). The investigator must assess adherence to the dosing regimen.

All IMP (used and unused) will be collected and a check of the returned IMP against usage should be made. For patients who withdraw early, the IVRS will be contacted to confirm withdrawal from the study.

Patients who have completed all of the scheduled study visits will be offered the option of entering an OLE study. Entry is to be on the same day as Visit 8 (Day 99) or within seven days of Visit 8.

For patients who enter the OLE study on Day 99, the IVRS will be contacted to confirm the patient’s completion of this study and the paper diaries will be collected. For patients 12 years of age and older, the trained investigator or study coordinator will complete the Study Medication Use and Behavior Survey as an interview with the patient/caregiver.

For patients not entering the OLE study on Day 99, the IVRS will be contacted to confirm start of the 10-day taper period and for additional treatment pack assignment (if required). The IVRS will generate the patient’s daily IMP dosing volumes for the 10-day taper period, during which time IVRS and diary information will continue to be recorded. The taper period may be interrupted if the patient wishes to enter the OLE study within the seven-day timeframe.
9.2.9 Visit 9 (Day 100–106 or Day 109, End of Taper Period)

This visit is required only for those patients who do not enter the OLE study on the day of Visit 8 (i.e., Day 99±3) or for those who withdraw early. For patients who do not enter the OLE study, Visit 9 should occur 10 (+3) days after Visit 8 (i.e., on Day 109). For patients who delay entry into the OLE study, Visit 9 should occur on the day the patient enters the OLE study and within seven days of Visit 8 (i.e., up to Day 106) to allow the patient to enter the OLE study within this timeframe.

The following assessments will be made at Visit 9: vital signs, physical examination (including height and body weight) and C-SSRS (Children’s Since Last Visit). The CWS will also be assessed. The patient’s IVRS report and paper diary will be reviewed and the information recorded along with information regarding AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs). The investigator must assess adherence to the down-titration regimen.

All IMP (used and unused) will be collected and a check of the returned IMP against usage should be made. The IVRS will be contacted to confirm the patient’s completion of the study and the paper diaries will be collected. For patients 12 years of age and older, the trained investigator or study coordinator will complete the Study Medication Use and Behavior Survey as an interview with the patient/caregiver.

9.2.10 Visit 10 (Day 137, Safety Follow-Up)

This visit is required for patients who do not enter the OLE study or who withdraw from the study early. This visit should occur four weeks after Visit 9 (±3 days), or withdrawal from treatment, and can be conducted by telephone.

The purpose of the follow-up is to ascertain the status of AEs continuing after Visit 9 or any new AEs commencing after Visit 9. Epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs) must also be recorded.

All causally related AEs that result in a patient’s premature termination from the study or are present at the end of the study, should be followed up until a satisfactory resolution occurs, that is, until the AE resolves or is considered clinically insignificant, or until an investigator is satisfied that the AE is not related to IMP and needs no further investigation.
9.2.11 Safety Telephone Calls

For patients not entering the OLE study, or who withdraw from the study early, safety telephone calls will be made weekly (±3 days) from Visit 9 until Visit 10. Patients or their caregivers will be asked for information on ongoing and new AEs, epilepsy-related hospitalizations, concomitant medications and/or changes to medication (including AEDs).
10 WITHDRAWAL

In accordance with the Declaration of Helsinki, the FDA regulations relating to good clinical practice (GCP) and clinical trials, the EU Clinical Trials Directive (2001/20/EC) and/or other applicable regulations, a patient has the right to withdraw from the study at any time and for any reason without prejudice to his or her future medical care by the physician or at the institution.

The patient must be withdrawn from the study if any of the following apply:

- Administrative decision by the investigator, GW, or a Regulatory Authority.
- Pregnancy.
- Protocol deviation that is considered to potentially compromise the safety of the patient.
- Withdrawal of patient consent/assent.
- Withdrawal of parent(s)/legal representative consent.
- Lost to follow-up.

Patients may also be withdrawn from the study for any of the following:

- Patient non-compliance.
- AE which, in the opinion of the investigator, would compromise the continued safe participation of the patient in the study.
- ALT or AST >3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
- ALT or AST >8 × ULN.
- ALT or AST >5 × ULN for more than two weeks.
- ALT or AST >3 × ULN and (TBL >2 × ULN or INR >1.5).
- Any evidence of drug abuse or diversion.
- Suicidal ideation or behavior of type four or five during the treatment period, as evaluated with the C-SSRS.

Should a patient request or decide to withdraw from the study, all efforts must be made to complete and report the observations as thoroughly as possible up to the date of withdrawal. Patients who withdraw should have their dose of IMP tapered gradually (10% each day) over a period of 10 days, beginning at the time the decision is made to discontinue. In some cases, tapering the dose of IMP may be inadvisable (e.g., continued dosing is not possible due to an AE). The decision on whether or not to taper IMP will be left to the investigator’s clinical judgment. All assessments required at Visit 8 should be conducted if possible. If the tapered dose is
administered, patients should return for Visit 9 if possible. Patients withdrawing due
to an AE should be followed up according to Section 12.7 safety follow-up visit. All
information should be reported on the applicable CRF pages (refer to Section 9.1).
Wherever possible, the safety follow-up visit should be conducted 28 days from the
date of the last dose of IMP (refer to Section 9.2.10).
11 URGENT SAFETY MEASURES

The sponsor and investigator may take appropriate urgent safety measures in order to protect the patients of a clinical trial against any immediate hazard to their health or safety. If such measures are taken by the investigator they must notify GW immediately or at least within 24 hours of awareness. GW will report urgent safety measures to Competent Authorities by telephone within 24 hours of awareness, wherever possible, and will provided a written report to the Competent Authorities and IRB/EC within three days.
12 ADVERSE EVENT REPORTING

12.1 Definitions

12.1.1 Adverse Event

For the purposes of this study an AE is defined as:

Any new unfavorable/unintended signs/symptoms (including abnormal laboratory findings), or diagnosis or worsening of a pre-existing condition, which is present following screening (Visit 1) and the post treatment, safety follow-up visit (Visit 10), which may or may not be considered to be related to the IMP. Any event that is the result of a study procedure must be recorded as an AE.

Surgical/Investigational procedures are not AEs. The medical reason for the procedure is the AE. Elective hospitalizations for pre-study existing conditions or elective procedures are not AEs. The exception may be if the patient has an AE during hospitalization which prolongs their scheduled hospital stay, in which case it would be considered a SAE (refer to Section 12.2).

If reporting a fatal event, the SAE term should be the underlying cause of the death (e.g., disease or medical condition leading to death).

12.1.2 Investigator

The term investigator refers to the study PI or a formally delegated study physician.

12.2 Serious Adverse Events

During clinical investigations, AEs may occur which, if suspected to be IMP related, might be significant enough to lead to important changes in the way the IMP is developed (e.g., change in dose, population, monitoring need, consent/assent forms). This is particularly true for events that threaten life or function. Such SAEs will be reported promptly to Regulatory/Competent Authorities, applicable IRB/ECs and investigators (expedited reporting) by GW.

An AE must only be classed as serious, i.e., a SAE, when the event falls into one of the following criteria:

- Results in death.
- Is life-threatening.*
- Requires inpatient hospitalization or prolongation of existing hospitalization.
- Results in persistent or significant disability/incapacity.
• Is a congenital anomaly/birth defect.

• Is medically significant.**

* The term “life-threatening” in the definition of “serious” refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event, which hypothetically might have caused death if it were more severe.

** Medical and scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations. Important medical events may not be immediately life threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. These should also usually be considered serious. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or development of drug dependency or drug abuse.

12.3 Reporting Procedures for Serious Adverse Events

All SAEs occurring during the study must be reported to GW with any other supporting information and recorded in the AE section of the CRF. Any on-going SAEs should be followed up until resolution wherever possible. For all deaths, the working diagnosis or cause of death as stated on a death certificate, available autopsy reports and relevant medical reports should be sent to GW promptly.

All SAEs must be reported directly to GW PVD within 24 hours of discovery or notification of the event. All SAE information must be recorded on the SAE forms provided in the site files and faxed to GW PVD. Additional information received for a case (follow-up or corrections to the original case) need to be detailed on a new SAE form, signed/dated and faxed to the GW PVD and the AE section of the CRF must be updated.

The investigator should continue to document all AEs which occur up to the last formal follow-up observational period (Visit 10). If the investigator subsequently becomes aware of a new IMP-related SAE after the last formal follow-up period of the study, these should still be reported to the GW PVD.

Any other problem discovered outside these time limits which is deemed to be an unexpected safety issue and is likely to have an impact on patients who have participated in the study, then these should be treated as an SAE and reported to GW PVD. Such post study SAEs do not need to be recorded on the patient’s CRF if editing rights to the CRF have been removed.
Contact details for the GW PVD are provided at the front of the site files for all study centers, and upon the GW SAE Report form.

12.3.1 Potential Cases of Drug-Induced Liver Injury

Abnormal values in AST and/or ALT concurrent with abnormal elevations in TBL that meet the criteria outlined below are considered potential cases of drug-induced liver injury and will be considered as protocol defined criteria for withdrawal and important medical events.

- ALT or AST >3 × ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
- ALT or AST >8 × ULN.
- ALT or AST >5 × ULN for more than two weeks.
- ALT or AST >3 × ULN and (TBL >2 × ULN or INR >1.5).

The investigator will arrange for the patient to return to the investigational site as soon as possible (within 24 hours of notice of abnormal results) for repeat assessment, detailed history and physical examination. Patients should be followed until all abnormalities have normalized (in the investigator’s opinion) or returned to the baseline state.

12.4 Pregnancy

Any patient, or patient’s partner, who has become pregnant whilst receiving IMP, or within 90 days of last dose of IMP, must be reported to the GW PVD within 24 hours of first awareness. Please use the GW Pregnancy Monitoring Forms provided. Where possible the investigator should provide the outcome of the pregnancy.

The investigator is not obliged to actively monitor for any pregnancies that commence more than 90 days after the final dose of IMP. However, if the investigator becomes aware of a new pregnancy outside this time limit then they should report it as above. GW PVD will follow-up for all pregnancy outcomes.

12.5 Causality Assessment

Causality assessment is required for all AEs and SAEs. Causality assessment must only be assigned by the investigator. All cases judged as having a reasonable suspected causal relationship to the IMP must be reported as such. The expression
“reasonable causal relationship” is meant to convey in general that there are facts (evidence) or arguments to suggest a causal relationship.

The following question which must be answered by the investigator for all AEs is used to capture the reasonable causal relationship of an event to the IMP:

“In your opinion is there a plausible relationship to the IMP?” The answer is “yes”, or “no”.

Events that start before the first dose of IMP (pre-treatment) should be considered as not causally related. Where a pre-treatment event worsens in severity following the first dose of IMP a new event record should be entered into the CRF.

Considering the explanation given above, investigators are strongly encouraged to express their opinion on what the cause of an AE might be. For individual patients, the investigator is usually in the best position to assess the underlying suspected cause of an AE. For all AEs and especially SAEs, it is important that the investigator assess not only the possible role of the IMP but also competing etiological factors as the underlying cause. Factors for consideration may include:

- Medical history.
- Lack of efficacy/worsening of treated condition.
- Concomitant or previous treatment.
- Withdrawal of IMP.
- Protocol-related procedure.

12.6 Reporting Procedures for All Adverse Events

All AEs (including SAEs) occurring during the study will be reported on the running logs in the AE section of the CRF. This includes all events from the time following screening (Visit 1) to post study follow-up (Visit 10), whether or not attributed to IMP and observed by the investigator or patient.

The following information will need to be provided for all AEs:

A) Adverse event (diagnosis or syndrome if known, or signs and symptoms)

Where the investigator cannot determine a diagnosis, signs or symptoms should be recorded on the AE section of the CRF. Once a diagnosis has been determined the AE section of CRF must be updated to reflect the diagnosis in replacement of the original symptoms. In circumstances where only a provisional diagnosis is possible (working diagnosis), the CRF must be updated to reflect the provisional diagnosis in replacement of the original symptoms. In some circumstances it may be relevant for
the investigator to include the symptoms alongside the diagnosis in the verbatim event description. However, the diagnosis (full or provisional) should be clearly stated e.g., fever and malaise due to a respiratory tract infection.

**B) Adverse Event Start date and Stop date**

The start and stop dates of the event must be provided. All AEs require these fields to be completed in full. Partial dates or missing dates are not normally acceptable and significant effort must be undertaken to obtain any unknown information. If a precise date is not known an estimated date should be provided instead. When a complete date cannot be given then record as much information as possible (i.e., month and year or in exceptional circumstances just year). When the actual start date becomes known the CRF must be updated to replace the previously recorded date.

**C) Outcome**

The outcome of the event must be recorded accurately and classified into one for the following categories:

- Recovered.
- Recovered with sequelae.
- Continuing.
- Patient died.

**D) Severity**

When describing the severity of an AE the terms mild, moderate, or severe should be used. Clinical judgment should be used when determining which severity applies to any AE.

If the severity of an AE fluctuates day-to-day, for example, a headache or constipation, the change in severity should not be recorded each time, instead only the worst observed severity should be recorded with AE start and stop dates relating to the overall event duration regardless of severity.

A severe AE is not the same as a SAE. For example, a patient may have severe vomiting but the event does not result in any of the SAE criteria above. Therefore it should not be classed as serious.

**E) Causality**

See Section 12.5 above.
F) Action taken with Study Medication

This question refers to the action taken with the IMP due to an AE. The action with the IMP must be classed as:

- None.
- Dose reduced temporarily.
- Dose reduced.
- Study medication interrupted.
- Study medication stopped.

12.7 Follow-up Procedures for Adverse Events

The investigator may be asked to provide follow-up information to the GW PVD for any AEs reported.

AEs considered related to the IMP by the investigator or the sponsor should be followed up until resolution or the event is considered stable.

It will be left to the investigator’s clinical judgment whether or not an AE is of sufficient severity to require the patient’s removal from treatment. A patient may also voluntarily withdraw from treatment due to what he or she perceives as an intolerable AE; further details of withdrawal are presented in Section 10. If either of these occurs, the patient must undergo an end of treatment assessment and be given appropriate care under medical supervision until symptoms cease or the condition becomes stable.

12.8 Reporting Clinically Significant Laboratory Results

All investigational sites are required to submit to the GW PVD the laboratory results for any patient after randomization that meet the criteria for the selected laboratory parameters as follows:

- ALT or AST \(>3 \times \text{ULN}\) with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (\(>5\%\)).
- ALT or AST \(>8 \times \text{ULN}\).
- ALT or AST \(>5 \times \text{ULN}\) for more than two weeks.
- ALT or AST \(>3 \times \text{ULN}\) and (TBL \(>2 \times \text{ULN}\) or INR \(>1.5\)).
These reports must be sent to the GW PVD using the same fax number for SAE reporting within 24 hours of becoming aware of the results. In addition, please send a copy of the patient’s baseline laboratory results with all reports to GW PVD.

12.9 Notification of Safety Information to Investigators, Regulatory Authorities and Ethics Committees

In accordance with the EU Clinical Trials Directive\(^69\), relevant parts of the FDA Code of Federal Regulations\(^70\) and any national regulations, GW will inform investigators, regulatory authorities and relevant IRB/ECs of all relevant safety information. This will include the reporting of relevant SAEs and all Suspected Unexpected Serious Adverse Reactions (SUSARs).

This information will be provided through three sources:

1) IB\(^63\): a compilation of the clinical and non-clinical safety data available on the IMP that is relevant to the study on the IMP in human patients. The IB is updated annually.

2) Development Core Safety Information: this document actually forms the Safety Section of the IB\(^63\), or is updated as an appendix of the IB\(^63\). This document is revised if necessary, when new important safety information becomes available (potentially up to a few times a year).

3) Council for International Organizations of Medical Sciences (CIOMS) reports: these reports are issued every time a SUSAR is reported to GW. They provide information on individual case reports and are sent to all the regulatory authorities, the relevant central IRB/ECs which have approved the study and investigators. As required, the investigator should notify their regional ethical committees of SAEs or SUSARs occurring at their site and other AE reports, i.e., CIOMS reports and any additional safety documentation received from GW, in accordance with local procedures.

In the USA, investigators are normally required to promptly report to their IRBs all unanticipated problems involving risks to human patients, or others, including AEs that should be considered unanticipated problems. Based on current FDA guidance\(^66\) the following clarification is provided in determining what constitutes an unanticipated problem:

In general, an AE observed during the conduct of a study should be considered an unanticipated problem involving risk to human patients, and reported to the IRB, only if it were unexpected, serious, and would have implications for the conduct of the study (e.g., requiring a significant, and usually safety-related, change in the protocol such as revising inclusion/exclusion criteria or including a new monitoring
requirement, informed consent/assent, or IB). An individual AE occurrence
ordinarily does not meet these criteria because, as an isolated event, its implications
for the study cannot be understood.

The FDA guidance\textsuperscript{70} states that, accordingly, to satisfy the investigator’s obligation to
notify the IRB of unanticipated problems, any investigators participating in a
multicenter study may rely on the sponsor’s assessment and provide to the IRB a
report of the unanticipated problem prepared by the sponsor.

GW will inform investigators (regulatory authorities and applicable IRB/ECs) of any
safety issues or case reports that are considered to be unanticipated and provide such
reports as mentioned above. It should be noted that a single SUSAR report notified to
investigators in the study does not necessarily constitute an unanticipated problem
unless identified by GW in the submission cover letter.

As a minimum, the recipient will be sent all of the above and relevant updates
between the period from ethical approval and final database lock.
13 STATISTICAL CONSIDERATIONS

A statistical analysis plan (SAP) will be produced prior to unblinding of the study. Any deviations from the original SAP will be described in the final clinical study report.

13.1 Sample Size, Power and Significance Levels

A total of 120 patients will be enrolled. The 120 patients will be randomly allocated on a 1:1:1 basis to the three treatment groups (40 patients per group). Patients in the placebo group will be split into two cohorts (20 receiving Low Dose Level dosing volumes and 20 receiving High Dose Level dosing volumes), but it is assumed that these two cohorts can be pooled for the analyses of efficacy.

If it is assumed that patients in the placebo group will experience a mean reduction in convulsive seizure frequency of 10% (from baseline), this sample size of 40 patients per group will be sufficient to detect a difference of 40% between treatments (i.e., patients receiving GWP42003-P will experience at least a 50% reduction in convulsive seizures). This is based on a standard deviation of 63%, using a two-tailed 5% significance level and 80% power.

13.2 Interim Analysis

No interim analysis is planned for this study.

13.3 Analysis Sets

There will be up to three analysis sets:

Intention to Treat (ITT)

- All patients who are randomized and receive IMP in the study will be included and analyzed according to their randomized treatment group.
- The ITT analysis set is the primary analysis set for all efficacy endpoints.

Per Protocol (PP)

If there are a sufficient number of significant protocol deviations in the study, a PP analysis set may also be presented.

- All patients who complete the study with no protocol deviations deemed to compromise the assessment of efficacy will be included and analyzed.
according to the treatment group they were randomized. The rules determining the PP analysis set will be fully defined prior to unblinding of the database.

Safety

All patients who received at least one dose of IMP in the study will be included and analyzed according to the treatment received. Only patients for whom it has been confirmed that they did not take any IMP will be excluded from this safety analysis set.

13.3.1 Protocol Deviations

Protocol deviations will be listed and reasons for exclusion from the analysis populations will be summarized.

13.4 General Considerations

Unless stated otherwise, continuous variables will be summarized showing the number of non-missing values \( (n) \), mean, standard deviation, median, minimum and maximum and categorical variables will be summarized showing the number and percentage of patients falling in each category.

13.5 Accountability and Background Characteristics

13.5.1 Enrollment and Disposition

All patients (screened, randomized, prematurely terminated IMP) will be accounted for in the enrollment and disposition summary tables.

13.5.2 Baseline and Demographic Characteristics

Age, sex, race and any other demographic or baseline characteristics will be summarized by randomized treatment group, using appropriate summary statistics.

13.5.3 Medical History

Previous and current medical conditions will be summarized by system organ class, including details of the duration of epilepsy and the types of seizures currently experienced by the patients.
13.5.4 Concomitant Medication

Concomitant medications (including standard AED and rescue medication) taken prior to and during the study will be summarized separately, by medication class and active ingredients.

13.6 Endpoints and Statistical Methods

Statistical hypothesis testing will be performed on the primary endpoint and other endpoints as appropriate. Since there is a single primary analysis endpoint, no formal adjustment of statistical significance for multiple testing on multiple endpoints is required, although such multiplicity should be allowed for when interpreting the results for secondary endpoints. However, there are three treatments, so multiple significance testing will occur when making comparisons between the treatments; the major comparisons of interest are those between each of the GWP42003-P Dose Levels and placebo and, in particular, the High Dose Level and placebo. The dose response effect between the two GWP42003-P Dose Levels and placebo will also be explored. No formal adjustment will be made for the comparisons between multiple treatment groups.

A Mixed-Effect Model Repeated Measures (MMRM) approach will be used for the analysis of continuous variables and logistic regression for categorical variables: the overall test from these procedures will determine whether there are any statistically significant differences between the treatment groups. Comparisons between individual treatments should be interpreted in the light of the result of the overall test, e.g., if the overall test is not statistically significant (indicating that there is little evidence of any difference between the treatments) then an individual comparison that does appear to be significant should be treated with caution.

13.6.1 Evaluable Period

The start of the evaluable period of the study (Day 1) is defined as the first day the patient took IMP, as recorded in the IVRS, or the day of randomization if this date is unknown.

The end of the evaluable period is defined as the earliest of:

(i) Day 99 of treatment for the IVRS reported efficacy data and the day of Visit 8 for the CRF-based efficacy data;
(ii) The last day on which study IMP was taken (as stated on the study outcome CRF) for the IVRS reported efficacy data and the day after this for the CRF-based efficacy data;

(iii) The day before a relevant change in prohibited or AED medications was made.

13.6.2 Primary Endpoint(s)

The primary endpoint is the mean percentage change from baseline in convulsive seizure frequency during the maintenance period of the study (Day 15 to the end of the evaluable period) in patients taking GWP42003-P compared with placebo.

If the data are found to be normally distributed, they will be analyzed using a MMRM approach. The model will include baseline as a covariate and treatment group as fixed factor. The time variable will be the assessment time-point (nominal visit number, corresponding to each 28 days of the maintenance period) treated as a categorical repeated factor. Assessments will be assigned to the nominal visit number using visit windows such that each assessment will be assigned to the earliest scheduled visit that occurs either within three days before the actual visit date or on or after the date of the actual visit. The baseline-by-time and treatment-by-time interactions will also be included. The model will have a separate unstructured covariance matrix in each treatment group.

The fitted model will then be used to produce a final time-point comparison, which implicitly adjusts for missing observations under the assumption of missing at random; there will be no imputations for missing values at individual time-points.

The time course of the treatment effect will also be examined by estimating treatment differences, together with their 95% confidence intervals (CIs), for each nominal visit during the randomized treatment period.

However, due to the nature of seizure data, if a normal distribution cannot be assumed, the data will be analyzed using appropriate non-parametric methods (e.g., Kruskal-Wallis and Wilcoxon Signed Rank tests).

13.6.3 Secondary Endpoint(s)

The following endpoints will be compared between the three treatment groups over the 12-week, double-blind maintenance period:
Number of patients experiencing a >25% worsening, −25 to +25% no change, 25–50% improvement, 50–75% improvement or >75% improvement in convulsive seizures from baseline.

Number of patients who are convulsive seizure free.

Percentage changes from baseline in non-convulsive seizure frequency.

Change in types of seizures.

Changes from baseline in usage of rescue medication.

Changes from baseline in number of inpatient hospitalizations due to epilepsy.

Changes from baseline in Sleep Disruption 0–10 NRS score.

Changes from baseline in EDSS score.

Changes from baseline in the QOLCE score.

Change in cognitive function as measured with the cognitive assessment battery.

Changes from baseline in the Vineland-II score.

CGIC.

The number of patients experiencing at least a 25%, 50% and 75% reduction in convulsive seizures and the number of patients seizure free will be summarized and analyzed using the difference in proportions and the odds ratios comparing the treatment groups will be presented together with 95% CIs.

For changes in non-convulsive seizure frequency, number of convulsive seizure free days, changes in frequency of other seizure type, usage of rescue medication, number of hospitalizations due to epilepsy, sleep disruption, daytime sleepiness, QOLCE, cognitive function and behavior assessments, the data will summarized at baseline and at each time point (or 28-day period, as appropriate) during the treatment period. Changes from baseline to the end of study will be analyzed using MMRM, as with the primary endpoint (or appropriate non-parametric methods if data are found to be not normally distributed).

The CGIC will be summarized at all time-points and the final assessments recorded at the end of treatment will be analyzed with ordinal logistic regression using the proportional odds model.

13.6.4 Handling of Missing Data

The primary efficacy analysis uses the ITT analysis set over the evaluable period. MMRM analysis will be used to handle missing values under the Missing at Random assumption.
If any patients have data censored then a sensitivity analysis will be done using all available data, including the data censored from the primary analyses, to assess the impact of censoring the data.

Analysis of covariance of the final time-point, using the Last Observation Carried Forward (LOCF) approach, will also be performed as sensitivity analyses for the primary and key secondary endpoints.

In order to explore the robustness of the primary analysis, further sensitivity analysis may be specified in the SAP.

Similar approaches, using the LOCF, will be applied if the data are analyzed using non-parametric methods.

### 13.6.5 Safety

In the presentation of safety data, data from the two cohorts of placebo patients (Low Dose Level and High Dose Level) will be presented separately and pooled together. This will allow the possibility to explore any effects of the volume of IMP on safety endpoints.

#### 13.6.5.1 Treatment Compliance and Extent of Treatment Exposure

Treatment compliance and exposure to treatment will be summarized.

#### 13.6.5.2 Adverse Events

AEs will be coded according to the Medical Dictionary for Regulatory Activities dictionary.

A treatment emergent AE is one that started, or worsened in severity or seriousness, following the first dose of IMP.

Descriptive presentations of treatment emergent AEs will be given by preferred term and system organ class for the safety analysis. The number of patients reporting at least one AE will be provided.

The following summaries will be produced:

- All-causality AEs.
- Treatment related AEs.
- All-causality AEs by severity.
- All-causality serious AEs.
• Treatment related serious AEs.
• AEs reported as leading to permanent cessation of study treatment.
• Fatal AEs.

13.6.5.3 Clinical Laboratory Data
Clinical laboratory data at screening, during and at the end of treatment and the change from baseline to end of treatment will be summarized for the safety analysis set using appropriate summary statistics. Categorical shift tables will also be presented, showing the numbers of patients with values outside of the normal range.

13.6.5.4 Vital Signs, 12-lead Electrocardiogram, Physical Examination, Columbia-Suicide Severity Rating Scale and Other Safety Data
Vital signs, ECG, physical examination and C-SSRS data will be summarized for the safety analysis set, at screening, baseline and at each time point during the treatment period using appropriate summary statistics. Changes in the vital signs from baseline to end of treatment will also be summarized. CWS and Study Medication Use and Behavior Survey data will be summarized for the safety analysis set using appropriate summary statistics.
14 DATA SAFETY MONITORING COMMITTEE

An independent DSMC will monitor the DS diagnosis of screened patients on an ongoing basis in order to ascertain the correct study population is randomized. Investigators will submit a documented history of DS, directly to the DSMC, for confirmation of diagnosis by the DSMC. The DSMC will provide written documentation of the confirmation of diagnosis directly to the investigator, for inclusion in the patient file.

Details of the composition and standard operating procedures of the DSMC will be detailed in a separate charter.
15 REGULATORY AND ETHICAL OBLIGATIONS

15.1 Declaration of Helsinki

The investigator will ensure that this study is conducted in full conformity with the Declaration of Helsinki, EU Clinical Trials Directive and the clinical trial regulations adopting European Commission Directives into national legislation.

15.2 Informed Consent/Assent

Initial master informed consent and assent forms will be provided to the investigator to prepare the informed consent/assent documents to be used at his or her center. The GW Clinical Manager will communicate updates to the templates by letter. The written informed consent/assent documents should be prepared in the language(s) of the potential patient population.

Before a patient’s participation in the trial, the investigator is responsible for obtaining written informed consent/assent from the patient and/or parent(s)/legal representative after adequate explanation of the aims, methods, anticipated benefits and potential hazards of the study and before any protocol specific screening procedures or any IMPs are administered. The patient and parent(s)/legal representative should have ample time for review to consider the information provided before giving written consent/assent; more specific definitions of ample time may be in force if required by ECs/IRBs or local regulations.

The acquisition of informed consent/assent should be documented in the patient’s medical records and the informed consent/assent forms should be signed and personally dated by the patient and/or parent(s)/legal representative (as applicable) and by the person who conducted the informed consent/assent discussion. GW also requires a physician to be present for consent/assent and to sign the consent/assent forms as well. The original signed informed consent/assent forms should be retained and a copy provided to the patient and/or parent(s)/legal representative. Please note that in certain countries there is a requirement for the patient’s family doctor to be informed of the patient’s participation in the clinical study.

15.3 Institutional Review Board/Ethics Committee

A copy of the protocol, proposed informed consent/assent forms, other patient information material, any proposed advertising material and any further
documentation requested must be submitted to the IRB/EC for written approval. GW
must receive a copy of the written approval of the protocol and informed
consent/assent forms before enrollment of patients into the study and shipment of
IMP.

The investigator must submit and, where necessary, obtain approval from the IRB/EC
for all subsequent protocol amendments and changes to the informed consent/assent
documents. The investigator should notify the IRB/EC of deviations from the
protocol or SAEs occurring at the center and other AE reports received from GW, in
accordance with local procedures.

The investigator will be responsible for obtaining on-going IRB/EC approval/renewal
throughout the duration of the study. Copies of the investigator’s reports and the
IRB/EC continuance of approval must be sent to GW.

15.4 Pre-Study Documentation Requirements

The investigator is responsible for forwarding the following documents to GW for
review before allowing any patients to consent/assent for entry into the study:

- Signed and dated protocol signature page.
- Copy of approved informed consent/assent forms and other patient
  information material.
- Copy of the IRB/EC approval of the protocol, informed consent/assent forms
  and other patient information material.
- Up to date curriculum vitae and medical licenses (as per local regulations) of
  the PI and all sub-investigators.
- The IRB/EC composition and/or written statement of the IRB/EC in
  compliance with the FDA regulations relating to GCP and clinical trials,66,67,
  the EU Clinical Trials Directive69, or International Conference on
  Harmonization Tripartite Guideline for Good Clinical Practice (ICH GCP)75
  where the EU Clinical Trials Directive does not apply.
- Signed laboratory normal ranges and documentation of laboratory certification
  (or equivalent) unless using central laboratory arranged by GW.
- Signed clinical trial agreement (including patient/investigator indemnity
  insurance and financial agreement).
- FDA 1572 form.
- Completed financial disclosure statements for the PI and all sub-investigators
  if relevant.
15.5 Patient Confidentiality

The investigator must ensure that the patient’s anonymity is maintained. On the CRFs and within the databases used to collect the trial data or other documents submitted to GW, patients should be identified by their initials (if allowed per local regulations) and a patient study number only. Documents that are not for submission to GW, e.g., signed informed consent/assent forms, should be kept in strict confidence by the investigator.

In compliance with the FDA regulations relating to GCP and clinical trials, and the EU Clinical Trials Directive/ICH GCP Guidelines, it is required that the investigator and institution permit authorized representatives of the company, the regulatory agencies and the IRB/EC direct access to review the patient’s original medical records for verification of study related procedures and data. Direct access includes examining, analyzing, verifying and reproducing any records and reports that are important to the evaluation of the study. The investigator is obligated to inform the patient that his/her study related records will be reviewed by the above named representatives without violating the confidentiality of the patient.

All information concerning the IMP and operations of GW such as patent applications, formulae, manufacturing processes, basic scientific data or formulation information supplied to the investigator by the company and not previously published is considered confidential by the company and shall remain the sole property of the company. The investigator will agree to use this information only in accomplishing the study and will not use it for any other purposes without the written consent of the company.
16 ADMINISTRATIVE AND LEGAL OBLIGATIONS

16.1 Protocol Amendments and End of Study or Termination

Protocol amendments must be made only with the prior approval of GW. Agreement from the investigator must be obtained for all protocol amendments and amendments to the informed consent/assent documents. The IRB/EC must be informed of all amendments and give approval for any substantial amendments. Amendments for administrative changes can be submitted to the IRB/EC for information only. The investigator must send a copy of the approval letter from the IRB/EC to GW.

Both GW and the investigator reserve the right to terminate the study, according to the clinical trial agreement. The investigator should notify the IRB/EC in writing of the study’s completion or early termination and send a copy of the notification to GW.

16.2 Study Documentation and Storage

The investigator should maintain a list of appropriately qualified persons to whom he/she has delegated study duties. All persons authorized to make entries and/or corrections on CRFs will be included on the GW delegation of authority and signature form.

Source documents are original documents, data and records from which the patient’s CRF data are obtained. These include, but are not limited to, hospital records, clinical and office charts, laboratory and pharmacy records, diaries, electronic data captured by IVRS, microfiches, radiographs and correspondence. CRF entries may be considered source data if the CRF is the site of the original recording, that is, there is no other written or electronic record of data. In the rare situations of this happening, then the source data from the CRF should be transcribed in the patient’s notes with appropriate signature and date to provide a full audit trail. A source data verification plan, identifying the source for each data point at each center, will be agreed with each center prior to patient recruitment.

The investigator and study staff are responsible for maintaining a comprehensive and centralized filing system of all study related, essential documentation (as outlined in ICH E6 Section 8.275), suitable for inspection at any time by representatives from GW and/or applicable regulatory authorities. Elements should include:

- Patient files containing completed CRFs, informed consent/assent forms and supporting copies of source documentation.
• Study files containing the protocol with all amendments, IB, copies of pre-
study documentation (see Section 15.4) and all correspondence to and from
the IRB/EC and GW.

• Proof of receipt, IMP accountability record, return of IMP for destruction,
final IMP reconciliation statement and all drug related correspondence.

In addition, all original source documents supporting entries on the CRFs, diary data
and electronic data captured by IVRS must be maintained and be readily available.

Following completion or termination of a clinical study GW will initiate proper
archive of clinical study related documentation and electronic records generated by
the investigator and/or GW. All clinical trial related documents and electronic
records will be retained within an archiving system for a period dependent upon need
and for a minimum of 20 years. Essential documents should be retained until at least
two years after the last approval of a marketing application in an ICH region and until
there are no pending or contemplated marketing applications in an ICH region or at
least two years have elapsed since the formal discontinuation of clinical development
of the IMP. These documents should be retained for a longer period however if
required by the applicable regulatory requirements or if needed by GW (EU Directive
2005/28/EC Chapter 4 Trial Master File and Archiving Article 16).

GW will inform the investigators for each site in writing of the need for record
retention. No study document should be destroyed without prior written agreement
between GW and the investigator. Should the investigator wish to assign the study
records to another party or move them to another location, he/she must notify GW in
writing of the new responsible person and/or the new location.

\section{16.3 Study Monitoring and Data Collection}

The GW representative and regulatory authority inspectors are responsible for
contacting and visiting the investigator for the purpose of inspecting the facilities and,
upon request, inspecting the various records of the study for example, CRFs and other
pertinent data provided that participant confidentiality is respected.

The GW study monitor, or designee, is responsible for inspecting the CRFs and
available IVRS/diary data at regular intervals throughout the study to verify
adherence to the protocol, completeness, accuracy and consistency of the data and
adherence to local regulations on the conduct of clinical research. The study monitor
should have access to patient medical records and other study related records needed
to verify the entries on the CRFs.
The investigator agrees to co-operate with the study monitor to ensure that any problems detected in the course of these monitoring visits are resolved.

The investigator is responsible for ensuring the data recorded in the CRFs are accurate and complete. The CRF should be completed within five working days after the patient’s visit and before review by the study monitor. Queries generated by GW or its representative are to be answered within a similar period of time. Shorter periods of time may apply during specific situations such as interim analysis or final database cleaning.

All handwritten medical records should be filled out with a black or blue ball-point pen and must be legible. Corrections to paper forms will be made by a single line stroke through the error and insertion of the correction above or beside the error. The change must be initialed and dated by the investigator or a member of the study staff authorized by the investigator. No correction fluid or tape may be used. The PI will sign and date the indicated places on the CRF. These signatures will indicate that the PI inspected or reviewed the data on the CRF, the data queries and the site notifications and agrees with the content.

To ensure the quality of clinical data across all patients and centers, a clinical data management review will be performed on patient data received at GW or a contract research organization (CRO). During this review, patient data will be checked for consistency, omissions and any apparent discrepancies. In addition, the data will be reviewed for adherence to the protocol and FDA regulations\textsuperscript{66, 67, 68, 74}, the ICH GCP Guideline\textsuperscript{75}, and all other applicable regulatory requirements; to resolve any questions arising from the clinical data management review process, data queries and/or center notifications will be sent to the center for completion and then returned to GW or the CRO, as applicable.

GW’s or the CRO’s Clinical Data Management Department will correct the following issues in CRFs without any notification to site staff:

- Misspellings that do not change the meaning of the word, excluding AEs and medications.
- Date errors that occur at the end of the year and into the New Year.
- Temperature unit errors (Fahrenheit vs Centigrade).
- Weight unit errors (pounds vs kilograms) if a baseline weight has been established.
- Administrative data for example, event names for unscheduled visits or retests.
- Clarifying “other, specify” if data are provided for example, race, physical exam.
• If a YES or NO question for example, ‘Were there any AEs?’ is left blank yet AEs are listed on the CRF, YES will be entered in the blank.
• Correct CRF page numbers.

16.4 Electronic Data collected by Interactive Voice Response System
Source data for the assessments collected via the IVRS will be managed by the service provider in accordance with GCP and in adherence to a quality management system. All data will be stored in a secure (for example, redundant hardware, password control, limited physical access to servers), fully audit trailed environment with appropriate industry standard back-up and off-site storage practices.
Access for patients providing assessments and investigators will be authenticated and meet industry standards and comply with FDA 21 CFR part 11 (subpart B – Electronic Records) requirements.
After database lock all investigators will receive a certified copy of all the IVRS assessment data. This data will be in an agreed, read-only format with a covering letter explaining the content of the data, a quality statement from the IVRS provider and the investigator’s responsibilities.
Regulatory and sponsor auditors will have the ability to review but not modify the IVRS data via an agreed means of access.

16.5 Quality Assurance
In accordance with the FDA regulations, EU Clinical Trials Directive/ICH GCP and the sponsor’s audit plans, representatives from GW’s Clinical Quality Assurance Department may select this study for audit. Inspection of site facilities for example, pharmacy, drug storage areas, laboratories and review of study related records will occur to evaluate the study conduct and compliance with the protocol, as per the EU Clinical Trials Directive/ICH GCP and applicable regulatory requirements.

16.6 Compensation
GW will indemnify the investigator and the study site in the event of any claim in respect of personal injury arising due to a patient’s participation in the study, providing that the study protocol has been adhered to. This would include claims arising out of or relating to the administration of the IMP or any clinical intervention or procedure provided for or required by the protocol to which the clinical study
patient would not otherwise have been exposed providing there is no evidence of negligence on behalf of the investigator or their team. GW will not be liable for any claims arising from negligence on the part of the investigator or their team.

16.7 Publication Policy

GW recognizes that there is a responsibility under the regulatory guidelines to ensure that results of scientific interest arising from this clinical study are appropriately published and disseminated. They will co-ordinate this dissemination and may solicit input and assistance from the chief/PIs. A summary of the results of this study will be made available on http://www.ClinicalTrials.gov, as required by U.S. Law.

The raw data from this study may be obtained by the PIs or by their steering committee representatives on request. Should they wish, PIs are allowed to conduct their own analysis and are permitted to present such information along with methods and results of the clinical study at symposia, national or regional professional meetings, and to publish it in theses or dissertations.

All publications e.g., manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW Medical Writing Department and, as applicable, GW Publication Committee for review before release. To ensure adequate time for GW to make comments and suggestions where pertinent, all such material should be submitted to them at least 60 days prior to the date for submission for publication, public dissemination, or review by a publication committee. The PIs must then incorporate all reasonable comments made by GW into the publication.

GW also reserve the right to delay the submission of such information by a period of up to six months from the date of first submission to them in order to allow them to take steps to protect proprietary information where applicable.

16.8 Intellectual Property Rights

All Intellectual Property Rights owned by or licensed to either GW or the PIs, other than those arising from the clinical study, will remain their property. All Intellectual Property Rights arising out of the clinical study will vest in or be exclusively licensed to GW and as such, the PI should promptly disclose all knowledge to GW and refrain from using such knowledge without the prior written consent of GW.
16.9 Confidential Information

GW and the PI should ensure that only personnel directly concerned with the study should be party to confidential information and that any information coming to either party about the other during the course of the study should be kept strictly confidential and should not be disclosed to any third party or made use of without the prior written consent of the other.
17 REFERENCES


3083 3084 3085 3086 3087 3088


62 GWMD09112 Clinical Study Report. A randomized, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of Cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease. 28 November 2013.
64 Topic M 3 Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals Note for Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (CPMP/ICH/286/95—Mod) November 2000.
65 World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects, October 2013, Fortaleza.
### APPENDIX 1. SCHEDULE OF ASSESSMENTS

<table>
<thead>
<tr>
<th>Visit Number</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Day Number</strong> (Visit window)</td>
<td>−28</td>
<td>1 (±3)</td>
<td>15 (±3)</td>
<td>29 (±3)</td>
<td>43 (±3)</td>
<td>57 (±3)</td>
<td>71 (±3)</td>
<td>99 (±3)</td>
<td>100–106 or 109 (±3)</td>
<td>137 (±3)</td>
</tr>
<tr>
<td>Informed consent/assent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility Criteria</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood sample for SCN1A analysis</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital signs</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postural blood pressure</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical examination (including height and body weight)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECG</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical laboratory blood sampling</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical laboratory urine sampling (dipstick urinalysis) §</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine THC screen</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum pregnancy test (if appropriate)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AEs</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Inpatient epilepsy-related hospitalizations</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>C-SSRS</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Sleep Disruption 0–10 NRS</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EDSS</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vineland-II</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CGIC ¶</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QOLCE</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Cognitive assessment battery</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Caregiver Impression of IMP Palatability</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CWS</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Patient diary review (seizures, AE information, concomitant AEDs, rescue medication, IMP dosing)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>IVRS Caregiver Training</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMP dispensing</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collection of IMP</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMP compliance review</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Medication Use and Behavior Survey</td>
<td>#</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>
Only required for those patients who delay entry into or do not participate in the OLE study or for
those who withdraw from the study early. Visit 9 should be within seven days of Visit 8 for
patients delaying entry to the OLE study. For patients who do not participate in the OLE study,
Visit 9 should be 10 days after Visit 8. Patients who opt not to enter the OLE study must have
weekly (±3 days) safety telephone calls until Visit 10.

** For patients who do not enter the OLE study or who withdraw from the study early.

§ Urine sample taken if possible.

† Sample can be taken at any clinic visit during the study.

¶ Caregivers are to compare to the memory aid from Visit 2.

# To be performed at final dosing visit (Visit 8 or 9, as applicable) for patients 12 years of age and
older.

Tel. Visit can be conducted by telephone.
APPENDIX 2. STUDY PERSONNEL

Appendix 2.1 Investigator Details

At the time of protocol production, the participating investigators had not been confirmed. A list of all investigators will be maintained within the GW Master Files (electronically and added to the Trial Master File at the end of the study).

Appendix 2.2 Sponsor Contact Details

Pharmacovigilance Department — SAE Reporting: Fax: PPD
USA Toll Free Fax: PPD
Tel: PPD
Fax: PPD

Sponsor: GW Research Ltd
Porton Down Science Park
Salisbury
Wiltshire SP4 0JQ
United Kingdom
Tel: PPD
Fax: PPD

Medical Monitor
EU
Tel: PPD
Mobile: PPD

USA
Cell: PPD
Clinical Project Manager/Clinical Operations: GW Research Ltd

Director: Sovereign House

GW Research Ltd
Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom

GW Pharma Ltd
Clinical Trials Supplies:

Tel: PPD
Fax: PPD

Tel: PPD
Fax: PPD
1.1 Changes in the Conduct of the Trial or Planned Analysis

1.1.1 Changes in the Conduct of the Trial

A summary of amendments to the protocol is provided in Table 1.1.1-1. The protocol amendments provide the rationale for each modification to the protocol.

### Table 1.1.1-1 Protocol Amendments and Administrative Changes

<table>
<thead>
<tr>
<th>Amendment Number</th>
<th>Date</th>
<th>Amendment Type</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>23 Oct 2014</td>
<td>Substantial</td>
<td>This amendment to Protocol Version 1 (creating Protocol Version 2) incorporated additional requirements identified by GW. Key changes included:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Adding a secondary objective/endpoint to evaluate change in duration of subtypes of seizures as assessed by the CGICSD.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Clarifying of the exclusion criteria addressing previous and current use of cannabinoids.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Adding collection of a full record of epilepsy-specific genetic testing and prior AEDs taken as part of the patient’s medical history for safety assessment and to aid/confirm diagnosis of DS.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Clarifying that IMP usage was to be recorded via the paper diary to reduce the IVRS call time.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Clarifying that the baseline period must be a minimum of 28 days to capture sufficient baseline data.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Clarifying that the safety follow-up period must be a minimum of 28 days after end of treatment to capture sufficient safety data.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Clarifying the subtypes of seizures and definition of “countable partial seizures” to aid identification of seizure types.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Clarifying that the Cognitive Assessment Battery would only be performed at sites that had expertise to conduct the test.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Clarifying that the pre-randomization pregnancy test was to be performed using urine rather than serum to provide an immediate result for assessment of inclusion/exclusion criteria.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Adding the PCWS for children 4–17 years of age.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Correcting minor spelling/formatting/consistency issues.</td>
</tr>
<tr>
<td>2</td>
<td>20 Nov 2014</td>
<td>Substantial</td>
<td>This amendment to Protocol Version 2 (creating Protocol Version 3) incorporated additional requirements identified by the Medicines and Healthcare products Regulatory Agency (MHRA) as follows:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Clarifying that patients randomized into the trial who were later found to meet criteria for DILI must be withdrawn from the trial.</td>
</tr>
<tr>
<td>3</td>
<td>20 Mar 2015</td>
<td>Substantial</td>
<td>This amendment to Protocol Version 3 (creating Protocol Version 4) incorporated additional requirements identified by the FDA and GW. Key changes included:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Specifying that patients would be stratified by age across treatment arms.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Adding assessment of growth and development through measurement of height, body weight, serum IGF-1 levels, and Tanner staging.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Adding measurement of effects of menstruation.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Amending the statistical methods for analysis of the primary and secondary endpoints.</td>
</tr>
</tbody>
</table>
### Table 1.1.1-1  Protocol Amendments and Administrative Changes

<table>
<thead>
<tr>
<th>Amendment Number</th>
<th>Date</th>
<th>Amendment Type</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>29 May 2015</td>
<td>Not submitted</td>
<td>This amendment to Protocol Version 4 (creating Protocol Version 5) incorporated additional requirements identified by the FDA and GW. However, due to subsequent recommendations received from the FDA, Protocol Amendment 4 and corresponding Protocol Version 5 were not submitted to any competent authority or IRB/IEC and hence Protocol Version 5 was never implemented at any trial sites.</td>
</tr>
<tr>
<td>5</td>
<td>29 Jun 2015</td>
<td>Substantial</td>
<td>This amendment to Protocol Version 4 (creating Protocol Version 6) incorporated additional requirements identified by the FDA and GW. Key changes included:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Updating statistical analyses of the primary and secondary endpoints to include the full treatment period (titration plus maintenance period).</td>
</tr>
</tbody>
</table>
### Table 1.1.1-1 Protocol Amendments and Administrative Changes

<table>
<thead>
<tr>
<th>Amendment Number</th>
<th>Date</th>
<th>Amendment Type</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>23 Feb 2017</td>
<td>Substantial</td>
<td>This amendment to Protocol Version 6 (creating Protocol Version 7) incorporated additional requirements identified by GW. Key changes included:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Increasing the number of patients per treatment group from 50 to 62 (a total increase from 150 to 186 patients).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Changing the statistical analyses of seizure data to use nonparametric rather than parametric methods.</td>
</tr>
</tbody>
</table>
### Table 1.1.1 Protocol Amendments and Administrative Changes

<table>
<thead>
<tr>
<th>Amendment Number</th>
<th>Date</th>
<th>Amendment Type</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Adding assessments of plasma and urine concentrations of THC and its major metabolites, and urine concentrations of CBD and its major metabolites.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Amending the PK parameters to allow for accurate determination of the defined parameters.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Adding instructions for patients to record the time of meals the day before and the day of PK sampling.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Clarifying that any clinical symptoms of concern resulting from possible drug-drug interactions should be discussed with the GW medical monitor and if required, adjustments to AEDs will be permitted.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Broadening the mode of IMP administration to encompass patients who have difficulty swallowing.</td>
</tr>
<tr>
<td>7</td>
<td>06 Sep 2018</td>
<td>Non-substantial</td>
<td>This amendment to Protocol Version 7 (creating Protocol Version 8) incorporated additional requirements identified by GW. Key changes included:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Updating the primary analysis method from the Wilcoxon rank-sum test to a negative binomial regression analysis.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Removing the words “percentage change” from the primary endpoint wording and for percentage change in other seizure types under secondary endpoints throughout the protocol.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Adding the replaced Wilcoxon rank-sum test primary analysis as a sensitivity analysis.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Updating other sensitivity analyses from Wilcoxon rank-sum tests to negative binomial regression analyses.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Amending the treatment allocation ratio to clarify that patients were allocated to one of 4 treatment groups</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(GWP42003-P 10 mg/kg/day, GWP42003-P 20 mg/kg/day, placebo 10 mg/kg/day dose volume equivalent, or placebo 20 mg/kg/day dose volume equivalent) at a 2:2:1:1 ratio, and that the 2 placebo groups will be pooled for the analyses of efficacy. The planned sample size was not changed.</td>
</tr>
</tbody>
</table>

Source: Appendix 1.1, Protocol amendments.

#### 1.1.2 Changes in the Planned Analyses

- The identification of 3 key secondary endpoints and the hierarchical testing procedure were not defined in the protocol but were included in the SAP prior to unblinding.
- Upon blinded review of IVRS data for the number of convulsive seizures greater than 30 minutes in duration and the number of non-convulsive seizures greater than 30 minutes in duration, it was determined that there were insufficient numbers of patients reporting these seizures to perform the analyses planned in the protocol.
- Upon blinded review of the number of patients with inpatient epilepsy-related hospitalizations, it was determined that there were insufficient numbers of patients to perform the analyses planned in the protocol.
The protocol included change from baseline in usage of rescue medication as an efficacy endpoint. However, due to inconsistencies in the collection of these data, no analyses were performed.

The endpoint planned in the protocol of number of patients experiencing a > 25% worsening, − 25 to + 25% no change, 25 − 50% improvement, 50 − 75% improvement or > 75% improvement in convulsive seizures from baseline was updated in the SAP to the following:

- Number of patients experiencing a > 25% increase, ≥ 0 to ≤ 25% increase, > 0 to < 25% reduction, ≥ 25 to < 50% reduction, ≥ 50 to < 75% reduction, or ≥ 75% reduction from baseline in convulsive seizure frequency.

The protocol included determination of THC, CBD, and their major metabolites in urine after multiple doses of GWP42003-P. However, none of the consented patients were able to provide a urine sample so no analyses were performed.

The IVRS system was designed to allow caregivers to report a maximum of 99 seizures per day for any individual seizure type since this was considered adequate during the trial design process. However, during the trial some caregivers reported that for some individual seizure types the patient was experiencing more than 99 per day. As described in Section 5.5.2 of the SAP (Appendix 1.9) a ‘> 99 seizure log’ was introduced into the CRF. If a caregiver’s patient experienced > 99 of any individual seizure type, they were instructed to enter ‘99’ into the IVRS and then record the actual number into the paper diary so it could be added to the CRF at the next clinic visit. This process was followed at some sites; however, for many sites the actual number of seizures was not provided by the caregiver. It was agreed that for any entries of ‘99’ within the IVRS where the actual number was not provided by the caregiver the seizure count would remain as 99.

The data showed that only 1 patient, randomized to placebo, recorded 99 for a convulsive seizure type (1 instance of 99 tonic-clonic seizures reported on Day 37). When reviewing the ePRO data profile for this patient it appears the entry should have been 9 and not 99, however this cannot be confirmed so 99 has been reported (Appendix 2; Listing 8.1.1). It has been concluded that this process did not change the interpretation of the primary endpoint.
GW Research Ltd.

Study Code: GWEP1424

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF CANNABIDIOL (GWP42003-P) IN CHILDREN AND YOUNG ADULTS WITH DRAVET SYNDROME

Statistical Analysis Plan

05 October 2018
# CONTENTS

1. Introduction 115
   1.1 Rationale 115

2. Study Objectives 115
   2.1 Primary 115
   2.2 Secondary 115

3. Investigational Plan 115
   3.1 Study Design 115
   3.2 Definition of Sample Size 116
   3.3 Efficacy and Safety Endpoints 117
      3.3.1 Primary Efficacy Endpoint 117
      3.3.2 Secondary Efficacy Endpoints 117
      3.3.3 Safety Variables 118

4. Blinded Data Review Meeting 118

5. Statistical Methods 119
   5.1 General Considerations 119
      5.1.1 Missing Data 120
      5.1.2 Day Numbering 120
      5.1.3 Definitions 121
   5.2 Analysis Sets and Protocol Deviations 121
      5.2.1 Safety Analysis Set 121
      5.2.2 Intention to Treat Analysis Set 122
      5.2.3 Per Protocol Analysis Set and Protocol Deviations 122
   5.3 Listings 122
   5.4 Demographic Data and Patient Characteristics 122
      5.4.1 Patient Disposition 122
      5.4.2 Analysis Sets 123
      5.4.3 Demographic Data and Baseline Characteristics 123
      5.4.4 Epilepsy and Dravet Syndrome History 124
      5.4.5 Medical and Surgical History and Current Medical Conditions 125
   5.5 Efficacy Analysis 125
      5.5.1 General Approach 125
      5.5.2 Primary Efficacy Endpoint 126
      5.5.3 Secondary Efficacy Endpoints 130
      5.5.4 Exploratory Efficacy Endpoints 139
      5.5.5 Subgroup Analyses 140
   5.6 Safety Evaluation 141
      5.6.1 Exposure to IMP 141
      5.6.2 Adverse Events 141
      5.6.3 Clinical Laboratory Evaluation 144
      5.6.4 Vital Signs, Other Physical Findings and Other Safety Data 146
   5.7 Other Measures 149
      5.7.1 Concomitant Medication 149
      5.7.2 Plasma Concentrations of Concomitant Antiepileptic Drugs 149
5.7.3 Caregiver Impression of Investigational Medicinal Product Palatability 150
5.7.4 Study Medication Use and Behavior Survey 150
5.7.5 Supplemental Drug Accountability Form 150
5.7.6 Supplemental Adverse Event Form 150
5.7.7 Site Classification Form 151
5.7.8 IVRS Compliance 151
5.7.9 Meal Times 151
5.8 Changes in the Conduct of the Study or Planned Analysis 152

6. References 152

7. Amendments 153

8. Attachments and Appendices 154

Appendix 1 Adverse Events of Special Interest – Abuse Liability 154

Appendix 2 Ranges for Clinically Significant Changes and Other Defined Flagged Values in Vital Signs 155

Appendix 3 Defined Flagged Values in ECG Parameters 155

Appendix 4 Toxicity Criteria for Laboratory Parameters 155

Appendix 5 List of Tables, Listings and Figures 157
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADHD</td>
<td>Attention Deficit Hyperactivity Disorder</td>
</tr>
<tr>
<td>AEDs</td>
<td>Antiepileptic Drugs</td>
</tr>
<tr>
<td>AEs</td>
<td>Adverse Events</td>
</tr>
<tr>
<td>ALQ</td>
<td>Above Limit of Quantification</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine Aminotransferase</td>
</tr>
<tr>
<td>ANCOVA</td>
<td>Analysis of Covariance</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate Aminotransferase</td>
</tr>
<tr>
<td>ATC</td>
<td>Anatomical Therapeutic Chemical</td>
</tr>
<tr>
<td>BDRM</td>
<td>Blinded Data Review Meeting</td>
</tr>
<tr>
<td>BLQ</td>
<td>Below Limit of Quantification</td>
</tr>
<tr>
<td>BSA</td>
<td>Body Surface Area</td>
</tr>
<tr>
<td>CGIC</td>
<td>Caregiver Global Impression of Change</td>
</tr>
<tr>
<td>CGICSD</td>
<td>Caregiver Global Impression of Change in Seizure Duration</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence Interval</td>
</tr>
<tr>
<td>CMH</td>
<td>Cochran–Mantel–Haenszel</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>C-SSRS</td>
<td>Columbia-Suicide Severity Rating Scale</td>
</tr>
<tr>
<td>CWS</td>
<td>Cannabis Withdrawal Scale</td>
</tr>
<tr>
<td>D-KEFS</td>
<td>Delis–Kaplan Executive Function System</td>
</tr>
<tr>
<td>DS</td>
<td>Dravet Syndrome</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>EDSS</td>
<td>Epworth Daytime Sleepiness Scale</td>
</tr>
<tr>
<td>EEG</td>
<td>Electroencephalography</td>
</tr>
<tr>
<td>eGFR</td>
<td>Estimated Glomerular Filtration Rate</td>
</tr>
<tr>
<td>IGF-1</td>
<td>Insulin-like Growth Factor-1</td>
</tr>
<tr>
<td>IMP</td>
<td>Investigational Medicinal Product</td>
</tr>
<tr>
<td>INR</td>
<td>Prothrombin International Normalized Ratio</td>
</tr>
<tr>
<td>ITT</td>
<td>Intention to Treat</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive Voice Response System</td>
</tr>
<tr>
<td>LOCF</td>
<td>Last Observation Carried Forward</td>
</tr>
<tr>
<td>MAR</td>
<td>Missing at Random</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MI</td>
<td>Multiple Imputation</td>
</tr>
<tr>
<td>MNAR</td>
<td>Missing Not at Random</td>
</tr>
<tr>
<td>NOCB</td>
<td>Next Observation Carried Backward</td>
</tr>
<tr>
<td>NRS</td>
<td>Numerical Rating Scale</td>
</tr>
<tr>
<td>OLE</td>
<td>Open Label Extension</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>PCWS</td>
<td>Pediatric Cannabinoid Withdrawal Scale</td>
</tr>
<tr>
<td>PK</td>
<td>Pharmacokinetics</td>
</tr>
<tr>
<td>PP</td>
<td>Per Protocol</td>
</tr>
<tr>
<td>QOLCE</td>
<td>Quality of Life in Childhood Epilepsy</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical Analysis Plan</td>
</tr>
<tr>
<td>SOC</td>
<td>System Organ Class</td>
</tr>
<tr>
<td>TEAE</td>
<td>Treatment Emergent Adverse Event</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper Limit of Normal</td>
</tr>
<tr>
<td>Vineland-II</td>
<td>Vineland Adaptive Behavior Scales, Second Edition</td>
</tr>
<tr>
<td>WAIS-4</td>
<td>Wechsler Adult Intelligence Scale - Fourth Edition</td>
</tr>
<tr>
<td>WASI-2</td>
<td>Wechsler Abbreviated Scale of Intelligence – Second Edition</td>
</tr>
<tr>
<td>WISC-4</td>
<td>Wechsler Intelligence Scale for Children – Fourth Edition</td>
</tr>
<tr>
<td>WPPSI-4</td>
<td>Wechsler Preschool and Primary Scale of Intelligence – Fourth Edition</td>
</tr>
</tbody>
</table>
1. Introduction

This statistical analysis plan (SAP) documents the statistical reporting to be performed for Study GWEP1424. Details of the analysis and reporting of pharmacokinetics (PK) of CBD and its major metabolites are not included as part of this SAP.

This SAP has been prepared based on the following study documents:
- Protocol GWEP1424 (Version 8, dated 06 September 2018).
- Case Report Form (CRF) GWEP1424, Version 1 (dated 08 April 2015).

1.1 Rationale

Dravet syndrome (DS), also known as severe myoclonic epilepsy in infancy, is a rare form of severe epilepsy with onset in early childhood.

DS is characterized by a variety of treatment-resistant seizures (febrile and afebrile, generalized and unilateral, clonic or tonic–clonic) that occur in the first year of life and have a poor cognitive prognosis.

DS is one of the most pharmacoresistant forms of epilepsy, with all seizure types extremely refractory to conventional antiepileptic drugs (AEDs), especially during the first several years.

In this study the active Investigational Medicinal Product (IMP) is GWP42003-P oral solution.

2. Study Objectives

The protocol defined the study objectives as:

2.1 Primary

To assess the efficacy of GWP42003-P as an adjunctive antiepileptic treatment compared with placebo, with respect to the change during the treatment period of the study compared to baseline in convulsive seizure frequency. The dose response effect between 2 GWP42003-P Dose Levels (10 mg/kg/day and 20 mg/kg/day) and placebo will also be explored. Convulsive seizures are defined as tonic–clonic, tonic, clonic or atonic and non-convulsive seizures as myoclonic, partial or absence.

2.2 Secondary

- To assess changes from baseline in non-convulsive seizure frequency, duration, usage of rescue medication, number of inpatient hospitalizations due to epilepsy, sleep disruption, daytime sleepiness, quality of life, growth and development, and conduct behavioral and cognitive assessments in patients taking GWP42003-P as an adjunctive treatment, when compared with placebo.
- To determine the PK of CBD and its major metabolites following single and multiple doses of GWP42003-P and to assess the presence of Δ⁹-tetrahydrocannabinol (THC) and its major metabolites in plasma and the presence of THC, CBD and their major metabolites in urine after multiple doses of GWP42003-P.
- To determine effects of GWP42003-P on plasma concentrations of concomitant AEDs, where available.
- To assess the safety of both GWP42003-P doses when compared with placebo.

3. Investigational Plan

3.1 Study Design

This study is a randomized, double-blind, 14-week comparison of 2 Dose Levels of GWP42003-P (10 mg/kg/day and 20 mg/kg/day) versus placebo. The treatment period will consist of a 2-week
titration period followed by a 12-week maintenance period. The treatment period will be followed
by a 10-day taper period and a 4-week follow-up period. The study will aim to determine the
efficacy, safety and tolerability of 2 Dose Levels of GWP42003-P compared with placebo.
Following study completion, all patients will be invited to continue to receive GWP42003-P in an
open label extension (OLE) study (under a separate protocol).

### 3.2 Definition of Sample Size

A total of 186 patients will be randomized to one of 4 treatment groups (GWP42003-P 10 mg/kg/day,
GWP42003-P 20 mg/kg/day, placebo 10 mg/kg/day dose volume equivalent, or placebo
20 mg/kg/day dose volume equivalent) at a 2:2:1:1 ratio. The randomization will be stratified by age
group (2–5 years, 6–12 years and 13–18 years). The placebo groups will be pooled for the analyses
of efficacy.

For a Wilcoxon–Mann–Whitney test comparing 2 distributions with a 2-sided significance level of
0.05, a sample size of 62 per group is required to obtain a power of at least 80%. This is based on a
gamma distribution for the GWP42003-P groups with scale parameter of 65.614 and shape parameter
of 1.0886, and a gamma distribution for the placebo group with scale parameter of 40.887 and shape
parameter of 2.3059.

Maximum likelihood estimates using the Newton–Raphson approximation were computed for the
scale and shape parameters using data from study GWEP1332 Part B.
3.3 Efficacy and Safety Endpoints

3.3.1 Primary Efficacy Endpoint

The primary endpoint is the change in total convulsive seizure frequency during the treatment period (Day 1 to the end of the evaluable period) compared to baseline in patients taking GWP42003-P compared with placebo.

3.3.2 Secondary Efficacy Endpoints

The secondary endpoints will be tested hierarchically, based on the order given in Section 5.5.1, Table 3. No multiplicity adjustments will be made for all other secondary endpoints.

3.3.2.1 Key Secondary Efficacy Endpoints

1. Change in total seizure frequency.
2. Number of patients considered treatment responders, defined as those with a ≥50% reduction in convulsive seizures from baseline.
3. Caregiver Global Impression of Change (CGIC) score.

3.3.2.2 Other Secondary Efficacy Endpoints

The following endpoints will be compared between treatment groups over the 14-week, double-blind treatment period:

- Number of patients experiencing a >25% increase, ≥0 to <25% increase, >0 to <25% reduction, ≥25 to <50% reduction, ≥50 to <75% reduction or ≥75% reduction in convulsive seizures from baseline.
- Number of patients considered treatment responders, defined as those with a ≥25% or ≥75% reduction in convulsive seizures from baseline (overall and 4-weekly).
- Number of patients who are convulsive seizure free.
- Change in non-convulsive seizure frequency.
- Change in subtypes of seizures.
- Changes from baseline in number of episodes of status epilepticus.
- Changes from baseline in duration of seizure subtypes as assessed by the Caregiver Global Impression of Change in Seizure Duration (CGICSD).
- Changes from baseline in usage of rescue medication.
- Changes from baseline in number of inpatient hospitalizations due to epilepsy.
- Changes from baseline in Sleep Disruption 0–10 Numerical Rating Scale (0-10 NRS) score.
- Changes from baseline in Epworth Sleepiness Scale (ESS) score.
- Changes from baseline in the Quality of Life in Childhood Epilepsy (QOLCE) score.
- Change from baseline in cognitive function as measured with a cognitive assessment battery.
- Changes from baseline in the Vineland Adaptive Behavior Scales, Second Edition (Vineland-II) score.
- Change from baseline in growth and development by measurement of height, weight, insulin-like growth factor-1 (IGF-1) levels and Tanner Staging (for patients aged 10–17 [inclusive], or earlier if clinically indicated by onset of menarche or other signs of precocious puberty).
PK:
- The plasma concentrations of CBD and its major metabolites will be determined following single and multiple doses of GWP42003-P. The following PK parameters will be calculated from sparse sampling:
  - The concentration at each time interval (C_t) of CBD and its metabolites.
  - Area under the plasma concentration curve (AUC_{0–t}) from time zero to the last measurable concentration.
- Plasma concentrations of concomitant AEDs before and after treatment with GWP42003-P, where available.
- The plasma concentrations of THC and its major metabolites will be determined at a single time point (Visit 8, 2–3 hours post-dose) following multiple doses of GWP42003-P.
- The concentrations of THC, CBD, and their major metabolites will be determined in urine after multiple doses of GWP42003-P.

3.3.3 Safety Variables

The safety profile of GWP42003-P compared with placebo will also be assessed at each Dose Level by measuring:
- Adverse events (AEs).
- Vital signs.
- Physical examination parameters.
- 12-lead electrocardiogram (ECG).
- Clinical laboratory parameters.
- Columbia-Suicide Severity Rating Scale (C-SSRS) score.
- Cannabis Withdrawal Scale (CWS) or Pediatric Cannabinoid Withdrawal Scale (PCWS) score, as appropriate.
- Abuse liability.
- Effects on menstruation cycles (in females).

4. Blinded Data Review Meeting

Prior to breaking the blind, it is anticipated that a Blinded Data Review Meeting (BDRM) will take place. The objectives of the meeting will include:
- Assessment of any study entry violations and protocol deviations.
- Assessment of the use of concomitant medications (including rescue medication) to identify changes which could affect the primary assessment of efficacy.
- Review of any protocol deviations and any potential effect on the study results. Assess the need for additional analyses using a per protocol (PP) population.
- Review of missing data and any potential effect on the study results.
- Safety reporting approach for any patients who potentially received the incorrect IMP during the double-blind phase.
- Assessment of any changes in concomitant AEDs for medical reasons.

The meeting will have access to the following blinded summary tables and listings:
- All pre-randomization patient data.
• All patient efficacy data.
• All concomitant medication data.
• All patient safety data.
• Patient protocol deviation logs.

This SAP documents the currently planned analyses for this study that will be approved prior to breaking the blind for the study. Changes to the analyses planned within any previously approved versions of the SAP will be summarized in Section 5.8 and integrated into the text of the SAP. The minutes of the BDRM will be documented separately.

5. Statistical Methods

5.1 General Considerations

In all tables, listings and figures, the treatment arms will be referred to and labelled as per Table 1.

**Table 1** Study Treatments

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Actual Treatment</th>
<th>Treatment Label</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy</td>
<td>Pooled Placebo</td>
<td>Placebo</td>
</tr>
<tr>
<td>Safety</td>
<td>10 mg/kg/day Placebo</td>
<td>Placebo 10 mg/kg</td>
</tr>
<tr>
<td></td>
<td>20 mg/kg/day Placebo</td>
<td>Placebo 20 mg/kg</td>
</tr>
<tr>
<td>All</td>
<td>10 mg/kg/day GWP42003-P</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>All</td>
<td>20 mg/kg/day GWP42003-P</td>
<td>20 mg/kg</td>
</tr>
</tbody>
</table>

For safety tables where placebo is split by dosing volume, an additional Pooled Placebo column will be included.

In all tables, listings and figures, the study visits will be referred to and labelled as per Table 2.

**Table 2** Study Visits

<table>
<thead>
<tr>
<th>Actual Visit</th>
<th>Visit Label</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 1: Screening</td>
<td>Screening</td>
</tr>
<tr>
<td>Visit 2: Day 1, baseline visit</td>
<td>Day 1</td>
</tr>
<tr>
<td>Visit 3: Day 15</td>
<td>Day 15</td>
</tr>
<tr>
<td>Visit 4: Day 29</td>
<td>Day 29</td>
</tr>
<tr>
<td>Visit 5: Day 43</td>
<td>Day 43</td>
</tr>
<tr>
<td>Visit 6: Day 57</td>
<td>Day 57</td>
</tr>
<tr>
<td>Visit 7: Day 71</td>
<td>Day 71</td>
</tr>
<tr>
<td>Visit 8: Day 99</td>
<td>End of Treatment</td>
</tr>
<tr>
<td>Visit 9: Day 109</td>
<td>End of Taper</td>
</tr>
<tr>
<td>Visit 10: Day 137</td>
<td>Safety Follow-Up</td>
</tr>
</tbody>
</table>

Unless stated otherwise, continuous variables will be summarized showing the number of non-missing values (n), mean, standard deviation, median, minimum and maximum and categorical variables will be summarized showing the number and percentage of patients falling into each category. For continuous summaries of seizure frequency, the lower and upper quartiles will also be presented.

Minimum and maximum values will be presented to the same decimal precision as the raw data. Mean and median will be presented to 1 more decimal place than the raw data, and standard deviation to 2 more decimal places than the raw data. Percentages will be presented to 1 decimal place.

All analyses and summaries will be produced using SAS Version 9.3 or higher.
5.1.1 Missing Data

5.1.1.1 Handling of Missing Data for the Primary Efficacy Endpoint

If a patient withdraws during the treatment period, then the primary analysis variable will be calculated from all the available data, during the treatment period, prior to the patient withdrawing.

Section 5.5.2.1 describes sensitivity analyses to account for missing data arising from unreported days in the Interactive Voice Response System (IVRS), and missing data arising from patients withdrawing during the treatment period.

5.1.1.2 Handling of Missing Data for the Secondary Efficacy Endpoints

5.1.1.2.1 Epworth Sleepiness Scale

If the scores of fewer than 4 of the 8 individual questions are missing, the missing items will be imputed as the mean of the remaining non-missing scores, for the calculation of the total score only.

If the scores of 4 or more of the individual questions are missing, the missing items will not be imputed and the total score will be missing; hence, the patient will not be included in the summary or analysis for that visit.

5.1.1.2.2 Quality of Life in Childhood Epilepsy

The calculations of subscale and overall scores for the QOLCE will treat responses of ‘Not Applicable’ as missing values.

For each subscale, if less than 50% of the items within the subscale are missing (including ‘Not Applicable’) then the subscale score will be calculated using the mean of the non-missing items. If 50% or more of the items within the subscale are missing then the subscale score will not be calculated and will be missing.

For the overall quality of life score, if fewer than 8 of the 16 subscale scores are missing then the overall quality of life score will be calculated using the mean of the non-missing subscale scores. If 8 or more of the subscale scores are missing then the overall quality of life score will not be calculated and will be missing.

5.1.1.3 Adverse Events

Missing and/or incomplete dates/times for AEs will be imputed in a manner resulting in the earliest onset or the longest duration during the treatment period, taking into account that the start date/time should not be after the stop date/time. Stop dates/times will not be imputed if the AE is ongoing.

The imputation method will only be used to determine treatment emergence, and imputed dates/times will not be presented in AE outputs.

A worst-case approach will be followed in the event of missing severity or causality data. If the severity is missing, ‘Severe’ will be imputed. If causality data is missing, ‘Yes’ will be imputed for the question ‘Plausible relationship to study medication’.

5.1.1.4 Concomitant Medication

Missing concomitant medication dates will be handled in a similar fashion as described for AEs in Section 5.1.1.3.

5.1.2 Day Numbering

The first day of treatment (Day 1) will be the date of the Visit 2. However, if the first dose of IMP was not administered on site (as indicated on the CRF) then the date of first dose will be calculated using the information on the ‘IMP Missed Doses Log’ CRF page.

Any days prior to Day 1 will be numbered relative to this day and calculated as:

\[ \text{Date} - (\text{Date of Day 1}) \]

to give Day \(-1, -2, -3\) etc.
Any days post Day 1 will be calculated as:

\[ 1 + \text{Date} - \text{(Date of Day 1)} \]

5.1.3 Definitions

5.1.3.1 Baseline

For clinic visit based endpoints, baseline is defined as the last record or measure collected prior to the first dose of IMP.

For IVRS based endpoints, baseline will include all available data prior to Day 1.

5.1.3.2 Last Visit

Last visit for endpoints assessed at clinic visits is defined as the last scheduled visit (not including the end of taper or safety follow-up visits) at which a patient’s last evaluation is performed.

5.1.3.3 Treatment Period

The treatment period is defined as Day 1 to the earlier of:

- Day 99.
- The date of last dose as recorded on the ‘End of Treatment Study Outcome’ CRF page.

5.1.3.4 Maintenance Period

The maintenance period is defined as Day 15 to the earlier of:

- Day 99.
- The date of last dose as recorded on the ‘End of Treatment Study Outcome’ CRF page.

5.1.3.5 Convulsive Seizures

Convulsive seizures are defined as tonic–clonic, tonic, clonic or atonic seizures.

5.1.3.6 Non-Convulsive Seizures

Non-convulsive seizures are defined as myoclonic, countable partial, other partial or absence seizures.

5.1.3.7 Total Seizures

Total seizures are defined as the combination of convulsive and non-convulsive seizures.

5.2 Analysis Sets and Protocol Deviations

There will be 3 analysis sets.

5.2.1 Safety Analysis Set

All randomized patients who received at least one dose of IMP will be included and analyzed according to the treatment received. Only patients for whom it has been confirmed that they did not take any IMP will be excluded from this safety analysis set.

Upon blinded review of the data, it was identified that 1 patient was randomized in error, but did not receive IMP. This patient will be excluded from the safety analysis set.
Upon blinded review of the data, it was identified that 4 patients randomized to receive the 10 mg/kg/day dose (GWP42003-P or placebo) incorrectly received up to 20 mg/kg/day (up to 50 mg/kg/day for 1 patient) during the treatment period. For safety reporting, these patients will be assigned to the 20 mg/kg/day dose groups (GWP42003-P or placebo).

### 5.2.2 Intention to Treat Analysis Set

All randomized patients who received at least one dose of IMP and have post-baseline efficacy data will be included and analyzed according to the treatment group to which they were randomized.

The intention to treat (ITT) analysis set is the primary analysis set for all efficacy endpoints.

Upon blinded review of the data, it was identified that 1 patient was randomized in error, but did not receive IMP. This patient will be excluded from the ITT analysis set.

### 5.2.3 Per Protocol Analysis Set and Protocol Deviations

If there are a sufficient number of significant protocol deviations in the study, a PP analysis set may also be presented.

All patients who complete the study, with no protocol deviations deemed to compromise the assessment of efficacy, will be included and analyzed according to the treatment group they were randomized to. The rules determining the PP analysis set will be fully defined prior to unblinding of the database.

A listing will be produced of protocol deviations for the clinical study report. These protocol deviations will be imported from the protocol deviations log. Protocol deviations will be classed as minor, important or major, where major deviations are classed as important protocol deviations leading to exclusion from the PP analysis set.

Protocol deviations were reviewed during the BDRM on 21st September 2018. In addition to patients in the ITT analysis set who withdrew from the study during the treatment phase, a number of patients were deemed to have protocol deviations that should lead to exclusion from the PP analysis set. These patients, together with their deviations, are detailed in a separate document finalized prior to unblinding.

### 5.3 Listings

All data will be listed and ordered by site, treatment, patient number and, where appropriate, chronological order of assessment. Listings will be created for each of the subsequent sections of the SAP.

Visit date need not be included on all of the listings, but day numbers will be included, where appropriate.

Other derived variables (e.g. changes from baseline values) that are calculated for analysis purposes or to aid interpretation of the data will be added to the listings as appropriate.

### 5.4 Demographic Data and Patient Characteristics

#### 5.4.1 Patient Disposition

Patient disposition, by site, by country and overall, will be summarized using standard summary statistics. The number screened, number of screen failures and number randomized will be included.

A screen failure disposition table will be presented, including number of patients screened, number failing screening, number randomized and the reasons for failing screening.

Patient disposition, including patients treated, patients completed the treatment phase and the
taper phase, patients discontinued (including reason for discontinuation) from the treatment
and taper phases will be summarized by absolute counts (n) and percentages (%). A further
table split by site, and by country will be produced, showing number of patients randomized,
withdrawn and completed the treatment phase at each site or in each country.

5.4.2 Analysis Sets
Patients included in the safety, ITT and PP analysis sets, and patients excluded together with
reasons for exclusion, will be summarized by absolute counts (n) and percentages (%).

5.4.3 Demographic Data and Baseline Characteristics
The following demographic data will be summarized by treatment group and overall for the
safety, ITT and PP analysis sets:
- Age (years);
- Age group (2-5 years, 6-12 years and 13-18 years);
- Sex;
- Race;
- Country;
- Region (United States, Rest of the World);
- Weight at baseline (kg);
- Height at baseline (cm);
- Body mass index at baseline (kg/m²).

Age will be calculated as:
(Date of screening – date of birth) \div 365.25.
The following baseline characteristics will be summarized by treatment group and overall for
the safety, ITT and PP analysis sets:
- Average number of convulsive seizures per 28 days.
- Average number of non-convulsive seizures per 28 days.
- Average number of total seizures per 28 days.
- Number of patients with seizures during the baseline period, by seizure type.
- Number of antiepileptic medications a patient has used, prior to the study.
- Number of antiepileptic medications a patient is currently taking.
- Total number of prior and current antiepileptic medications.
- Number of patients taking clobazam (Yes, No, and if no, Prior).
- Number of patients taking valproic acid (Yes, No, and if no, Prior).
- Number of patients taking stiripentol (Yes, No, and if no, Prior).
- Number of patients taking levetiracetam (Yes, No, and if no, Prior).
- Number of patients taking topiramate (Yes, No, and if no, Prior).

The number of prior antiepileptic medications a patient has used will be taken from the
‘History of antiepileptic medications and therapies’ CRF page. The number of antiepileptic
medications a patient is currently taking is based on the ‘Concomitant antiepileptic medications’ CRF page. If a patient has a medication listed on both the ‘History of antiepileptic medications and therapies’ and ‘Concomitant antiepileptic medications’ CRF pages, then the medication is considered concomitant (see Section 5.7.1); this will not be included in the number of prior antiepileptic medications for that patient. Antiepileptic medications starting after the last dose of IMP during the treatment period will not be counted.

Patients taking the same antiepileptic medication type, but where the medications were coded to different generic terms will be counted only once within the medication type. For example, valproate sodium, valproic acid, valproate semisodium and ergenyl chrono will all be counted as valproic acid and counted once under that term.

The number of patients taking clobazam is defined as the number of patients taking clobazam at any point during baseline period or treatment period. The same definition will apply for the number of patients taking valproic acid, stiripentol, levetiracetam and topiramate.

Previous cannabis use will be included within the baseline characteristics listing.

5.4.4 Epilepsy and Dravet Syndrome History

5.4.4.1 Dravet Syndrome History

The following DS history data will be summarized by treatment group and overall for the safety analysis set:

- Was development ever normal? (Yes, No, Unknown).
- If developmental delay is present, age concerns first arose (years).
- Is there intellectual disability, mental retardation or learning disability? (Yes, No).
  - If yes, how severe is the intellectual disability, mental retardation or learning disability? (Mild, Moderate, Severe, Profound, Other, Unknown).
- Was there developmental regression? (Yes, No).
  - If yes, at what age (years).
- Is the patient verbal or nonverbal? (Verbal, Non-Verbal).
  - If Verbal, extent of vocabulary (Single words, 2–3 word phrases, Long sentences, Other).
- Age patient started walking (years).
- Has any medication increased seizure frequency? (Yes, No).
- Has any medication reduced seizure frequency? (Yes, No).
- Has there been a prolonged seizure free period greater than 6 months? (Yes, No).
  - If yes, age at last occurrence (years).

5.4.4.2 History of Seizures No Longer Occurring and History of Current Seizures

Data will be summarized by treatment group and overall for the safety analysis set, separately, for history of seizures no longer occurring and history of current seizures.

The following will be summarized by each seizure type:

- Number of patients with the seizure type.
• Age at onset (years).
• Age of last occurrence (years). For history of seizures no longer occurring only.
• Seizure duration (<2 minutes, 2–10 minutes, >10 minutes, Unknown). For history of current seizures only.

Seizure frequency and trigger data will be listed only.
For patients with more than 1 record for a particular seizure type, the earliest onset, most recent age of last occurrence and longest duration will be used for the summary table.

5.4.4.3 Electroencephalography History

The following electroencephalography (EEG) history data will be summarized by treatment group and overall for the safety analysis set:

• Has the patient ever had a normal EEG? (Yes, No).
  - If yes, how old was the patient when they last had a normal EEG? (Years).
• Has the patient ever had an abnormal EEG? (Yes, No, Unknown).
  - If yes:
    - EEG findings (Focal spikes, Generalized spike wave discharges, Hypsarrhythmia, Electrographic seizures).
    - Seizure type (Partial (focal) seizures, Generalized seizures, Other).
      - Generalized seizures type (Generalized spike & wave, Generalized paroxysmal fast activity, Generalized electrodecrement at onset).
    - Seizure features (Background slowing and/or disorganization, Focal slowing, Other).

5.4.4.4 Neuroimaging History

Neuroimaging history data will be listed only.

5.4.5 Medical and Surgical History and Current Medical Conditions

All conditions and diagnoses on the ‘non-epilepsy medical history’ CRF page will be coded using Version 17.1 of the Medical Dictionary for Regulatory Activities (MedDRA v17.1). The number of patients with relevant or significant non-epilepsy medical or surgical history and medical history by system organ class, and preferred term, will be summarized by absolute counts (n) and percentages (%). Percentages will be calculated based on the number of patients in the specific treatment group. Two tables will be produced, one including any events classified as resolved at screening, and the other including all current conditions.

5.5 Efficacy Analysis

5.5.1 General Approach

The primary analyses will use the ITT analysis set. Further analyses using the PP analysis set will also be performed for the primary endpoint and secondary endpoints where specified in the sections below.
The primary null hypothesis is:

- Following 14 weeks of treatment there is no difference in effect between the 20 mg/kg/day GWP42003-P treatment group and the placebo treatment group in terms of the change in convulsive seizure frequency during the treatment period compared to baseline.

The null hypothesis will be rejected if there is statistical evidence of a difference between the treatment groups at the $\alpha$-level of 0.05 for the primary endpoint.

Statistical hypothesis testing will be performed on the primary endpoint and other endpoints as appropriate. Each endpoint, including the primary will have 2 comparisons against placebo (20 mg/kg/day GWP42003-P and 10 mg/kg/day GWP42003-P vs. placebo). Also, 3 key secondary endpoints have been defined.

The primary and key secondary endpoints will be tested with their Type I error controlled by use of a hierarchical gate-keeping procedure, in the sequence given in Table 3. One must reject the null hypothesis of an endpoint at the level of 0.05 (2-sided) to test the hypothesis of the subsequent endpoint in the sequence at the level of 0.05 (2-sided). If a null hypothesis is not rejected then testing will stop and all subsequent analyses will be declared not statistically significant.

**Table 3**  
Hierarchy for Analysis

<table>
<thead>
<tr>
<th>Test</th>
<th>Endpoint</th>
<th>Treatment Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Primary endpoint</td>
<td>20 mg/kg/day GWP42003-P vs. Placebo</td>
</tr>
<tr>
<td>2</td>
<td>Primary endpoint</td>
<td>10 mg/kg/day GWP42003-P vs. Placebo</td>
</tr>
<tr>
<td>3</td>
<td>1st key secondary endpoint</td>
<td>20 mg/kg/day GWP42003-P vs. Placebo</td>
</tr>
<tr>
<td>4</td>
<td>1st key secondary endpoint</td>
<td>10 mg/kg/day GWP42003-P vs. Placebo</td>
</tr>
<tr>
<td>5</td>
<td>2nd key secondary endpoint</td>
<td>20 mg/kg/day GWP42003-P vs. Placebo</td>
</tr>
<tr>
<td>6</td>
<td>2nd key secondary endpoint</td>
<td>10 mg/kg/day GWP42003-P vs. Placebo</td>
</tr>
<tr>
<td>7</td>
<td>3rd key secondary endpoint</td>
<td>20 mg/kg/day GWP42003-P vs. Placebo</td>
</tr>
<tr>
<td>8</td>
<td>3rd key secondary endpoint</td>
<td>10 mg/kg/day GWP42003-P vs. Placebo</td>
</tr>
</tbody>
</table>

All statistical tests will be 2-sided and use the 5% significance level.

The assumptions of normality and homogeneity of variance, for endpoints analyzed using parametric tests, will be checked where appropriate via examination of residual plots as well as computation of summary statistics for normality using the Shapiro–Wilk statistical test. If assumptions are violated then alternative non-parametric techniques will be used. In this instance the original parametric tests will be presented as a sensitivity analysis.

### 5.5.2 Primary Efficacy Endpoint

The primary endpoint is the change in convulsive seizure frequency during the treatment period (see Section 5.1.3.3) of the study compared to baseline (see Section 5.1.3.1) in patients taking GWP42003-P compared with placebo.

The primary endpoint will be analyzed using negative binomial regression on the sum of the convulsive seizure counts during the treatment period. However, convulsive seizure frequency (28-day average) and percentage change in seizure frequency will be presented using summary statistics. Percentage change from baseline in convulsive seizure frequency will be calculated as:

$$\frac{\text{Frequency during the treatment period} - \text{Frequency during baseline}}{\text{Frequency during baseline}} \times 100$$

The frequency during each period will be based on 28-day averages and calculated as:

$$\frac{\text{Number of seizures in the period} \div \text{Number of reported days in IVRS in the period}}{28}$$

For convulsive seizure endpoints only, if patients are randomized with no convulsive
seizures during the baseline period then the percentage change from baseline will be calculated as:

\[
\frac{(\text{Frequency during the treatment period} + 1) \times 100}{100}
\]

A mixed effect model with repeated measures will be performed modelling the observed number of convulsive seizures in the baseline period and treatment period implemented within the framework of general linear models using the negative binomial response distribution. The model will include stratified age group (2–5 years, 6–12 years and 13–18 years), time, treatment arm and treatment arm by time interaction as fixed effects and patient as a random effect. The log transformed number of days in which seizures were reported will be included as an offset. The time variable corresponds to an indicator for the baseline period and treatment period.

The GLIMMIX procedure in SAS will be utilized to perform the analysis with the option maxopt=300 applied. If the model fails to converge, then the statement ‘nloptions tech=nrridg;’ will be added. However, if convergence is still not possible, then the model will be changed to utilize the log normal response distribution (log rate model). If the log rate model is required and there are patients with a seizure frequency during the baseline or treatment period of 0 then all patients will have their baseline and treatment period seizure frequency adjusted by adding a value of 1.

The estimated ratio of least squares means for treatment period to baseline period and 95% confidence intervals (CIs) will be presented for each treatment arm. In addition, the estimated ratio of each GWP42003-P group to placebo and 95% CIs will be presented along with the p-value testing the null hypothesis that this ratio is 1.

For each ratio and upper and lower bound of the 95% CI, the percentage reduction will also be presented, calculated as:

\[
\left[1 - \left(\frac{X}{Y}\right)\right] \times 100\%
\]

Where X corresponds to the treatment period estimate, or GWP42003-P ratio, and Y corresponds to the baseline period estimate, or placebo arm ratio.

Primary efficacy analysis will be performed using ITT analysis set.

For a period of time, the limit for the number of daily seizures for each seizure type recorded in IVRS was 99. A >99 seizure log was added to the CRF to allow the capture of the exact number of seizures where the count on a particular day was >99. When deriving the seizure frequencies, the count >99 provided on the CRF will replace the recorded 99 seizures in IVRS for the corresponding seizure type. This will only be done when the corresponding IVRS record was exactly 99.

5.5.2.1 Sensitivity Analyses for the Primary Efficacy Endpoint

The following sensitivity analyses will be conducted for the primary endpoint:

- Primary endpoint analysis repeated using the PP analysis set.

- Wilcoxon rank-sum test on percentage change from baseline in convulsive seizure frequency during the treatment period. An estimate of the median differences between each GWP42003-P group and placebo, together with approximate 95% CIs, will be calculated using the Hodges–Lehmann approach.

- A rank analysis of covariance (ANCOVA) on percentage change from baseline in convulsive seizure frequency during the treatment period.

The ranks of the percentage change from baseline and the baseline convulsive seizure frequency will be calculated. The rank of the percentage change from baseline will then be analyzed using an ANCOVA model with the rank of the baseline convulsive...
seizure frequency and age group (2–5 years, 6–12 years and 13–18 years) as
covariates and treatment group as a fixed factor. The estimated least squares means,
treatment differences, together with the 95% CIs and p-values will be presented.
• ANCOVA of log transformed convulsive seizure frequency during the treatment
period.
The convulsive seizure frequency during the treatment period and the baseline
convulsive seizure frequency will be log transformed prior to analysis. The log
transformed convulsive seizure frequency during the treatment period will then be
analyzed using an ANCOVA model with the log transformed baseline convulsive
seizure frequency and age group as covariates and treatment group as a fixed factor.
The back transformed estimated treatment ratios, together with the 95% CIs and p-
values will be presented.
If there are any patients with no seizures during the baseline or treatment periods,
then 1 will be added to the convulsive seizure frequency for all patients prior to log
transformation.
• ANCOVA on percentage change from baseline in convulsive seizure frequency
during the treatment period including baseline and age group as covariates and
treatment group as a fixed factor. The estimated least squares means, treatment
differences, together with the 95% CIs and p-values will be presented.
• Primary endpoint analysis repeated using the maintenance period (see Section
5.1.3.4) rather than the treatment period.
This analysis will include only patients who have at least 7 days of seizure data
within the maintenance period.
• Primary endpoint analysis repeated using each 4 weeks of the maintenance period
(Week 1–4, Week 5–8 and Week 9–12 of the 12-week maintenance period).
This analysis will include only patients who have at least 7 days of seizure data
within each corresponding 4-week period rather than the treatment period.
• Primary endpoint analysis repeated using the worst case of last observation carried
forward (LOCF), next observation carried backward (NOCB) and the daily mean
from the non-missing data for each patient (rounded up to the nearest integer) to
impute missing data arising from unreported days in IVRS during the treatment
period only (not the baseline period).
Any intermittent missing data for the number of convulsive seizures arising from
unreported days in IVRS will be imputed using the worst (highest number of
seizures) of the following for each patient: LOCF, NOCB and the mean daily number
of seizures during the treatment period (rounded up to the nearest integer) based on
using non-missing data:
\[
\text{Number of seizures} \div \text{Number of reported days in IVRS}
\]
• Wilcoxon rank-sum test on percentage change from baseline in convulsive seizure
frequency during the treatment period, using multiple imputation (MI) to impute data
under the Missing Not at Random (MNAR) assumption (see Section 5.5.2.1.1).
• Primary endpoint analysis repeated using the safety analysis set.

5.5.2.1.1 Sensitivity Analysis of Missing Data

Missing data in this trial could potentially arise from the mechanism of MNAR. In order to
understand the impact on the trial findings from missing data under the MNAR assumption,
sensitivity analyses of the primary endpoint will be carried out for the ITT analysis set by
multiple imputations on convulsive seizure frequency, based on time-points corresponding to each 14 days of the treatment period. The final period will consist of 15 days to include Day 99, if applicable.

For each 14 calendar days of the treatment period (15 days for the final period), the convulsive seizure frequency will be calculated as:

\[
\text{Number of convulsive seizures in the period ÷ Total number of reported days in IVRS for all combined periods (maximum of 99 days)} \times 28
\]

For patients with any periods with no reported days in IVRS, the total number of reported days in IVRS will include an additional 14 days for each missing period. For example, if a patient withdraws with 80 reported days in IVRS from 6 of the 7 14-calendar-day periods, then the total number of reported days in IVRS for the above calculation will be the sum of 80 and 14, i.e., 94 days.

Intermittent missing values for intermediate nominal visits before the last nominal visit will be imputed using the MCMC method in PROC MI with an IMPUTE=MONOTONE statement for 100 times for each treatment group separately. The resulting 100 partially imputed datasets will have a monotone missing pattern and will be further imputed under an MNAR assumption that the imputed value for the missing efficacy data of GWP42003-P patients (discontinued for certain reasons) are similar to, worse than, or better than those of placebo patients for the following 2 scenarios:

1. MNAR assumed for missing values resulting from discontinuation due to AEs in the GWP42003-P groups and Missing at Random (MAR) for others, including other patients discontinued in the GWP42003-P groups and patients in placebo group;
2. MNAR assumed for missing values resulting from discontinuation due to any reason or any other monotone missing data in the GWP42003-P groups and MAR for others, including patients in placebo group.

For each of the 2 scenarios above, imputation will be carried out once on each of the 100 imputed datasets using the SAS MI procedure (with the 100 imputed datasets included in the ‘BY’ statement of the MI procedure) as follows:

- **Step 1:** Monotone missing data under the MAR assumption at treatment period time-point t will be imputed by means and covariance from the observed convulsive seizure frequency at baseline and at each treatment period time-point up to time-point t (in chronological order) in their corresponding treatment groups (i.e., patients in the GWP42003-P groups whose missing data are assumed to be MAR and all patients in the placebo group). The imputation will be realized using the MI procedure with the ‘MONOTONE REG’ option, for each treatment group separately. The imputation model will include convulsive seizure frequency at baseline and each treatment period time-point up to time-point t (in chronological order).

- **Step 2:** With the data imputed from Step 1, monotone missing data of patients in the GWP42003-P groups under the MNAR assumption will be imputed. At each treatment period time-point t, the input dataset for the MI procedure will include all placebo patients and those patients from each GWP42003-P group that have values missing under MNAR at that time-point. The imputation model will include convulsive seizure frequency at baseline and each treatment period time-point up to time-point t (in chronological order). After the sequential imputation is completed for all time-points, the imputed values at time-point t plus, a sensitivity parameter, k × standard error of the observed convulsive seizure frequency in the placebo group at the corresponding time-point (calculated using the denominator of the total number of reported days in IVRS for all combined periods, as given above) will then form the final imputed values. The sensitivity parameter k (where, for example, k = 0, ± 0.5, ± 1.0, ± 1.5, etc.) will be used to explore the robustness of the estimated treatment
difference to the degree of decrease or increase (positive values of k represent
decrease and negative values represent increase) in MNAR efficacy from the placebo
patients.

After missing values at all the time-points are imputed, the overall percentage change from
baseline in convulsive seizure frequency will be calculated as:

\[
[(\text{The sum of the frequencies of each 14 days of the treatment period} - \text{Frequency during
baseline}) \div \text{Frequency during baseline}] \times 100
\]

If the sum of the frequencies of each 14 days of the treatment period becomes less than zero,
as a result of imputation, then the percentage change from baseline in convulsive seizure
frequency will be set to −100%.

The data will then be analyzed using a Wilcoxon rank-sum test.

The results of the Wilcoxon rank-sum test on the 100 imputed datasets will be combined to
derive an overall p-value. The test statistic will be based on the method provided by Rubin
1
and a modified macro from Mogg2.

For each analysis, the increment in the positive value of k will stop once the overall p-value
is greater than 0.05. The decrease in the negative values of k will continue until the overall
p-value becomes smaller than the p-value from the primary efficacy analysis, for the
corresponding Dose Level.

5.5.3 Secondary Efficacy Endpoints

5.5.3.1 Key Secondary Efficacy Endpoints

5.5.3.1.1 1st Key Secondary Endpoint: Total Seizures

Summaries and analyses of total seizures (see Section 5.1.3.7) will be performed as per the primary
endpoint (Section 5.5.2).

The analysis will be performed on the ITT analysis set and repeated on the PP analysis set.

Sensitivity analyses will be performed on the ITT analysis set, repeating the above analysis, using
data for only the maintenance period, and during each 4 weeks of the maintenance period (Week 1–4,
Week 5–8 and Week 9–12 of the 12-week maintenance period).

Analyses on the maintenance period and by each 4 weeks of the maintenance period will include only
patients who have at least 7 days of seizure data within each corresponding period.

5.5.3.1.2 2nd Key Secondary Endpoint: Convulsive Seizure Treatment Responders

(≥50% Reduction in Convulsive Seizure Frequency)

The proportion of patients considered treatment responders, defined as those with a ≥50% reduction
in convulsive seizure frequency from baseline, during the treatment period, will be summarized by
treatment group and analyzed using a Cochran–Mantel–Haenszel (CMH) test stratified by age group.

The proportion of patients who are considered treatment responders, the difference in proportions
along with the 95% CI for the difference, the estimated odds ratios (GWP42003-P groups vs.
placebo), 95% CI for the odds ratios, and the p-values from the CMH test will be presented. If no
patients in a particular treatment group are considered responders then the odds ratio and 95% CI for
the odds ratio will not be calculated.

The analysis will be performed on the ITT analysis set and repeated on the PP analysis set.

Sensitivity analyses will be performed on the ITT analysis set, repeating the above analysis, using
data for the maintenance period only, and during each 4 weeks of the maintenance period (Week 1–4,
Week 5–8 and Week 9–12 of the 12-week maintenance period).

Analyses on the maintenance period and by each 4 weeks of the maintenance period will include only
patients who have at least 7 days of seizure data within each period.
5.5.3.1.3 3rd Key Secondary Endpoint: Caregiver Global Impression of Change

The CGIC will be assessed at Visits 3, 4, 6 and 8 (end of treatment). The CGIC comprises the following question to be rated on a 7-point scale:

• Since your child started treatment, please assess the status of your child’s overall condition (comparing their condition now to their condition before treatment) using the scale below.

The possible responses are: Very Much Improved; Much Improved; Slightly Improved; No Change; Slightly Worse; Much Worse; Very Much Worse.

The responses above are based on comparison with a brief description of the patient’s overall condition used as a memory aid from Visit 2.

Each response will be coded with a score from 1 to 7, where 1 = Very Much Improved, and 7 = Very Much Worse.

The CGIC response/score, recorded at each visit, will be summarized, on both a categorical and continuous scale, by treatment group.

The score at the end of treatment visit and last visit (if different to the end of treatment) will be analyzed using ordinal logistic regression. Proportional odds modelling will be carried out by including treatment group as a factor. The estimated odds ratios (GWP42003-P arms vs. placebo), 95% CI for the odds ratios, and the p-value testing the null hypothesis that the odds ratio is equal to 1, will be presented. Analysis performed at the last visit will be considered the main analysis for this endpoint, with the analysis at the end of treatment visit considered a sensitivity analysis.

Should the proportional odds assumption not hold, i.e. if the p-value for the score test for proportional odds assumption is <0.05, then, as a sensitivity analysis, the scores will also be analyzed using a Cochran-Armitage trend test. This will be presented together with the results of the ordinal logistic regression.

5.5.3.2 Other Secondary Efficacy Endpoints

5.5.3.2.1 Convulsive Seizure Treatment Responders and Convulsive Seizure Freedom

The number of patients experiencing >25% increase, ≥0 to ≤25% increase, >0 to <25% reduction, ≥25 to <50% reduction, ≥50 to <75% reduction or ≥75% reduction in convulsive seizure frequency from baseline during the treatment period will be summarized by treatment group.

In addition to the key secondary endpoint, the proportion of patients considered treatment responders, defined as those with a ≥25% or ≥75% reduction in convulsive seizure frequency from baseline and the proportion of patients who are convulsive seizure free, defined as those with a 100% reduction in convulsive seizure frequency from baseline, during the treatment period, will be summarized by treatment group and analyzed using a CMH test stratified by age as described in Section 5.5.3.1.2.

Additionally, the proportion of patients responding will be presented graphically, by treatment arm, by plotting the percent reduction against the cumulative proportion of patients achieving that level of reduction. The x-axis will be the percent reduction from baseline and the y-axis will be the proportion of patients with at least that amount of reduction, i.e. \( y = \Pr(X \geq x) \).

Sensitivity analyses will be performed on the ITT analysis set, repeating the above analysis, using data for the maintenance period only, and during each 4 weeks of the maintenance period (Week 1–4, Week 5–8 and Week 9–12 of the 12-week maintenance period).

Analyses on the maintenance period and by each 4 weeks of the maintenance period will include only patients who have at least 7 days of seizure data within each corresponding period.

5.5.3.2.2 Status Epilepticus

The number of convulsive seizures greater than 30 minutes in duration and the number of non-
convulsive seizures greater than 30 minutes in duration will be collected daily via IVRS.

The number of patients with convulsive and non-convulsive seizures greater than 30 minutes in duration, will be presented for the baseline and treatment periods.

In addition, the number of patients with any episodes post-baseline and no episodes during the baseline period, will be summarized by treatment group.

### 5.5.3.2.3 Non-Convulsive Seizures

Non-convulsive seizures will be summarized and analyzed as per the primary endpoint (Section 5.5.2). Patients with no non-convulsive seizures during the baseline period will be excluded from the analysis.

Sensitivity analyses will be performed on the ITT analysis set, repeating the above analysis, using data for only the maintenance period, and during each 4 weeks of the maintenance period (Week 1–4, Week 5–8 and Week 9–12 of the 12-week maintenance period).

Analyses on the maintenance period and by each 4 weeks of the maintenance period will include only patients who have at least 7 days of seizure data within each corresponding period.

Non-convulsive seizure responders and freedom will also be summarized and analyzed using the methods described in Section 5.5.3.2.1. Patients with no non-convulsive seizures during the baseline period will be excluded from the analysis.

### 5.5.3.2.4 Individual Seizure Types

For each individual seizure type (tonic–clonic, tonic, clonic, atonic, myoclonic, countable partial, other partial and absence seizures) summaries and analyses will be performed as per the primary endpoint (Section 5.5.2). Patients with no seizures during the baseline period, for a particular seizure type, will be excluded from the analysis of that seizure type.

Sensitivity analyses will be performed on the ITT analysis set, repeating the above analysis for tonic, tonic–clonic, atonic and clonic seizures only, using data for only the maintenance period, and during each 4 weeks of the maintenance period (Week 1–4, Week 5–8 and Week 9–12 of the 12-week maintenance period).

Analyses on the maintenance period and by each 4 weeks of the maintenance period will include only patients who have at least 7 days of seizure data within each corresponding period.

Individual seizure type responders and freedom will also be summarized and analyzed using the methods described in Section 5.5.3.2.1. However, the summaries and analyses during the maintenance period and during each 4 weeks of the maintenance period will be produced for tonic, tonic–clonic, atonic and clonic seizures only. Patients with no corresponding seizures, for a particular seizure type, during the baseline period will be excluded from the analysis for that seizure type.

In addition, the number of patients with an occurrence of an individual seizure type not experienced in the baseline period will be summarized by treatment group.

An occurrence of an individual seizure type not experienced in the baseline period is calculated as seizure types with no seizures experienced during the baseline period and at least one seizure experienced at any time post first dose of IMP.

### 5.5.3.2.5 Caregiver Global Impression of Change in Seizure Duration

The CGICSD comprises the following question to be rated on a 3-point scale for each seizure type:

- Since the patient started treatment, please assess the average duration of the patient’s seizures (comparing their condition now to their condition before treatment) using the scale below.

The 3 possible responses are:

- Decrease in average duration.
- No change in average duration.
- Increase in average duration.

The caregiver will be asked to assess the average duration of the patient’s seizures at Visit 2 (prior to
commencement of IMP) as a memory aid for assessment at the end of treatment visit.

Each response will be coded with a score from 1 to 3, where 1 = Decrease in average duration, and 3 = Increase in average duration.

For each seizure type, the CGICSD will be summarized by treatment group and analyzed using ordinal logistic regression.

Proportional odds modelling will be carried out by including treatment group and age group as factors. The estimated odds ratios (GWP42003-P groups vs. placebo), 95% CI for the odds ratios, and the p-values testing the null hypothesis that the odds ratio is equal to 1, will be presented.

5.5.3.2.6 Inpatient Hospitalizations due to Epilepsy

The number of inpatient epilepsy-related hospitalizations since the previous visit are recorded at every visit starting from Visit 2 (Day 1).

The number of patients with inpatient epilepsy-related hospitalizations will be presented for the baseline and treatment periods.

5.5.3.2.7 Sleep Disruption 0-10 Numerical Rating Scale

The sleep disruption 0-10 NRS will be performed at Visits 2 (Day 1), 3, 4, 6 and 8 (end of treatment). The patient’s caregiver will be asked:

- “On a scale of ‘0 to 10’, please indicate the number that best describes your child’s sleep disruption in the last week.”

The markers range from 0 = slept extremely well, to 10 = unable to sleep at all.

The sleep disruption 0-10 NRS score, recorded at each visit, will be summarized, on a continuous scale, by treatment group. The change from baseline (Visit 2) will also be included.

The change from baseline to the end of treatment visit and last visit (if different to the end of treatment) will be analyzed using ANCOVA. The model will include baseline and age group as covariates and treatment group as fixed factor. Analysis performed at the last visit will be considered the main analysis for this endpoint, with the analysis at the end of treatment visit considered a sensitivity analysis.

The estimated least squares means, treatment difference, together with the 95% CIs and p-value will be presented.

5.5.3.2.8 Epworth Sleepiness Scale

The ESS is a questionnaire that provides a measure of a person’s general level of daytime sleepiness, or their average sleep propensity in daily life. The ESS contains 8 questions that are rated on a 4-point numerical scale (0–3). The total ESS score is the sum of the 8 item-scores and can range between 0 and 24. Higher total scores represent greater levels of daytime sleepiness.

The ESS questionnaire will be completed at Visits 2 (Day 1), 3, 4, 6 and 8 (end of treatment) by the patient’s caregiver.

The total score, recorded at each visit, will be summarized, on a continuous scale, by treatment group. The change from baseline (Visit 2) will also be included.

The change from baseline in the total score to the end of treatment visit and last visit (if different to the end of treatment) will be analyzed using the same ANCOVA approach as specified in Section 5.5.3.2.7. Analysis performed at the last visit will be considered the main analysis for this endpoint, with the analysis at the end of treatment visit considered a sensitivity analysis.

Missing data arising from missing individual questions will be handled according to Section 5.1.1.2.1.
5.5.3.2.9 Quality of Life in Childhood Epilepsy

The QOLCE is a parent-reported questionnaire that evaluates health related quality of life in children aged 4–18 years old. It contains 76 items with 16 subscales covering 7 domains of life function: physical activities, social activities, cognition, emotional well-being, behavior, general health, and general quality of life. The QOLCE will be completed by the parent or caregiver at Visits 2 (Day 1) and 8 (end of treatment).

All items in the questionnaire are rated on a 5-point or 6-point categorical scale. Based on the responses to the items in each domain, scores for 16 subscales are derived. The subscales are presented in Table 4.

<table>
<thead>
<tr>
<th>Subscale</th>
<th>Item Domains</th>
<th>Items Used</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical Restrictions</td>
<td>Physical Activities</td>
<td>3.1 (a to j)</td>
</tr>
<tr>
<td>Energy/Fatigue</td>
<td>Physical Activities</td>
<td>3.2 (a,b)</td>
</tr>
<tr>
<td>Attention/Concentration</td>
<td>Cognition</td>
<td>5.1 (a,d,e,f,g)</td>
</tr>
<tr>
<td>Memory</td>
<td>Cognition</td>
<td>5.1 (j,k,l,m,n,o)</td>
</tr>
<tr>
<td>Language</td>
<td>Cognition</td>
<td>5.1 (p,q,r,s,t,u,v,w)</td>
</tr>
<tr>
<td>Other Cognitive</td>
<td>Cognition</td>
<td>5.1 (b,c,h)</td>
</tr>
<tr>
<td>Depression</td>
<td>Emotional Well-Being</td>
<td>4.1 (a,d,e,l)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>Emotional Well-Being</td>
<td>4.1 (b,g,j,n,o,p)</td>
</tr>
<tr>
<td>Control/Helplessness</td>
<td>Emotional Well-Being</td>
<td>4.1 (c,f,h,i)</td>
</tr>
<tr>
<td>Self-esteem</td>
<td>Emotional Well-Being</td>
<td>4.1 (k,m,q,r,s)</td>
</tr>
<tr>
<td>Social Interactions</td>
<td>Social Activities</td>
<td>6.1 (c,f,h)</td>
</tr>
<tr>
<td>Social Activities</td>
<td>Social Activities</td>
<td>6.1 (a,e) and 6.2</td>
</tr>
<tr>
<td>Stigma Item</td>
<td>Social Activities</td>
<td>6.1 (i)</td>
</tr>
<tr>
<td>Behavior</td>
<td>Behavior</td>
<td>7.1 (a,c,f,g,h,I,j,k,l,m,o,q,r,s,t)</td>
</tr>
<tr>
<td>General Health Item</td>
<td>General Health</td>
<td>8.1</td>
</tr>
<tr>
<td>Quality of Life Item</td>
<td>Quality of Life</td>
<td>9.1</td>
</tr>
</tbody>
</table>

Items within each subscale will be coded and linearly transformed, according to the methods of Sabaz et al.\(^3\), to a score of 0 to 100, where 0 represents the lowest or poorest category and 100 represents the highest level of functioning.

A subscale score is calculated for each subscale by computing the mean of the items within the subscale. An ‘Overall Quality of Life Score’ can be calculated by taking the mean of the subscale scores.

Individual items will be listed only. The subscale scores and the overall quality of life score, recorded at each visit, will be summarized, on a continuous scale, by treatment group. The change from baseline (Visit 2) will also be included.

The change from baseline to the end of treatment visit, for the overall quality of life score, and the attention/concentration, memory, language, other cognitive, social interactions and behavior subscale scores only, will be analyzed using the same ANCOVA approach as specified in Section 5.5.3.2.7. Exploratory analyses may also be performed on other subscale scores.

Missing data will be handled according to Section 5.1.1.2.2.

5.5.3.2.10 Vineland Adaptive Behavior Scales, Second Edition

The Vineland-II is an individually administered instrument for assessing adaptive behaviors.

The Vineland-II assessments will be made at Visits 2 (Day 1), 3, 4, 6 and 8 (end of treatment).

The Vineland-II consists of 44 adaptive behavior domains and a maladaptive behavior domain. The details of each domain are presented in Table 5.
<table>
<thead>
<tr>
<th>Domains and Subdomains</th>
<th>Number of Items</th>
<th>Age Range (Years)</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adaptive Behavior Domains</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Communication Domain</td>
<td>99</td>
<td>≥0</td>
<td></td>
</tr>
<tr>
<td>Receptive</td>
<td>20</td>
<td>≥0</td>
<td>How the individual listens and pays attention, and what he or she understands</td>
</tr>
<tr>
<td>Expressive</td>
<td>54</td>
<td>≥0</td>
<td>What the individual says, how he or she uses words and sentences to gather and provide information</td>
</tr>
<tr>
<td>Written</td>
<td>25</td>
<td>≥3</td>
<td>What the individual understands about how letters make words, and what he or she reads and writes</td>
</tr>
<tr>
<td><strong>Daily Living Skills Domain</strong></td>
<td>109</td>
<td>≥0</td>
<td></td>
</tr>
<tr>
<td>Personal</td>
<td>41</td>
<td>≥0</td>
<td>How the individual eats, dresses and practices personal hygiene</td>
</tr>
<tr>
<td>Domestic</td>
<td>24</td>
<td>≥1</td>
<td>What household tasks the individual performs</td>
</tr>
<tr>
<td>Community</td>
<td>44</td>
<td>≥1</td>
<td>How the individual uses time, money, the telephone, the computer and job skills</td>
</tr>
<tr>
<td><strong>Socialization Domain</strong></td>
<td>99</td>
<td>≥0</td>
<td></td>
</tr>
<tr>
<td>Interpersonal Relationships</td>
<td>38</td>
<td>≥0</td>
<td>How the individual interacts with others</td>
</tr>
<tr>
<td>Play and Leisure Time</td>
<td>31</td>
<td>≥0</td>
<td>How the individual plays and uses leisure time</td>
</tr>
<tr>
<td>Coping Skills</td>
<td>30</td>
<td>≥1</td>
<td>How the individual demonstrates responsibility and sensitivity to others</td>
</tr>
<tr>
<td><strong>Motor Skills Domain</strong></td>
<td>76</td>
<td>≥0 to &lt;7</td>
<td>How the individual uses arms and legs for movement and coordination</td>
</tr>
<tr>
<td>Gross</td>
<td>40</td>
<td>≥0 to &lt;7</td>
<td>How the individual uses hands and fingers to manipulate objects</td>
</tr>
<tr>
<td>Fine</td>
<td>36</td>
<td>≥0 to &lt;7</td>
<td></td>
</tr>
<tr>
<td><strong>Maladaptive Behavior Domain</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maladaptive Behavior Index</td>
<td>36</td>
<td>≥3</td>
<td>A composite of Internalizing, Externalizing, and Other types of undesirable behavior that may interfere with the individual’s adaptive functioning</td>
</tr>
<tr>
<td>Internalizing (Section A)</td>
<td>11</td>
<td>≥3</td>
<td></td>
</tr>
<tr>
<td>Externalizing (Section B)</td>
<td>10</td>
<td>≥3</td>
<td></td>
</tr>
<tr>
<td>Other (Section C)</td>
<td>15</td>
<td>≥3</td>
<td></td>
</tr>
<tr>
<td><strong>Maladaptive Behavior Critical</strong></td>
<td>14</td>
<td>≥3</td>
<td>More severe maladaptive behaviors that may provide clinically important information</td>
</tr>
</tbody>
</table>

For each subdomain, a raw score is calculated based on the responses to the individual items within the subdomain. For the maladaptive behavior index, the raw score is the sum of the 3 subdomain raw scores. Using the raw score and the patients’ age the following are obtained:

- v-Scale Score: a type of standard score scale (standardized by age) to describe an individual’s relative level of functioning. Ranging from a score of 1 to 24.
- 90% CI for the v-Scale Score: a range of scores that has a certain likelihood of including the individual’s true score.
- Adaptive Level: a means to describe an individual’s performance using terms that are nearly universal (Low, Moderately Low, Adequate, Moderately High, High).
  - For the maladaptive behavior index and maladaptive behavior subdomains the adaptive levels are: Average, Elevated or Clinically Significant.
• Age Equivalent: the age at which the raw score is average. Not applicable for the maladaptive behavior index and maladaptive behavior subdomains.

For each adaptive behavior domain, the sum of the v-scale scores of the subdomains is used along with the patients’ age to obtain the following:

• Standard Score (standardized by age). Ranging from a score of 20 to 160.
• 90% CI for the domain standard score.
• Percentile Rank: the percentage of people whom the individual outperformed in his or her age group.
• Adaptive Level (Low, Moderately Low, Adequate, Moderately High, High).
• Stanine: whole number score ranging from 1 to 9 and representing a specific range of percentile ranks.

An adaptive behavior composite can then be obtained using the sum of the adaptive behavior domain standard scores (excluding the motor skills domain for patients ≥7 years of age).

The same derived information as the adaptive behavior domain is obtained for the adaptive behavior composite.

For the maladaptive behavior index, all items within each section must be answered for a raw score to be calculated. If any of the items are missing then the maladaptive behavior index score will be missing.

For the adaptive behavior subdomains, the derivation of the raw score allows for up to 2 missing values or answers of “Don’t Know” within the items used for scoring. If there are more than 2 missing values or answers of “Don’t Know” then the raw score will not be calculated and the subdomain score, domain score and adaptive behavior composite score will be missing.

The adaptive levels corresponding to the v-scale scores and standard scores are presented in Table 6.

### Table 6 Adaptive Levels by v-Scale Scores and Standard Scores

<table>
<thead>
<tr>
<th>Adaptive Level</th>
<th>v-Scale Score for Subdomains and Maladaptive Behavior Index</th>
<th>Standard Score for Domains and Adaptive Behavior Composite</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adaptive Behavior Domains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>1 to 9</td>
<td>20 to 70</td>
</tr>
<tr>
<td>Moderately Low</td>
<td>10 to 12</td>
<td>71 to 85</td>
</tr>
<tr>
<td>Adequate</td>
<td>13 to 17</td>
<td>86 to 114</td>
</tr>
<tr>
<td>Moderately High</td>
<td>18 to 20</td>
<td>115 to 129</td>
</tr>
<tr>
<td>High</td>
<td>21 to 24</td>
<td>130 to 160</td>
</tr>
<tr>
<td>Maladaptive Behavior Domain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinically Significant</td>
<td>21 to 24</td>
<td></td>
</tr>
<tr>
<td>Elevated</td>
<td>18 to 20</td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>1 to 17</td>
<td></td>
</tr>
</tbody>
</table>

The v-scale score from the 11 adaptive behavior subdomains, 3 maladaptive behavior subdomains and the maladaptive behavior index, and the standard score from the 4 adaptive behavior domains and the adaptive behavior composite, recorded at each visit, will be summarized, on a continuous scale, by treatment group. The change from baseline (Visit 2) will also be included.

The change from baseline to the end of treatment visit and last visit (if different to the end of treatment), for the 4 adaptive behavior domains, the adaptive behavior composite and the
maladaptive behavior index only, will be analyzed using the same ANCOVA approach as specified in Section 5.5.3.2.7. Analysis performed at the last visit will be considered the main analysis for this endpoint, with the analysis at the end of treatment visit considered a sensitivity analysis.

The adaptive level from the 11 adaptive behavior subdomains, 4 adaptive behavior domains, the adaptive behavior composite, the 3 maladaptive behavior subdomains and the maladaptive behavior index, recorded at each visit, will be summarized, on a categorical scale, by treatment group.

The adaptive level from the 4 adaptive behavior domains, the adaptive behavior composite and the maladaptive behavior index only will be analyzed using ordinal logistic regression. Factors for treatment and age group will be included along with the baseline adaptive level as a covariate. The estimated odds ratios (GWP42003-P groups vs. placebo), 95% CI for the odds ratios, and the p-values testing the null hypothesis that the odds ratio is equal to 1, will be presented.

Each adaptive level for adaptive behavior will be coded with a score from 1 to 5, where 1 = Low, and 5 = High. Each adaptive level for the maladaptive behavior index will be coded with a score from 1 to 3, where 1 = Clinically Significant, and 3 = Average.

The individual responses within each domain will not be listed, only the derived information for each subdomain and domain will be listed.

5.5.3.2.11 Cognitive Assessment Battery

The cognitive assessment battery will be administered at Visit 2 (baseline) and Visit 8 (end of treatment). The items are age specific and the age of the patient at entry is the age used when choosing the items to be given. Children and adults are to complete the battery as able. It is expected that a number of patients will only be able to complete part of the battery and some may not be able to complete it at all. Parents and/or caregivers are to complete certain items.

The battery items will only be administered to a sub-group of sites that have the expertise to conduct the test. Assessments are conducted by an experienced psychometrician.

A summary of the patient and parent measures are given in Table 7.
### Table 7: Neuropsychological Protocol for Epilepsy Patients Treated with Cannabidiol – Patient and Parent Measures

<table>
<thead>
<tr>
<th>Category</th>
<th>Function</th>
<th>Measures</th>
<th>Age Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
<td>Intelligence IQ</td>
<td>Wechsler Preschool and Primary Scale of Intelligence – Fourth Edition (WPPSI-4) Vocabulary, Matrix Reasoning</td>
<td>2.6 - 5;11 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wechsler Abbreviated Scale of Intelligence – Second Edition (WASI-2) Vocabulary, Matrix Reasoning (Including Wechsler: ‘Digit Span’ subtest from Wechsler Intelligence Scale for Children – Fourth Edition (WISC-4) and Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-4); ‘Coding’ subtest from WISC-4 &amp; WAIS-4; ‘Bug Search’ from WPPSI-4)</td>
<td>6 - adult</td>
</tr>
<tr>
<td></td>
<td>Attention/Executive</td>
<td>Trail Making Test Delis–Kaplan Executive Function System (D-KEFS)</td>
<td>9 - adult</td>
</tr>
<tr>
<td></td>
<td>Trail Making</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Language</td>
<td>Expressive One-Word Picture Vocabulary Test-4th Edition</td>
<td>2 - adult</td>
</tr>
<tr>
<td></td>
<td>Naming Fluency</td>
<td>NEPSY-2 Word Generation</td>
<td>2 - 5 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>F-A-S and Animals</td>
<td>6 - adult</td>
</tr>
<tr>
<td></td>
<td>Visual-Spatial VMI</td>
<td>Developmental Test of Visual Motor Integration-6</td>
<td>2 - adult</td>
</tr>
<tr>
<td></td>
<td>Fine Motor Speed Pegs</td>
<td>Purdue Pegboard</td>
<td>4 - adult</td>
</tr>
<tr>
<td>Parent</td>
<td>Executive</td>
<td>Behavior Rating Inventory of Executive Function (Parent and Teacher)</td>
<td>3 - 21 years</td>
</tr>
<tr>
<td></td>
<td>Attention</td>
<td>Attention deficit hyperactivity disorder (ADHD) Checklist (Parent and Teacher)</td>
<td>All ages</td>
</tr>
<tr>
<td></td>
<td>Mood/Anxiety</td>
<td>Behavior Assessment System for Children – Second Edition (BASC-2) (Parent and Teacher)</td>
<td>3 - 21 years</td>
</tr>
<tr>
<td></td>
<td>Free-form report</td>
<td>Behavior Report Form (Parent and Teacher)</td>
<td>All ages</td>
</tr>
</tbody>
</table>

The following patient measures will be summarized, on a continuous scale, by treatment group at each visit and including the change from baseline using the score recorded on the CRF:

- **Intelligence:**
  - WPPSI-4 T score:
    - Receptive Vocabulary.
    - Matrix Reasoning.
    - Bug Search.
  - WASI-2 T score:
    - Vocabulary.
    - Matrix Reasoning.
  - WISC-4 and WAIS-4:
    - Coding scaled score.
    - Digit Span (Forward, Backward, Longest forward, Longest Backward).

- **Attention/Executive:**
  - D-KEFS scaled scores.

- **Language:**
- NEPSY-2 Word Generation scaled score.

- Visual-Spatial:
  - Developmental Test of Visual Motor Integration-6 standard score.

- Fine Motor Speed:
  - Dominant hand, non-dominant hand and both hands Z scores.

The following parent measures will be summarized, on a continuous scale, by treatment group at each visit and including the change from baseline using the scored recorded on the CRF:

- Executive:
  - Behavior Rating Inventory of Executive Function T scores for indexes and composite.

- Mood/Anxiety:
  - BASC-2 T scores for composite scores.

The behavior report form will be summarized, on a categorical scale, by treatment at each visit. The ADHD checklist consists of 18 questions, questions 1 to 9 relate to inattention and questions 10 to 18 relate to hyperactivity. A derived Inattention and Hyperactivity score can be calculated by taking the sum of the corresponding question responses, where 0 = ‘Not at all’ and 3 = ‘Very much’ and dividing by 9. A combined score can also be calculated by taking the sum of the responses from questions 1 to 18 and dividing by 18. The Inattention, Hyperactivity and combined scores will be summarized, on a continuous scale, at each visit and by treatment group. The change from baseline (Visit 2) will also be included.

### 5.5.4 Exploratory Efficacy Endpoints

#### 5.5.4.1 Time to Baseline Convulsive Seizure Frequency

Time to baseline convulsive seizure frequency is defined as the number of reported days in IVRS, from Day 1, that it takes for the cumulative number of convulsive seizures experienced to be greater than or equal to the number of seizures (per 28 days) experienced during the baseline period and will be calculated as:

\[
\text{Date criterion was achieved} = \text{Date of Day 1} - \text{Number of unreported days in IVRS between Day 1 and date criterion was achieved} + 1
\]

Patients who complete the study without experiencing greater than or equal to the number of seizures (per 28 days) experienced during the baseline period, or who withdraw from the study, will be censored at the earlier of:

- Day 99.
- The date of last dose as recorded on the ‘End of Treatment Study Outcome’ CRF page.

The exact day used for censoring will be the day obtained from above minus the number of unreported days in IVRS between Day 1 and the day obtained from above.

Time to baseline convulsive seizure frequency will be summarized on a continuous scale, by treatment group, for patients in the ITT analysis set. The lower and upper quartiles will also be presented. The Kaplan–Meier estimates for the median time to baseline convulsive seizure frequency will be presented along with 95% CIs for the median and p-values from log-rank tests comparing each GWP42003-P group with placebo. A Kaplan–Meier plot will also be produced.

The above will be repeated using Day 15 instead of Day 1 as the start day for counting the cumulative number of convulsive seizures.

#### 5.5.4.2 Number of Convulsive Seizure Free Days

The number of convulsive seizure free days during each period will be based on 28-day averages and
calculated as:
(Number of seizure free days in the period ÷ Number of reported days in IVRS in the period) × 28

The change from baseline in convulsive seizure free days per 28 days will be analyzed for
the treatment period using an ANCOVA approach. The model will include baseline and age
group as covariates and treatment group as fixed factor.
The estimated least squares means, treatment difference, together with the 95% CIs and p-value will
be presented.
The analysis will be repeated for the maintenance period. Analysis on the maintenance period will
include only patients who have at least 7 days of seizure data within the maintenance period.

5.5.5 Subgroup Analyses

To assess the degree of effect heterogeneity, effect modifier analyses are proposed, on the
ITT analysis set, for the primary efficacy endpoint and the key secondary efficacy endpoint
of ≥50% reduction in convulsive seizure frequency.

For the primary efficacy endpoint, the effect modifier analysis will be performed using the
negative binomial regression analysis as described in Section 5.5.2. The model will be
updated to include covariates for each level of the effect being tested (excluding a reference
level), individually and with interactions with time, interactions with treatment arm and
interactions with time and treatment. A separate model will be used for testing each effect.
The treatment ratios (GWP42003-P vs. placebo), percent reduction and 95% confidence
intervals will be presented for each level of the effect. In addition, the effect by time by
treatment arm interaction p-value, testing the hypothesis that the effect level treatment ratios
are homogeneous, will be presented.

For the key secondary efficacy endpoint of ≥50% reduction in convulsive seizure frequency,
patients with a ≥50% reduction in seizure frequency will be modelled using logistic
regression, including stratified age group and treatment arm as covariates. The model will
also include covariates for each level of the effect being tested (excluding a reference level),
individually and with interactions with treatment arm. A separate model will be used for
testing each effect. The number and percent of responders, and odds ratios and 95%
confidence intervals will be presented for each level of the effect. In addition, the effect by
treatment arm interaction p-value, testing the hypothesis that the effect level odds ratios are
homogeneous, will be presented.

The following effects will be tested:

- Age group (2-5 years, 6-12 years and 13-18 years). Note: stratified age group will be
  removed as a covariate for this model.
- Sex (Male, Female).
- Region (US, Rest of the World).
- Clobazam use (Yes, No).
- Valproic acid use (Yes, No).
- Stiripentol use (Yes, No).
- Clobazam use and Stiripentol use (Yes/Yes, Yes/No, No/Yes, No/No).
- Levetiracetam use (Yes, No).
- Topiramate use (Yes, No).
- Baseline average convulsive seizure frequency per 28 days (≤ observed Tertile 1, >
  observed Tertile 1 to ≤ observed Tertile 2, > observed Tertile 2). The observed tertile
  values will be rounded to the nearest whole number.
• Number of concurrent AEDs (<3, ≥3).
• Number of prior AEDs (<4, ≥4).
• Number of prior and concurrent AEDs (<8, ≥8).

5.6 Safety Evaluation

5.6.1 Exposure to IMP

Patients are required to take IMP twice daily (morning and evening). The first dose will be taken in the clinic on Day 1. The date of final dose in the treatment phase will be recorded on the CRF. The date of final dose, for patients who enter the taper period, will be recorded on the CRF at the end of taper visit.

The total number of dosing days in the treatment phase will be calculated as:

\[(\text{Date of last dose in the treatment phase} - \text{Date of Day 1}) + 1\]

The date of last dose in the treatment phase will be obtained from the CRF at the end of treatment visit.

Any missed doses during treatment should be recorded on the ‘IMP Missed Doses Log’ CRF page. The number of days with any missed doses and the number of days where IMP was not taken in the AM nor PM will be summarized based on data in the treatment phase (Day 1 to end of treatment visit).

In addition, the number of days in which IMP was taken at least once (AM or PM) will be summarized and calculated as:

Total number of dosing days – the number of days where IMP was not taken in the AM nor PM

The number of days in which IMP was taken both AM and PM will be summarized and calculated as:

\[(\text{Total number of dosing days} - \text{the number of days with any missed doses})\]

The above summaries will be presented for all patients and repeated for patients who completed the treatment phase.

In addition, the expected daily volume of IMP to be administered during the treatment phase, once a patient has titrated to target dose, will be summarized by treatment.

The expected daily volume of IMP will be calculated as:

\[2 \times \left(\frac{\text{Weight (kg) at Day 1}}{10} \text{ and rounded to the nearest 0.1}\right)\]

for patients randomized to the 20 mg/kg/day dose level and:

\[2 \times \left(\frac{\text{Weight (kg) at Day 1}}{20} \text{ and rounded to the nearest 0.1}\right)\]

for patients randomized to the 10 mg/kg/day dose level.

Finally, IMP compliance will be summarized by treatment and calculated as:

\[100 \times \left(\frac{\text{Number of days IMP taken at least once + number of days IMP taken both AM and PM}}{2 \times \text{day of completion or withdrawal during the treatment period}}\right)\]

5.6.2 Adverse Events

All reported AEs will be classified by system organ class (SOC), preferred term and lower level term using Version 17.1 of MedDRA.

Summaries will be presented by treatment group as well as SOC and preferred term.

A treatment emergent AE (TEAE) is defined as an AE with a start date on or after the first dose of IMP. If an AE has a partial start date and it is unclear from the partial date (or the stop date) whether the AE started prior to or post first dose of IMP then the AE will be considered treatment emergent. If the start date of the AE is the same as the date of first dose of IMP and the plausible relationship to IMP is marked on the CRF as “Prior to study
medication” then the AE will not be considered treatment emergent.

An AE will be considered treatment-related if the plausibility relationship to IMP is recorded on the CRF as ‘yes’. If the data on plausibility relationship to IMP is missing then the AE will be considered treatment-related.

An AE will be considered leading to permanent discontinuation of IMP if the action taken with IMP is recorded on the CRF as ‘study medication stopped’ or the outcome is recorded on the CRF as ‘patient died’.

An AE will be considered leading to IMP dose reduction excluding permanent discontinuation if the action taken with IMP is recorded on the CRF as ‘dose reduced’, ‘dose reduced temporarily’ or ‘study medication interrupted’.

An AE will be considered leading to temporary IMP dose reduction if the action taken with IMP is recorded on the CRF as ‘dose reduced temporarily’.

An AE will be considered leading to permanent IMP dose reduction excluding permanent discontinuation if the action taken with IMP is recorded on the CRF as ‘dose reduced’.

An AE will be considered fatal if the outcome is recorded on the CRF as ‘patient died’.

The following summaries will be generated (counts are by patient unless specified otherwise):

- Overall summary of AEs, including number of patients reporting each of: TEAEs, treatment-related TEAEs, TEAEs leading to withdrawal, treatment-related TEAEs leading to withdrawal, serious TEAEs, treatment-related serious TEAEs.
- Summary of TEAEs.
- Summary of TEAEs by event.
- Summary of treatment-related TEAEs.
- Summary of treatment-related TEAEs by event
- Summary of TEAEs by maximal severity.
- Summary of TEAEs by sex.
- Summary of serious TEAEs.
- Summary of serious TEAEs by event.
- Summary of non-serious TEAEs.
- Summary of non-serious TEAEs by event.
- Summary of treatment-related serious TEAEs.
- Summary of treatment-related serious TEAEs by event.
- Summary of TEAEs leading to permanent discontinuation of IMP.
- Summary of treatment-related TEAEs leading to permanent discontinuation of IMP.
- Summary of TEAEs leading to IMP dose reduction excluding permanent discontinuation (by resolution and overall).
- Summary of treatment-related TEAEs leading to IMP dose reduction excluding permanent discontinuation (by resolution and overall).
- Summary of TEAEs leading to temporary IMP dose reduction (by resolution and overall).
• Summary of treatment-related TEAEs leading to temporary IMP dose reduction (by resolution and overall).
• Summary of TEAEs leading to permanent IMP dose reduction excluding permanent discontinuation (by resolution and overall).
• Summary of treatment-related TEAEs leading to permanent IMP dose reduction excluding permanent discontinuation (by resolution and overall).
• Summary of fatal TEAEs.
• Summary of TEAEs by time of first onset of AE.
• Summary of TEAEs by time to AE resolution.
• Summary of TEAEs reported in ≥2% of patients (after rounding) in the GWP42003-P treatment groups and where the incidence is greater than the placebo treatment group.
• List of patients experiencing TEAEs by SOC and preferred term.
• Summary of pre-treatment AEs.

For the summary of TEAEs by maximal severity, for each patient, the worst severity recorded by preferred term, SOC and overall will be used for summary purposes. If severity is missing, the worst case (severe) will be assumed.

For summaries by resolution, AEs with an outcome of ‘recovered’ or ‘recovered with sequelae’ will be summarized as ‘Resolved’ and AEs with an outcome of ‘continuing’, ‘patient died’ or those with a missing outcome will be summarized as ‘Not resolved’.

For the summary of TEAEs by time of first onset of AE, data will be summarized under the following categories:

- Weeks 1–2 (Day 1–14).
- Weeks 3–6 (Day 15–42).
- Weeks 7–10 (Day 43–70).
- Weeks 11–14 (Day 71–98).
- >14 weeks (> Day 98).

The time to first onset of AE will be calculated for TEAEs as:

\[ \text{Start date of AE} - \text{Date of first dose of IMP} + 1 \]

If patients have multiple occurrences of an AE then the AE will be counted once for the first occurrence only. Percentages will be based on the number of patients in the safety analysis set who have a visit or follow-up call within each time period above.

For the summary of TEAEs by time to AE resolution, data will be summarized under the following categories:

- 1 week (≤7 days).
- 2 weeks (8–14 days).
- 3 weeks (15–21 days).
- 4 weeks (22–28 days).
- >4 weeks (>28 days).
- Ongoing (for AEs not resolved).
The time to AE resolution will be calculated for TEAEs as:

\[ \text{Stop date of AE} - \text{Start date of AE + 1} \]

If patients have multiple occurrences of an AE then the AE will be counted once for the occurrence with the longest time to AE resolution. However, if any of the AE values are not resolved then the AE will be counted once within the ‘Ongoing’ category.

The start and stop day of the AE relative to the first dose of IMP (as recorded on the CRF) will be calculated as per Section 5.1.2. For partial dates, if it is clear from the partial date that the start/stop day was prior to the first dose of IMP, then ‘pre’ will be listed, similarly if it is clear that the event was post the first dose of IMP then ‘post’ will be listed as the start/stop day as appropriate.

All AEs will be listed. Listings will include the start and stop day of the AE, a flag for treatment emergence, and limited demographic information about the patient (age, sex, race and weight at screening). A separate listing will be provided for pre-treatment AEs, serious AEs and events of special interest (see Appendix 1).

### 5.6.3 Clinical Laboratory Evaluation

#### 5.6.3.1 Hematology and Biochemistry

Hematology and biochemistry safety parameters are measured at Visit 1 (screening), Visit 2 (Day 1), Visit 3, Visit 4, Visit 6, Visit 8 (end of treatment) and Visit 9 (end of taper).

Summaries will be presented by treatment group for each laboratory parameter at each visit. Change from baseline to each post-baseline visit will also be presented.

If values for any of the parameters are below or above the limit of quantification of the assay (BLQ or ALQ), then they will be included in the summary tables at the BLQ or ALQ thresholds. However, for estimated creatinine clearance, results >60 are reported only as ‘>60’. Hence, estimated glomerular filtration rate (eGFR) will be calculated as:

For patients who are ≥18 years at screening, the Cockroft-Gault equation will be used:

\[
eGFR (\text{mL/min}) = \frac{[(140 - \text{age}) \times \text{weight} \times k]}{\text{serum creatinine}}\]

where age is measured in years, weight is measured in kg, k = 1.23 if male, k = 1.04 if female and serum creatinine is measured in µmol/L. eGFR will be indexed to body surface area (BSA) using the following formula:

\[
eGFR (\text{mL/min}/1.73\text{m}^2) = eGFR (\text{mL/min}) \times 1.73/\text{BSA} \]

where BSA is based on the Du Bois and Du Bois formula:

\[
\text{weight}^{0.425} \times \text{height}^{0.725} \times 0.007184
\]

where weight is measured in kg and height is measured in cm.

For patients who are <18 years at screening, the revised Schwartz estimate will be used:

\[
(36.2 \times \text{height}) / \text{serum creatinine}
\]

where height is measured in cm and serum creatinine is measured in µmol/L. When available, enzymatic serum creatinine will be used. Otherwise, the Jaffe serum creatinine will be used. If height or weight is missing at the collection date, then the closest value to the sample date will be used. If there is more than one height or weight value on the same day or 2 height or weight values equally distant from the collection date, then the mean will be used. The eGFR will be summarized separately for each method.

Where laboratory samples are repeated, the baseline value is defined as the final recorded value prior to the first dose of IMP. If the Visit 2 data are missing then, where possible, the Visit 1 measurements will be used as baseline.

Shift tables for hematology and biochemistry parameters will be constructed, based upon normal ranges and GW toxicity limits (See Section 8), to determine the categorical shifts from baseline to each post-baseline visit. Values will be categorized as ‘Normal’, ‘Low’ or ‘High’ based on normal ranges and ‘Toxically Low’, ‘Toxically Normal’ or ‘Toxically High’
based on GW toxicity limits.
For eGFR, results will be assigned to the following grades:
- Normal: >60 ml/min/1.73 m²
- Grade 1: 60 ml/min/1.73 m²
- Grade 2: ≥30 and <60 ml/min/1.73 m²
- Grade 3: ≥15 and <30 ml/min/1.73 m²
- Grade 4: <15 ml/min/1.73 m²

A separate shift table will be produced for eGFR based upon the above grades to determine
the categorical shifts from baseline to each post-baseline visit.
Scatter plots will be produced for each laboratory parameter presenting the maximum post
baseline result divided by the upper limit of normal (ULN) on the Y-axis, and the baseline
result divided by the ULN on the X-axis. However, for prothrombin international
normalized ratio (INR), both axes will present the raw results rather than dividing by ULN.
An additional table will be produced, summarizing the number of patients meeting the
following criteria:
- Alanine aminotransferase (ALT) > 1×ULN at baseline
- Aspartate aminotransferase (AST) > 1×ULN at baseline
- AT > 1×ULN at baseline
- Treatment emergent ALT > 3×ULN, > 5×ULN and > 8×ULN
- Treatment emergent AST > 3×ULN, > 5×ULN and > 8×ULN
- Treatment emergent AT > 3×ULN, > 5×ULN and > 8×ULN
- Treatment emergent AT > 3×ULN and either bilirubin > 2×ULN or INR > 1.5

where AT is AST or ALT, and treatment emergent is defined as criteria not met at baseline,
but met at any time post-baseline. The above will be summarized overall and for the
following subgroups: Sex (Male, Female).
- Valproic acid use (Yes, No).
- Clobazam use (Yes, No).
- Valproic acid use and Clobazam use (Yes/Yes, Yes/No, No/Yes, No/No).
- Patients taking 3 or more current AEDs.
- Patients taking 4 or more current AEDs.

A separate table will be produced, by treatment group and visit, presenting the incidence of
patients with urinalysis or blood results indicative of a medical condition at Visit 1 and
indicative of an AE after Visit 1.
All laboratory data will be listed; listings will include limited demographic information
about the patient (age, sex, race and weight at baseline). Abnormal laboratory values will be
listed separately. A further listing will be created for the laboratory reference ranges and
toxicity limits.

5.6.3.2 Urinalysis

Urinalysis is assessed, using dipsticks, at the same visits as biochemistry and hematology.
Urinalysis results will be listed only.
5.6.3.3 Pregnancy Test and Urine THC Screen

Serum pregnancy test results and urine THC screen results will be summarized by treatment group and visit.

5.6.4 Vital Signs, Other Physical Findings and Other Safety Data

5.6.4.1 Vital Signs

Vital signs (systolic blood pressure, diastolic blood pressure, pulse rate, temperature and respiratory rate) are measured at Visit 1 (screening), Visit 2 (Day 1), Visit 3, Visit 4, Visit 6, Visit 8 (end of treatment) and Visit 9 (end of taper).

At Visit 1 and Visit 2, systolic and diastolic blood pressure are collected in the sitting, supine and standing positions. At all other visits, systolic and diastolic blood pressure are collected in the sitting position only.

Summaries will be presented by treatment group for each vital sign parameter at each visit. Change from baseline to each post-baseline visit will also be presented. A separate table will be produced, by treatment group and visit, presenting the incidence of patients with vital signs indicative of a medical condition at Visit 1 and indicative of an AE after Visit 1.

Based on the criteria presented in Section 8, potentially clinically significant changes from baseline in vital signs measurements and other defined flagged values will be identified at each visit. The number of patients with a potentially clinically significant change from baseline will be summarized by parameter, visit and treatment group. The number of patients with at least one post-baseline flagged vital sign parameter value will be summarized by parameter, flagged criteria and treatment group.

5.6.4.2 Electrocardiogram

An ECG will be performed at Visit 1 (screening), Visit 2 (Day 1), Visit 3, Visit 4, Visit 6, Visit 8 (end of treatment) and Visit 9 (end of taper).

Summaries will be presented by treatment group for ventricular rate, PR interval, QRS duration, QT interval and QTcB, at each visit. Change from baseline to each post-baseline visit will also be presented. A separate table will be produced, by treatment group and visit, presenting the incidence of patients with an ECG indicative of a medical condition at Visit 1 and indicative of an AE after Visit 1.

Based on the criteria presented in Section 8, defined flagged values will be identified at each visit. The number of patients with at least one post-baseline flagged ECG parameter value will be summarized by parameter, flagged criteria and treatment group.

5.6.4.3 Physical Examination

A physical examination will be performed at Visit 1 (screening), Visit 2 (Day 1), Visit 3, Visit 4, Visit 6, Visit 8 (end of treatment) and Visit 9 (end of taper).

Any relevant findings at screening are included as part of the patient’s medical history. Any changes seen after screening that are indicative of an AE are to be recorded as such on the AE form and included as part of the AE summaries.

Additionally, height and weight are recorded as part of the physical examination. Height and weight will be summarized and listed together with the vital signs parameters.

Incidence of patients with a physical examination indicative of a medical condition at Visit 1
and indicative of an AE after Visit 1 will be summarized by treatment group and visit.

5.6.4.4 Columbia-Suicide Severity Rating Scale (Children’s)

The C-SSRS is completed at Visit 1 (screening), Visit 2 (Day 1), Visit 3, Visit 4, Visit 6, Visit 8 (end of treatment) and Visit 9 (end of taper), for patients who are 6 years and older and capable of understanding and answering the questions, in the investigator’s opinion. Questions are asked on suicidal behavior, suicidal ideation and intensity of ideation. At the screening visit, questions are in relation to lifetime experiences and all subsequent questioning in relation to the last assessment.

The following C-SSRS data will be summarized by treatment group at each visit for patients in the safety analysis set:

- Incidence of the following suicidal ideation:
  - Wish to be dead.
  - Non-specific active suicidal thoughts.
  - Active suicidal ideation with any methods (not plan) without intent to act.
  - Active suicidal ideation with some intent to act, without specific plan.
  - Active suicidal ideation with specific plan and intent.

- Incidence of the following suicidal behavior:
  - Actual attempt.
  - Interrupted attempt.
  - Aborted attempt.
  - Preparatory acts or behavior.
  - Suicidal behavior.
  - Completed suicide.

In addition, the number of patients with any suicidality, any suicidal ideation and any suicidal behavior will be summarized by treatment group at screening, baseline and at any time post-baseline.

Suicidality is defined as at least one occurrence of suicidal behavior or suicidal ideation. The number of patients experiencing the following, at any time post-baseline, will also be summarized:

- Complete suicidality.
- Emergence of suicidal ideation.
- Worsening of suicidal ideation.
- Emergence of suicidal behavior.

Emergence of suicidal ideation is defined as having no suicidal ideation at baseline and having reported any type of suicidal ideation at any time post-baseline. Worsening of suicidal ideation is defined to occur when the most severe suicidal ideation rating at any time post-baseline is more severe than its rating at baseline. Emergence of suicidal behavior is defined as having no suicidal behavior at baseline and reporting any type of suicidal behavior at any time post-baseline. If the C-SSRS was not completed at screening or baseline then the patient will not be included in summaries of emergence or worsening of suicidal ideation or behavior.

5.6.4.5 Growth and Development

IGF-1 levels will be analyzed as part of the clinical laboratory testing. IGF-1 levels will be summarized on a continuous scale, including change from baseline, by treatment group. Change from baseline to the end of treatment visit for IGF-1 levels will also be plotted against the Tanner Stages, weight, and height recorded at baseline.
The pubic hair growth (both sexes), genital (males only) and breast (females only) development of all adolescent patients (i.e., 10 to less than 18 years of age at the time of signing the informed consent form, or earlier if clinically indicated by onset of menarche or other signs of precocious puberty) will be assessed using Tanner Staging. The patients will undergo a discreet physical examination and be assigned a value under each category of Pubic Hair Growth (both sexes), Genitals (male patients only), and Breasts (female patients only).

Patients will be examined at Visit 2 (Day 1) and Visit 8 (end of treatment). Once a patient reaches a score of V (i.e., 5) the examination need not be performed again. Tanner Stages will be summarized on a categorical scale, by treatment group.

5.6.4.6 Menstruation

Caregivers will be asked if the female patient is menstruating and details will be recorded as part of their medical history (Visit 2); any changes in normal cycles will be captured at Visit 8 (end of treatment).

Menstruation details will be summarized as appropriate, including any changes in normal cycles at the end of treatment, by treatment group.

5.6.4.7 Cannabis Withdrawal Scale (18 Years)

The CWS is a 19-item scale with each item (withdrawal symptom) measured on a 0–10 NRS (0 = Not at all; 5 = Moderately; 10 = Extremely). The patient or their caregiver is asked to record the extent to which each withdrawal symptom was experienced in the last 24 hours and also to rate the negative impact on normal daily activities (i.e., 2 separate scores are recorded for each item using the same 0–10 NRS). Scores are calculated as the sum of the 19 items for each measure, i.e., each separate score has a theoretical maximum of 190.

The CWS will be used at Visit 2, to establish a baseline score, and then again at Visit 9, the safety follow-up telephone call on Day 123 and Visit 10 for any patient completing the study or withdrawing early. Patients entering the OLE on the day of Visit 8 will continue taking IMP; in this instance withdrawal will be evaluated at the end of their participation in the OLE.

The 2 derived scores, recorded at each visit, will be summarized, on a continuous scale, by treatment group. The change from baseline (Visit 2) will also be included.

If any of the individual items are missing, for each measure, then the corresponding derived score will not be calculated.

The summary will be presented separately for all patients with a completed scale and patients 18 years of age.

5.6.4.8 Pediatric Cannabinoid Withdrawal Scale (4–17 Years)

The PCWS was developed from the 19-item validated CWS (adults) that assesses mood, behavioral and physical symptoms associated with cannabis, which was based on the Marijuana Withdrawal Checklist. The modified 10-item PCWS was developed from a low literacy version of the CWS. Symptoms specific to adult cannabis withdrawal have been removed and the wording has been amended to be comprehensible to children of the specified age range.

Ratings are based on a 4-point scale where 0 = none, 1 = a little bit, 2 = quite a bit, and 3 = a lot.

This rating scale has been compacted from the original 11-point Likert scale used for the CWS in order to simplify the range of options to consider for potential intellectually disabled children. The PCWS was designed with epileptic children in mind as a tool to assess the safety of cannabinoid medications with respect to the stimulation of cannabinoid withdrawal syndrome when medications are withdrawn. As there may be a wide range of intellectual or developmental difficulties in severely epileptic children, from no intellectual or developmental impairment to extreme, the PCWS has been designed to be administered by a treating clinician, either directly to the child, or to the parent or caregiver of the child, reflecting on the child’s symptoms within the chosen timeframe.

A derived score is calculated as the sum of the 10 items and has a theoretical maximum score of 30.

The PCWS will be used at Visit 2, to establish a baseline score, and then again at Visit 9, the safety follow-up telephone call on Day 123 and Visit 10 for any patient completing the study or
withdrawing early. Patients entering the OLE on the day of Visit 8 will continue taking IMP; in this instance withdrawal will be evaluated at the end of their participation in the OLE. The derived score, recorded at each visit, will be summarized, on a continuous scale, by treatment group. The change from baseline (Visit 2) will also be included. If any of the individual items are missing, then the derived score will not be calculated. The summary will be presented separately for all patients with a completed scale and patients 4–17 years of age.

5.7 Other Measures

5.7.1 Concomitant Medication

Medications will be coded using the World Health Organization Drug Dictionary, Version June 2014. A medication will be considered concomitant if it has a start date on or after the first dose of IMP or if it was started prior to the first dose of IMP and was ongoing. If a medication has a partial or missing start/stop date and it is unclear from the date whether the medication was taken after the first dose of IMP then it will be considered concomitant. For summaries and listings of medications the following approach will be used to determine the Anatomical Therapeutic Chemical (ATC) term to be presented:

- If coded to level 4 then the level 4 coded term will be presented.
- If coding is not performed at level 4 but level 3 coding is present then level 3 coded term will be presented.
- If coding is not performed at level 3 but level 2 coding is present then the level 2 coded term will be presented.
- If coding is not performed at level 2 but level 1 coding is present then the level 1 coded term will be presented.

Summaries of each of the following by ATC term and preferred term will be summarized by absolute counts (n) and percentages (%):

- History of antiepileptic medications;
- Concomitant antiepileptic medications;
- Concomitant rescue medications; and
- Other concomitant medications.

The ATC term, preferred term, reported generic name and reported brand name will be listed. An additional summary table will be produced for concomitant antiepileptic therapies, displaying the number and percentage of patients with a vagus nerve stimulation device or on a ketogenic diet. The start day and stop day will be included in the listing according to Section 5.1.2. If the date is partial and the exact day is unknown then the text ‘pre’ or ‘post’ will replace the start or stop day if it is clear from the partial date that the medication started or stopped prior to or after the first dose of IMP.

5.7.2 Plasma Concentrations of Concomitant Antiepileptic Drugs

Blood sampling for AEDs will be performed at Visit 2 (Day 1), Visit 4, Visit 6 and Visit 8 (end of treatment). For each AED, plasma concentrations will be summarized by treatment
group at each visit for patients in the safety analysis set.

5.7.3 Caregiver Impression of Investigational Medicinal Product Palatability

The caregiver’s impression of palatability of the IMP will be assessed at Visit 8 (end of treatment).

The Caregiver will be asked the following question to be rated on a 5-point scale:

- Overall, how acceptable did your child find the study medication?

The possible responses are: Liked it a lot; Liked it; Neither liked nor disliked it; Didn’t like it; Didn’t like it at all.

The caregiver’s impression of palatability of the IMP will be summarized, on a categorical scale, by treatment group.

5.7.4 Study Medication Use and Behavior Survey

This form consists of 18 questions regarding the use of the IMP. The trained investigator or study coordinator will complete this survey as an interview with the patient/caregiver at the final dosing visit (Visit 8 or Visit 9, as applicable).

The form will be completed for all patients 12 years of age and older in the study.

Each question will be summarized, on a categorical scale, by treatment group. Percentages will be based on the number of patients completing the survey, in each treatment group. The summary will be presented separately for all patients with a completed form and patients 12 years of age and older.

5.7.5 Supplemental Drug Accountability Form

This form consists of 7 questions regarding various aspects of drug accountability and patient usage. It is completed as part of an interview with the patient/caregiver when a triggering drug accountability discrepancy is identified.

The triggering drug accountability discrepancies are as follows:

- Missing bottle(s).
- Compliance issues where one or more bottles are used compared to what was the expected use, according to the IVRS report and paper diary.
- Returned IMP supply with evidence of tampering.
- Greater than the target daily dose as recorded in the IVRS report and paper diary.

The number of patients completing a form will be summarized by treatment group. The summary will be presented separately for all patients with a completed form and patients 12 years of age and older.

5.7.6 Supplemental Adverse Event Form

This form consists of 15 questions regarding the AE and use of IMP. It is completed as part of an interview with the patient/caregiver when a triggering AE of interest is reported.

The categories for triggering AEs of interest are:

- Euphoria or inappropriate elation.
- Inappropriate laughter or exhilaration.
- Mood changes.
- Drunk, high or intoxicated.
- Hallucinations (visual or auditory), dissociations, disorientation, agitation.
- Disturbance in cognition, memory, or attention.
- Drug abuse.
- Drug withdrawal or drug withdrawal syndrome.
- Addiction.
- Overdose.
- Misuse of IMP.
- Thoughts of suicide, attempted suicide or suicide.

The number of patients completing a form will be summarized by treatment group. The summary will be presented separately for all patients with a completed form and patients 12 years of age and older.

### 5.7.7 Site Classification Form

The investigator reviews the applicable Supplemental Adverse Event Form or Supplemental Drug Accountability Form, and then completes a Site Classification Form. For each Supplemental Adverse Event Form or Supplemental Drug Accountability Form completed, there should be an associated Site Classification Form.

The Site Classification Form requires the investigator to assign the finding to an appropriate classification and then to also assign the possible relationship to the IMP. The investigator is also required to indicate the level of the certainty of the classification.

The number of patients completing a form and the possible relationship and level of the certainty for each category will be summarized, on a categorical scale, by treatment group. If more than one form is completed for a particular patient then they will be summarized under each category for all forms. However, if more than one form is completed with and assigned to the same category, then ‘related’ would be used over ‘not related’ and the highest level of certainty will be used for the corresponding chosen relationship. The summary will be presented separately for all patients with a completed form and patients 12 years of age and older.

### 5.7.8 IVRS Compliance

The number of unreported days in IVRS, during the baseline and treatment periods, will be summarized, on a continuous and categorical scale, by treatment group for patients in the ITT analysis set. For the summary on a continuous scale, the lower and upper quartiles will also be presented.

The percentage IVRS compliance, during the baseline and treatment periods, will also be summarized, on a continuous and categorical scale, and calculated as:

\[
\text{IVRS Compliance} = \left( \frac{\text{Number of reported days in IVRS}}{\text{Number of reported days in IVRS} + \text{Number of unreported days in IVRS}} \right) \times 100
\]

### 5.7.9 Meal Times

Patient meal times will be recorded for the day prior to and the day of Visit 2 (Day 1) and Visit 8 (end of treatment). Meal times will be listed only.
5.8 Changes in the Conduct of the Study or Planned Analysis

The identification of 3 key secondary endpoints and the hierarchical testing procedure were not defined in the protocol, but have been included in the SAP prior to unblinding.

Upon blinded review of IVRS data for the number of convulsive seizures greater than 30 minutes in duration and the number of non-convulsive seizures greater than 30 minutes in duration, it was determined that there were insufficient numbers of patients reporting these seizures to perform analyses planned in the protocol.

Upon blinded review of the number of patients with inpatient epilepsy-related hospitalizations, it was determined that there were insufficient numbers of patients to perform analyses planned in the protocol.

The protocol included changes from baseline in usage of rescue medication as an efficacy endpoint. However, due to inconsistencies in the collection of this data, no analyses are proposed.

The endpoint of number of patients experiencing a >25% worsening, −25 to +25% no change, 25–50% improvement, 50–75% improvement or >75% improvement in convulsive seizures from baseline has been updated to the following:

- Number of patients experiencing a >25% increase, ≥0 to ≤25% increase, >0 to <25% reduction, ≥25 to <50% reduction, ≥50 to <75% reduction or ≥75% reduction in convulsive seizures from baseline.

6. References


4941
7. Amendments

Notable changes to the SAP that were completed prior to unblinding, are given below.

Minor changes, clarifications and corrections are not listed.

<table>
<thead>
<tr>
<th>Date</th>
<th>Section</th>
<th>Description of Change</th>
</tr>
</thead>
</table>

4945

4946
## 8. Attachments and Appendices

### Appendix 1  Adverse Events of Special Interest – Abuse Liability

#### Withdrawal

<table>
<thead>
<tr>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug withdrawal convulsions</td>
</tr>
<tr>
<td>Drug withdrawal headache</td>
</tr>
<tr>
<td>Drug withdrawal maintenance therapy</td>
</tr>
<tr>
<td>Drug withdrawal syndrome</td>
</tr>
<tr>
<td>Drug withdrawal syndrome neonatal</td>
</tr>
<tr>
<td>Drug rehabilitation</td>
</tr>
<tr>
<td>Rebound effect</td>
</tr>
<tr>
<td>Steroid withdrawal syndrome</td>
</tr>
<tr>
<td>Withdrawal arrhythmia</td>
</tr>
<tr>
<td>Withdrawal syndrome</td>
</tr>
</tbody>
</table>

#### Drug abuse and dependence

<table>
<thead>
<tr>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dopamine dysregulation syndrome</td>
</tr>
<tr>
<td>Drug abuse</td>
</tr>
<tr>
<td>Drug abuser</td>
</tr>
<tr>
<td>Drug dependence</td>
</tr>
<tr>
<td>Drug dependence, antepartum</td>
</tr>
<tr>
<td>Drug dependence, postpartum</td>
</tr>
<tr>
<td>Intentional drug misuse</td>
</tr>
<tr>
<td>Intentional overdose</td>
</tr>
<tr>
<td>Maternal use of illicit drugs</td>
</tr>
<tr>
<td>Neonatal complications of substance abuse</td>
</tr>
<tr>
<td>Polysubstance dependence</td>
</tr>
<tr>
<td>Substance abuse</td>
</tr>
<tr>
<td>Substance abuser</td>
</tr>
<tr>
<td>Accidental overdose</td>
</tr>
<tr>
<td>Dependence</td>
</tr>
<tr>
<td>Disturbance in social behaviour</td>
</tr>
<tr>
<td>Drug administered at inappropriate site</td>
</tr>
<tr>
<td>Drug detoxification</td>
</tr>
<tr>
<td>Drug diversion</td>
</tr>
<tr>
<td>Drug level above therapeutic</td>
</tr>
<tr>
<td>Drug level increased</td>
</tr>
<tr>
<td>Drug screen</td>
</tr>
<tr>
<td>Drug screen positive</td>
</tr>
<tr>
<td>Drug tolerance</td>
</tr>
<tr>
<td>Drug tolerance decreased</td>
</tr>
<tr>
<td>Drug tolerance increased</td>
</tr>
<tr>
<td>Medication overuse headache</td>
</tr>
<tr>
<td>Narcotic bowel syndrome</td>
</tr>
<tr>
<td>Needle track marks</td>
</tr>
<tr>
<td>Overdose</td>
</tr>
<tr>
<td>Prescribed overdose</td>
</tr>
<tr>
<td>Prescription form tampering</td>
</tr>
<tr>
<td>Substance use</td>
</tr>
<tr>
<td>Substance-induced mood disorder</td>
</tr>
<tr>
<td>Substance-induced psychotic disorder</td>
</tr>
<tr>
<td>Toxicity to various agents</td>
</tr>
</tbody>
</table>
Appendix 2  Ranges for Clinically Significant Changes and Other Defined Flagged Values in Vital Signs

The range of values that will be used to identify clinically significant changes in vital signs parameters (See Section 5.6.4.1) are presented in Table 8.

Table 8  Ranges for Potentially Clinically Significant Changes in Vital Signs

<table>
<thead>
<tr>
<th>Vital Sign</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitting Systolic BP</td>
<td>Change: &lt; -20, &gt; 20</td>
</tr>
<tr>
<td>Sitting Diastolic BP</td>
<td>Change: &lt; -10, &gt; 10</td>
</tr>
<tr>
<td>Pulse Rate</td>
<td>Change: &lt; -10, &gt; 10</td>
</tr>
<tr>
<td>Weight</td>
<td>Percent Change: ≤ -7, ≥ 7</td>
</tr>
</tbody>
</table>

Defined flagged values that will be used to identify low or high vital signs parameters (See Section 5.6.4.1) are presented in Table 9.

Table 9  Other Defined Flagged Values for Vital Signs

<table>
<thead>
<tr>
<th>Vital Sign</th>
<th>Flag</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sitting Systolic BP</td>
<td>&lt; 90, &gt; 140, &gt; 160</td>
</tr>
<tr>
<td>Sitting Diastolic BP</td>
<td>&lt; 50, &gt; 90, &gt; 100</td>
</tr>
<tr>
<td>Pulse Rate</td>
<td>&lt; 60, &gt; 100</td>
</tr>
<tr>
<td>Temperature</td>
<td>&gt; 38.0, &lt; 36.0</td>
</tr>
<tr>
<td>Respiratory Rate</td>
<td>&lt; 12, &gt; 20</td>
</tr>
</tbody>
</table>

Appendix 3  Defined Flagged Values in ECG Parameters

Defined flagged values that will be used to identify low or high ECG parameters (See Section 5.6.4.2) are presented in Table 10.

Table 10  Defined Flagged Values for ECG Parameters

<table>
<thead>
<tr>
<th>ECG Parameter</th>
<th>Flag</th>
</tr>
</thead>
<tbody>
<tr>
<td>QTc</td>
<td>&gt; 450, &gt; 480, &gt; 500</td>
</tr>
</tbody>
</table>

Appendix 4  Toxicity Criteria for Laboratory Parameters

The toxicity criteria that will be used to identify abnormal laboratory parameters are presented in Table 11 and Table 12.

Table 11  Toxicity Criteria for Biochemistry Parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Toxicity Decrease</th>
<th>Toxicity Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chloride</td>
<td>≤0.96xLL</td>
<td>≥1.04xUL</td>
</tr>
<tr>
<td>Calcium</td>
<td>≤0.89xLL</td>
<td>≥1.16xUL</td>
</tr>
<tr>
<td>Sodium</td>
<td>≤0.96xLL</td>
<td>≥1.04xUL</td>
</tr>
<tr>
<td>Potassium</td>
<td>≤0.90xLL</td>
<td>≥1.10xUL</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>≤3.2</td>
<td>≥16</td>
</tr>
<tr>
<td>Phosphate</td>
<td>≤0.79xLL</td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td>≤0.85xLL</td>
<td>≥1.6xUL</td>
</tr>
<tr>
<td>AST</td>
<td>≥3xUL</td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td>≥3xUL</td>
<td></td>
</tr>
<tr>
<td>Lactate Dehydrogenase</td>
<td>≥2.6xUL</td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>≥2xUL</td>
<td></td>
</tr>
</tbody>
</table>
### Table 12  Toxicity Criteria for Hematology Parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Toxicity Decrease</th>
<th>Toxicity Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/dL)</td>
<td>≤9.4</td>
<td>≥1.5xUL</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>≤28</td>
<td>&gt;1.5</td>
</tr>
<tr>
<td>Red cell count</td>
<td>≤0.84xLL</td>
<td>&gt;2xUL</td>
</tr>
<tr>
<td>Mean corpuscular volume</td>
<td>≤0.84xLL</td>
<td>≥1.11xUL</td>
</tr>
<tr>
<td>Mean corpuscular hemoglobin</td>
<td>≤0.84xLL</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Mean corpuscular hemoglobin concentration</td>
<td>≤0.84xLL</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Platelets (x10^9/L)</td>
<td>≤74</td>
<td>≥1.16xUL</td>
</tr>
<tr>
<td>Prothrombin time</td>
<td>&gt;1.5xUL</td>
<td>&gt;2.6xUL</td>
</tr>
<tr>
<td>Prothrombin international normalized ratio</td>
<td>&gt;1.5</td>
<td>&gt;2.6xUL</td>
</tr>
<tr>
<td>Total white blood cell count (x10^9/L)</td>
<td>≤2.9</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Total neutrophil count (x10^9/L)</td>
<td>≤1.36</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Segmented neutrophil count (x10^9/L)</td>
<td>≤0.75</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Eosinophils (x10^9/L)</td>
<td>≥0.31</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Basophils (x10^9/L)</td>
<td>≥0.31</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Monocytes (x10^9/L)</td>
<td>≥0.31</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Lymphocytes (x10^9/L) for patients &lt;18 years (auto hematology)</td>
<td>≤1.0</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Lymphocytes (x10^9/L) for patients &lt;18 years (manual hematology)</td>
<td>≤0.2</td>
<td>≥2.6xUL</td>
</tr>
<tr>
<td>Lymphocytes (x10^9/L) for patients ≥18 years</td>
<td>≤0.2</td>
<td>≥2.6xUL</td>
</tr>
</tbody>
</table>

UL = upper limit of reference range  
LL = lower limit of reference range
### Appendix 5  List of Tables, Listings and Figures

Lists of the tables, listings and figures to be provided are given below in Table 13, Table 14 and Table 15, respectively.

#### Table 13  List of Tables

<table>
<thead>
<tr>
<th>Table Number</th>
<th>Title</th>
<th>Analysis Set</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.1.1</td>
<td>Summary of Patient Disposition – Number of Patients Screened and Randomized by Site</td>
<td>All Screened Patients</td>
</tr>
<tr>
<td>Table 1.1.2</td>
<td>Summary of Patient Disposition – Number of Patients Screened and Randomized by Country</td>
<td>All Screened Patients</td>
</tr>
<tr>
<td>Table 1.2</td>
<td>Summary of Patient Disposition – Reasons for Screen Failure</td>
<td>All Screened Patients</td>
</tr>
<tr>
<td>Table 1.3.1</td>
<td>Summary of Patient Disposition – Numbers of Patients Randomized, Withdrawn or Completed the Treatment Period by Site</td>
<td>All Randomized Patients</td>
</tr>
<tr>
<td>Table 1.3.2</td>
<td>Summary of Patient Disposition – Numbers of Patients Randomized, Withdrawn or Completed the Treatment Period by Country</td>
<td>All Randomized Patients</td>
</tr>
<tr>
<td>Table 1.4</td>
<td>Summary of Overall Patient Disposition</td>
<td>All Randomized Patients</td>
</tr>
<tr>
<td>Table 2.1</td>
<td>Summary of Important Protocol Deviations</td>
<td>All Randomized Patients</td>
</tr>
<tr>
<td>Table 2.2</td>
<td>Summary of Analysis Sets</td>
<td>All Randomized Patients</td>
</tr>
<tr>
<td>Table 3.1.1</td>
<td>Summary of Demographic Data</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 3.1.2</td>
<td>Summary of Demographic Data</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 3.1.3</td>
<td>Summary of Demographic Data</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Table 3.2.1</td>
<td>Summary of Baseline Characteristics</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 3.2.2</td>
<td>Summary of Baseline Characteristics</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 3.2.3</td>
<td>Summary of Baseline Characteristics</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Table 4.1</td>
<td>Summary of Dravet Syndrome History</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 4.2.1</td>
<td>Summary of Seizure Types No Longer Occurring</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 4.2.2</td>
<td>Summary of Current Seizure Types</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 4.3</td>
<td>Summary of Electroencephalography History</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 5.1</td>
<td>Summary of Previous Significant Non-Epilepsy Medical or Surgical History Now Resolved</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 5.2</td>
<td>Summary of Significant Non-Epilepsy Medical or Surgical History – Current Conditions</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 6.1</td>
<td>Summary of History of Antiepileptic Medications</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 6.2</td>
<td>Summary of Concomitant Antiepileptic Therapies</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 6.3</td>
<td>Summary of Concomitant Antiepileptic Medications</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 6.4</td>
<td>Summary of Concomitant Rescue Medications</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 6.5</td>
<td>Summary of Other Concomitant Medications</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 7.1</td>
<td>Summary of Treatment Compliance</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 7.2</td>
<td>Summary of IVRS Compliance</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 8.1.1</td>
<td>Summary of Convulsive Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 8.1.2</td>
<td>Negative Binomial Regression Analysis of Convulsive Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.1.1</td>
<td>Summary of Convulsive Seizure Frequency</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.1.2</td>
<td>Negative Binomial Regression Analysis of Convulsive Seizure Count During Baseline and Treatment Periods</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.2</td>
<td>Analysis of Percentage Change from Baseline in Convulsive Seizure Frequency During the Treatment Period – Wilcoxon Rank-Sum Test</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table Number</td>
<td>Title</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Table 8.2.3</td>
<td>Analysis of Percentage Change from Baseline in Convulsive Seizure Frequency During the Treatment Period – Rank ANCOVA</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.4</td>
<td>Analysis of Convulsive Seizure Frequency During the Treatment Period – Log-transformed ANCOVA</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.5</td>
<td>Analysis of Percentage Change from Baseline in Convulsive Seizure Frequency During the Treatment Period – ANCOVA</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.6</td>
<td>Negative Binomial Regression Analysis of Convulsive Seizure Count During Baseline and the Maintenance Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.7</td>
<td>Negative Binomial Regression Analysis of Convulsive Seizure Count During Baseline and Treatment Periods After Imputing Unreported Days in IVRS</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.8</td>
<td>Analysis of Percentage Change from Baseline in Convulsive Seizure Frequency During the Treatment Period After Multiple Imputation to Account for MNAR – Wilcoxon Rank-Sum Test</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.9.1</td>
<td>Summary of Convulsive Seizure Frequency</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 8.2.9.2</td>
<td>Negative Binomial Regression Analysis of Convulsive Seizure Count During Baseline and Treatment Periods</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 9.1.1.1</td>
<td>Summary of Total Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.1.1.2</td>
<td>Negative Binomial Regression Analysis of Total Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.1.2.1</td>
<td>Summary of Total Seizure Frequency</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Table 9.1.2.2</td>
<td>Negative Binomial Regression Analysis of Total Seizure Count During Baseline and Treatment Periods</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Table 9.1.3</td>
<td>Negative Binomial Regression Analysis of Total Seizure Count During Baseline and Maintenance Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.2.1</td>
<td>Summary and Analysis of Convulsive Seizure Treatment Responders and Convulsive Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.2.2</td>
<td>Summary and Analysis of Convulsive Seizure Treatment Responders and Convulsive Seizure Freedom During the Treatment Period</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Table 9.2.3</td>
<td>Summary and Analysis of Convulsive Seizure Treatment Responders and Convulsive Seizure Freedom During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.3.1.1</td>
<td>Summary of the Caregiver Global Impression of Change</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.3.1.2</td>
<td>Analysis of the Caregiver Global Impression of Change</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.3.2.1</td>
<td>Summary of the Caregiver Global Impression of Change</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Table 9.3.2.2</td>
<td>Analysis of the Caregiver Global Impression of Change</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Table 9.4.1</td>
<td>Summary of Patients with Status Epilepticus</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.4.2</td>
<td>Summary of Occurrence of Status Epilepticus When Not Experienced During the Baseline Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.5.1</td>
<td>Summary and Analysis of Total Seizure Treatment Responders and Total Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.5.2</td>
<td>Summary and Analysis of Total Seizure Treatment Responders and Total Seizure Freedom During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.6.1.1</td>
<td>Summary of Non-Convulsive Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.6.1.2</td>
<td>Negative Binomial Regression Analysis of Non-Convulsive Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.6.2</td>
<td>Negative Binomial Regression Analysis of Non-Convulsive Seizure Count During Baseline and Maintenance Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table Number</td>
<td>Title</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>--------------</td>
<td>-------</td>
<td>--------------</td>
</tr>
<tr>
<td>Table 9.6.3</td>
<td>Summary and Analysis of Non-Convulsive Seizure Treatment Responders and Non-Convulsive Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.6.4</td>
<td>Summary and Analysis of Non-Convulsive Seizure Treatment Responders and Non-Convulsive Seizure Freedom During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.1.1.1</td>
<td>Summary of Tonic-Clonic Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.1.1.2</td>
<td>Negative Binomial Regression Analysis of Tonic-Clonic Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.1.2</td>
<td>Negative Binomial Regression Analysis of Tonic-Clonic Seizure Count During Baseline and Maintenance Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.1.3</td>
<td>Summary and Analysis of Tonic-Clonic Seizure Treatment Responders and Tonic-Clonic Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.1.4</td>
<td>Summary and Analysis of Tonic-Clonic Seizure Treatment Responders and Tonic-Clonic Seizure Freedom During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.2.1.1</td>
<td>Summary of Tonic Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.2.1.2</td>
<td>Negative Binomial Regression Analysis of Tonic Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.2.2</td>
<td>Negative Binomial Regression Analysis of Tonic Seizure Count During Baseline and Maintenance Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.2.3</td>
<td>Summary and Analysis of Tonic Seizure Treatment Responders and Tonic Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.2.4</td>
<td>Summary and Analysis of Tonic Seizure Treatment Responders and Tonic Seizure Freedom During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.3.1.1</td>
<td>Summary of Atonic Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.3.1.2</td>
<td>Negative Binomial Regression Analysis of Atonic Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.3.2</td>
<td>Negative Binomial Regression Analysis of Atonic Seizure Count During Baseline and Maintenance Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.3.3</td>
<td>Summary and Analysis of Atonic Seizure Treatment Responders and Atonic Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.3.4</td>
<td>Summary and Analysis of Atonic Seizure Treatment Responders and Atonic Seizure Freedom During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.4.1.1</td>
<td>Summary of Clonic Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.4.1.2</td>
<td>Negative Binomial Regression Analysis of Clonic Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.4.2</td>
<td>Negative Binomial Regression Analysis of Clonic Seizure Count During Baseline and Maintenance Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.4.3</td>
<td>Summary and Analysis of Clonic Seizure Treatment Responders and Clonic Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.4.4</td>
<td>Summary and Analysis of Clonic Seizure Treatment Responders and Clonic Seizure Freedom During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.5.1.1</td>
<td>Summary of Myoclonic Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.5.1.2</td>
<td>Negative Binomial Regression Analysis of Myoclonic Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.5.2</td>
<td>Summary and Analysis of Myoclonic Seizure Treatment Responders and Myoclonic Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.6.1.1</td>
<td>Summary of Countable Partial Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table Number</td>
<td>Title</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Table 9.7.6.1.2</td>
<td>Negative Binomial Regression Analysis of Countable Partial Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.6.2</td>
<td>Summary and Analysis of Countable Partial Seizure Treatment Responders and Countable Partial Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.7.1.1</td>
<td>Summary of Other Partial Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.7.1.2</td>
<td>Negative Binomial Regression Analysis of Other Partial Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.7.2</td>
<td>Summary and Analysis of Other Partial Seizure Treatment Responders and Other Partial Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.8.1.1</td>
<td>Summary of Absence Seizure Frequency</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.8.1.2</td>
<td>Negative Binomial Regression Analysis of Absence Seizure Count During Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.7.8.2</td>
<td>Summary and Analysis of Absence Seizure Treatment Responders and Absence Seizure Freedom During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.8</td>
<td>Summary of Occurrences of Seizure Types Not Experienced During the Baseline Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.9.1</td>
<td>Summary of Caregiver Global Impression of Change in Seizure Duration</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.9.2</td>
<td>Analysis of Caregiver Global Impression of Change in Seizure Duration</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.10</td>
<td>Summary of Inpatient Hospitalizations due to Epilepsy</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.11.1.1</td>
<td>Summary of Sleep Disruption 0-10 Numerical Rating Scale Score</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.11.2.1</td>
<td>Analysis of Change from Baseline in the Sleep Disruption 0-10 Numerical Rating Scale Score</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.12.1</td>
<td>Summary of Epworth Daytime Sleepiness Scale Score</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.12.2</td>
<td>Analysis of Change from Baseline in the Epworth Daytime Sleepiness Scale Score</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.13.1</td>
<td>Summary of Quality of Life in Childhood Epilepsy Scores</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.13.2</td>
<td>Analysis of Change from Baseline in Quality of Life in Childhood Epilepsy Scores</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.14.1.1</td>
<td>Summary of the Vineland-II Adaptive Behavior Subdomain, Domain and Composite Scores</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.14.1.2</td>
<td>Summary of the Vineland-II Adaptive Behavior Subdomain, Domain and Composite Adaptive Levels</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.14.1.3</td>
<td>Analysis of Change from Baseline in the Vineland-II Adaptive Behavior Domain and Composite Scores</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.14.1.4</td>
<td>Analysis of the Vineland-II Adaptive Behavior Domain and Composite Adaptive Levels</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.14.2.1</td>
<td>Summary of the Vineland-II Maladaptive Behavior Subdomain and Index Scores</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.14.2.2</td>
<td>Summary of the Vineland-II Maladaptive Behavior Subdomain and Index Adaptive Levels</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.14.2.3</td>
<td>Analysis of Change from Baseline in the Vineland-II Maladaptive Behavior Index Score</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.14.2.4</td>
<td>Analysis of the Vineland-II Maladaptive Behavior Index Adaptive Level</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.15.1</td>
<td>Summary of Cognitive Assessment Battery Parent Measures</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.15.2.1</td>
<td>Summary of Cognitive Assessment Battery Parent Measures – Executive (Behavior Rating Inventory of Executive Function)</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table Number</td>
<td>Title</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Table 9.15.2.2</td>
<td>Summary of Cognitive Assessment Battery Parent Measures – Attention (ADHD Checklist)</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.15.2.3</td>
<td>Summary of Cognitive Assessment Battery Parent Measures – Mood/Anxiety (BASC-2)</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.15.2.4</td>
<td>Summary of Cognitive Assessment Battery Parent Measures – Behavior Report Form</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.16.1</td>
<td>Analysis of Time to Baseline Convulsive Seizure Frequency from the Start of the Treatment Period (Day 1)</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.16.2</td>
<td>Analysis of Time to Baseline Convulsive Seizure Frequency from the Start of the Maintenance Period (Day 15)</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.17.1</td>
<td>Analysis of Change from Baseline in Convulsive Seizure Free Days Per 28 Days During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.17.2</td>
<td>Analysis of Change from Baseline in Convulsive Seizure Free Days Per 28 Days During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.18.1</td>
<td>Negative Binomial Regression Effect Modification Analysis of Convulsive Seizure Count during Baseline and Treatment Periods</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 9.18.2</td>
<td>Logistic Regression Effect Modification Analysis of Convulsive Seizure Responders (&gt;=50% Reduction) During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Table 10.1</td>
<td>Summary of Exposure</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 10.2</td>
<td>Summary of Expected Daily Volumes of IMP Taken Post-Titration</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.1</td>
<td>Overall Summary of Treatment Emergent Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.2</td>
<td>Summary of Treatment Emergent Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.3</td>
<td>Summary of Treatment-Related Treatment Emergent Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.4</td>
<td>Summary of Treatment Emergent Adverse Events by Maximal Severity</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.5</td>
<td>Summary of Treatment Emergent Adverse Events by Sex</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.6</td>
<td>Summary of TEAEs by Time of First Onset of AE</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.7</td>
<td>Summary of TEAEs by Time to AE Resolution</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.8</td>
<td>Summary of TEAEs Reported in &gt;=2% of Patients in the GWP42003-P Treatment Groups</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.9</td>
<td>Summary of Non-Serious Treatment Emergent Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.10</td>
<td>List of Patients Experiencing Treatment Emergent Adverse Events by System Organ Class and Preferred term</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.11</td>
<td>Summary of Pre-Treatment Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.12</td>
<td>Summary of Treatment Emergent Adverse Events by Event</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.13</td>
<td>Summary of Treatment-Related Treatment Emergent Adverse Events by Event</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 11.14</td>
<td>Summary of Non-Serious Treatment Emergent Adverse Events by Event</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.1</td>
<td>Summary of Serious Treatment Emergent Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.2</td>
<td>Summary of Treatment-Related Serious Treatment Emergent Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.3</td>
<td>Summary of Treatment Emergent Adverse Events Leading to Permanent Discontinuation of IMP</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.4</td>
<td>Summary of Treatment-Related Treatment Emergent Adverse Events Leading to Permanent Discontinuation of IMP</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.5</td>
<td>Summary of Treatment Emergent Adverse Events Leading to IMP Dose Reduction Excluding Permanent Discontinuation and by Resolution and Overall</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table Number</td>
<td>Title</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Table 12.6</td>
<td>Summary of Treatment-Related Treatment Emergent Adverse Events Leading to IMP Dose Reduction Excluding Permanent Discontinuation and by Resolution and Overall</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.7</td>
<td>Summary of Treatment Emergent Adverse Events Leading to Temporary IMP Dose Reduction by Resolution and Overall</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.8</td>
<td>Summary of Treatment-Related Treatment Emergent Adverse Events Leading to Temporary IMP Dose Reduction Excluding Permanent Discontinuation and by Resolution and Overall</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.9</td>
<td>Summary of Treatment Emergent Adverse Events Leading to Permanent IMP Dose Reduction Excluding Permanent Discontinuation and by Resolution and Overall</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.10</td>
<td>Summary of Treatment-Related Treatment Emergent Adverse Events Leading to Permanent IMP Dose Reduction Excluding Permanent Discontinuation and by Resolution and Overall</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.11</td>
<td>Summary of Fatal Treatment Emergent Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.12</td>
<td>Summary of Serious Treatment Emergent Adverse Events by Event</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 12.13</td>
<td>Summary of Treatment-Related Serious Treatment Emergent Adverse Events by Event</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.1.1</td>
<td>Summary of Laboratory Safety Parameters – Hematology</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.1.2</td>
<td>Summary of Laboratory Safety Parameters – Biochemistry</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.2.1</td>
<td>Shift Table for Hematology Laboratory Parameters – Based on Reference Ranges</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.2.2</td>
<td>Shift Table for Biochemistry Laboratory Parameters – Based on Reference Ranges</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.3.1</td>
<td>Shift Table for Hematology Laboratory Parameters – Based on Toxicity Limits</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.3.2</td>
<td>Shift Table for Biochemistry Laboratory Parameters – Based on Toxicity Limits</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.3.3</td>
<td>Shift Table for eGFR – Based on Derived Grades</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.4</td>
<td>Summary of Liver Parameter Flags</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.5</td>
<td>Incidence of Laboratory Abnormalities</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 13.6</td>
<td>Summary of Pregnancy Test and Urine THC Screen Results</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.1.1</td>
<td>Summary of Vital Signs</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.1.2</td>
<td>Incidence of Clinically Significant Changes from Baseline for Vital Signs</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.1.3</td>
<td>Incidence of Defined Flagged Vital Signs</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.1.4</td>
<td>Incidence of Vital Signs Abnormalities</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.2.1</td>
<td>Summary of ECG Parameters</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.2.2</td>
<td>Incidence of Defined Flagged ECG Parameter Values</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.2.3</td>
<td>Incidence of ECG Abnormalities</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.3.1</td>
<td>Summary of Children’s Columbia-Suicide Severity Rating Scale</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.3.2</td>
<td>Summary of Children’s Columbia-Suicide Severity Rating Scale by Type</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.4</td>
<td>Incidence of Physical Examination Abnormalities</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.5</td>
<td>Summary of Tanner Stages</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.6</td>
<td>Summary of Menstruation Details</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.7</td>
<td>Summary of Cannabis Withdrawal Scale (18 Years)</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.8</td>
<td>Summary of Pediatric Cannabinoid Withdrawal Scale (4–17 Years)</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.9</td>
<td>Summary of Plasma Concentrations of Concomitant Antiepileptic Drugs</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.10</td>
<td>Summary of Caregiver Impression of IMP Palatability</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table Number</td>
<td>Title</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Table 14.11</td>
<td>Summary of Study Medication Use and Behavior Survey</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.12.1</td>
<td>Summary of Supplemental Drug Accountability Form</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.12.2</td>
<td>Summary of Supplemental Adverse Event Form</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Table 14.12.3</td>
<td>Summary of Site Classification Form</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing Number</td>
<td>Title</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Listing 1.1</td>
<td>Screen Failures</td>
<td>All Screen Failure Patients</td>
</tr>
<tr>
<td>Listing 1.2.1</td>
<td>Patient Disposition – End of Treatment</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 1.2.2</td>
<td>Patient Disposition – End of Taper</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 1.3</td>
<td>Inclusion/Exclusion Criteria Not Met</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 1.4</td>
<td>Visit Dates</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 2.1.1</td>
<td>Important Protocol Deviations</td>
<td>All Randomized Patients</td>
</tr>
<tr>
<td>Listing 2.1.2</td>
<td>All Protocol Deviations</td>
<td>All Randomized Patients</td>
</tr>
<tr>
<td>Listing 2.2</td>
<td>Analysis Sets</td>
<td>All Randomized Patients</td>
</tr>
<tr>
<td>Listing 3.1</td>
<td>Demography</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 3.2</td>
<td>Baseline Characteristics</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 4.1.1</td>
<td>Dravet Syndrome History – Part 1</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 4.1.2</td>
<td>Dravet Syndrome History – Part 2</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 4.2.1</td>
<td>History of Seizures No Longer Occurring</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 4.2.2</td>
<td>History of Current Seizures</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 4.3.1</td>
<td>Electroencephalography History – Part 1</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 4.3.2</td>
<td>Electroencephalography History – Part 2</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 4.4</td>
<td>Neuroimaging History</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 5</td>
<td>Significant Non-Epilepsy Medical or Surgical History</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 6.1</td>
<td>History of Antiepileptic Medications</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 6.2</td>
<td>Prior and Concomitant Antiepileptic Therapies</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 6.3</td>
<td>Prior and Concomitant Antiepileptic Medications</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 6.4</td>
<td>Prior and Concomitant Rescue Medications</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 6.5</td>
<td>Other Prior and Concomitant Medications</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 7</td>
<td>IVRS Compliance</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 8.1.1</td>
<td>IVRS Diary Data – Part 1</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 8.1.2</td>
<td>IVRS Diary Data – Part 2</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 8.2.1</td>
<td>Derived Convulsive, Non-Convulsive and Total Seizure Data</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 8.2.2</td>
<td>Derived Tonic-Clonic, Tonic, Atonic and Clonic Seizure Data</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 8.2.3</td>
<td>Derived Myoclonic, Countable Partial, Other Partial and Absence Seizure Data</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 8.2.4</td>
<td>Derived Status Epilepticus Data</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.1</td>
<td>Caregiver Global Impression of Change in Seizure Duration</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.2</td>
<td>Inpatient Hospitalizations due to Epilepsy</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.3</td>
<td>Sleep Disruption 0-10 Numerical Rating Scale</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.4</td>
<td>Epworth Daytime Sleepiness Scale</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.5.1</td>
<td>Quality of Life in Childhood Epilepsy – Physical Activities</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.5.2</td>
<td>Quality of Life in Childhood Epilepsy – Social Activities</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.5.3</td>
<td>Quality of Life in Childhood Epilepsy – Cognition</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.5.4</td>
<td>Quality of Life in Childhood Epilepsy – Emotional Well-Being</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.5.5</td>
<td>Quality of Life in Childhood Epilepsy – Behavior</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.5.6</td>
<td>Quality of Life in Childhood Epilepsy – General Health and Quality of Life</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.5.7</td>
<td>Quality of Life in Childhood Epilepsy – Derived Scores</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.6.1</td>
<td>Vineland-II Adaptive Behavior – Derived Data</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.6.2</td>
<td>Vineland-II Maladaptive Behavior – Derived Data</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.7</td>
<td>Caregiver Global Impression of Change</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.8.1.1</td>
<td>Cognitive Assessment Battery Patient Measures – Intelligence</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.8.1.2</td>
<td>Cognitive Assessment Battery Patient Measures – Attention/Executive</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing Number</td>
<td>Title</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>----------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Listing 9.8.2.1</td>
<td>Cognitive Assessment Battery Parent Measures – Executive (Behavior Rating Inventory of Executive Function)</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.8.2.2.1</td>
<td>Cognitive Assessment Battery Parent Measures – Attention (ADHD Checklist) – Part 1</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.8.2.2.2</td>
<td>Cognitive Assessment Battery Parent Measures – Attention (ADHD Checklist) – Part 2</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.8.2.3</td>
<td>Cognitive Assessment Battery Parent Measures – Mood/Anxiety (BASC-2)</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.8.2.4</td>
<td>Cognitive Assessment Battery Parent Measures – Behavior Report Form</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.9</td>
<td>Time to Baseline Convulsive Seizure Frequency</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 9.10</td>
<td>Convulsive Seizure Free Days Per 28 Days</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 10.1</td>
<td>Exposure and Compliance</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 10.2</td>
<td>Exposure by Time</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 10.3</td>
<td>IMP Accountability</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 11.1.1</td>
<td>Treatment Emergent Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 11.1.2</td>
<td>Treatment Emergent Adverse Events of Special Interest</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 11.2</td>
<td>Pre-Treatment Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 12</td>
<td>Serious Adverse Events</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 13.1.1</td>
<td>Laboratory Parameters</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 13.1.2.1</td>
<td>Abnormal Laboratory Parameters by Patient</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 13.1.2.2</td>
<td>Abnormal Laboratory Parameters by Parameter</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 13.1.3</td>
<td>Laboratory Comments</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 13.1.4</td>
<td>Laboratory Liver Parameters</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 13.2</td>
<td>Laboratory Reference Ranges and Toxicity Limits</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.1.1</td>
<td>Vital Signs – Blood Pressures</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.1.2</td>
<td>Vital Signs – Pulse Rate, Respiratory Rate and Temperature</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.1.3</td>
<td>Vital Signs – Height, Weight and BMI</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.2</td>
<td>Potentially Clinically Significant Changes from Baseline for Vital Signs</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.3.1</td>
<td>ECG Data – Part 1</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.3.2</td>
<td>ECG Data – Part 2</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.4.1</td>
<td>Columbia-Suicide Severity Rating Scale (C-SSRS) – Suicidal Ideation and Intensity</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.4.2</td>
<td>Columbia-Suicide Severity Rating Scale (C-SSRS) – Suicidal Behavior</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.4.3</td>
<td>Columbia-Suicide Severity Rating Scale (C-SSRS) – Actual Attempts</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.5</td>
<td>Physical Examination</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.6</td>
<td>Tanner Stages</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.7</td>
<td>Menstruation Details</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.8</td>
<td>Cannabis Withdrawal Scale (18 Years)</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.9</td>
<td>Pediatric Cannabinoid Withdrawal Scale (4–17 Years)</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.10</td>
<td>Plasma Concentrations of Concomitant Antiepileptic Drugs</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.11</td>
<td>Caregiver Impression of IMP Palatability</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.12.1</td>
<td>Study Medication Use and Behavior Survey – Part 1</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.12.2</td>
<td>Study Medication Use and Behavior Survey – Part 2</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.13</td>
<td>Supplemental Drug Accountability Form</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.13.2</td>
<td>Supplemental Adverse Events Form</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.13.3</td>
<td>Site Classification Form</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 14.14</td>
<td>Meal Times</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Listing 15</td>
<td>Investigators' General Comments</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Figure Number</td>
<td>Title</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Figure 9.1.1.1</td>
<td>Cumulative Distribution Function for Convulsive Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.1.1.2</td>
<td>Cumulative Distribution Function for Convulsive Seizures During the Treatment Period</td>
<td>PP Analysis Set</td>
</tr>
<tr>
<td>Figure 9.1.2</td>
<td>Cumulative Distribution Function for Convulsive Seizures During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.1.3</td>
<td>Cumulative Distribution Function for Convulsive Seizures During Weeks 1 to 4 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.1.4</td>
<td>Cumulative Distribution Function for Convulsive Seizures During Weeks 5 to 8 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.1.5</td>
<td>Cumulative Distribution Function for Convulsive Seizures During Weeks 9 to 12 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.2.1</td>
<td>Cumulative Distribution Function for Total Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.2.2</td>
<td>Cumulative Distribution Function for Total Seizures During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.2.3</td>
<td>Cumulative Distribution Function for Total Seizures During Weeks 1 to 4 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.2.4</td>
<td>Cumulative Distribution Function for Total Seizures During Weeks 5 to 8 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.2.5</td>
<td>Cumulative Distribution Function for Total Seizures During Weeks 9 to 12 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.3.1</td>
<td>Cumulative Distribution Function for Non-Convulsive Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.3.2</td>
<td>Cumulative Distribution Function for Non-Convulsive Seizures During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.3.3</td>
<td>Cumulative Distribution Function for Non-Convulsive Seizures During Weeks 1 to 4 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.3.4</td>
<td>Cumulative Distribution Function for Non-Convulsive Seizures During Weeks 5 to 8 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.3.5</td>
<td>Cumulative Distribution Function for Non-Convulsive Seizures During Weeks 9 to 12 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.4.1</td>
<td>Cumulative Distribution Function for Tonic-Clonic Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.4.2</td>
<td>Cumulative Distribution Function for Tonic-Clonic Seizures During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.4.3</td>
<td>Cumulative Distribution Function for Tonic-Clonic Seizures During Weeks 1 to 4 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.4.4</td>
<td>Cumulative Distribution Function for Tonic-Clonic Seizures During Weeks 5 to 8 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.4.5</td>
<td>Cumulative Distribution Function for Tonic-Clonic Seizures During Weeks 9 to 12 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.5.1</td>
<td>Cumulative Distribution Function for Tonic Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.5.2</td>
<td>Cumulative Distribution Function for Tonic Seizures During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.5.3</td>
<td>Cumulative Distribution Function for Tonic Seizures During Weeks 1 to 4 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.5.4</td>
<td>Cumulative Distribution Function for Tonic Seizures During Weeks 5 to 8 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.5.5</td>
<td>Cumulative Distribution Function for Tonic Seizures During Weeks 9 to 12 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.6.1</td>
<td>Cumulative Distribution Function for Atonic Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>Analysis Set</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Figure 9.6.2</td>
<td>Cumulative Distribution Function for Atonic Seizures During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.6.3</td>
<td>Cumulative Distribution Function for Atonic Seizures During Weeks 1 to 4 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.6.4</td>
<td>Cumulative Distribution Function for Atonic Seizures During Weeks 5 to 8 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.6.5</td>
<td>Cumulative Distribution Function for Atonic Seizures During Weeks 9 to 12 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.7.1</td>
<td>Cumulative Distribution Function for Clonic Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.7.2</td>
<td>Cumulative Distribution Function for Clonic Seizures During the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.7.3</td>
<td>Cumulative Distribution Function for Clonic Seizures During Weeks 1 to 4 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.7.4</td>
<td>Cumulative Distribution Function for Clonic Seizures During Weeks 5 to 8 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.7.5</td>
<td>Cumulative Distribution Function for Clonic Seizures During Weeks 9 to 12 of the Maintenance Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.8</td>
<td>Cumulative Distribution Function for Myoclonic Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.9</td>
<td>Cumulative Distribution Function for Countable Partial Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.10</td>
<td>Cumulative Distribution Function for Other Partial Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.11</td>
<td>Cumulative Distribution Function for Absence Seizures During the Treatment Period</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.12.1</td>
<td>Kaplan-Meier Plot of Time to Baseline Convulsive Seizure Frequency from the Start of the Treatment Period (Day 1)</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 9.12.2</td>
<td>Kaplan-Meier Plot of Time to Baseline Convulsive Seizure Frequency from the Start of the Maintenance Period (Day 15)</td>
<td>ITT Analysis Set</td>
</tr>
<tr>
<td>Figure 14.1</td>
<td>Box Plot of Change from Baseline to the End of Treatment Visit in IGF-1 Levels by Tanner Stages at Baseline</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Figure 14.2</td>
<td>Scatter Plot of Change from Baseline to the End of Treatment Visit in IGF-1 Levels Against Weight at Baseline</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Figure 14.3</td>
<td>Scatter Plot of Change from Baseline to the End of Treatment Visit in IGF-1 Levels Against Height at Baseline</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Figure 14.4.1.X</td>
<td>Scatter Plot of Shift from Baseline to Maximum Post First Dose Laboratory Result - Hematology</td>
<td>Safety Analysis Set</td>
</tr>
<tr>
<td>Figure 14.4.2.X</td>
<td>Scatter Plot of Shift from Baseline to Maximum Post First Dose Laboratory Result - Biochemistry</td>
<td>Safety Analysis Set</td>
</tr>
</tbody>
</table>